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General introduction 
Information on almost any disease and cure is available on the internet, even for 
exotic ones. When the information is based on adequate summarization of high 
quality research, patient and doctor can communicate on a more equal level 
than they ever did before. However, much of the information that is so easy to 
grasp (and which may lead to much patient worry and anxiety), comes from 
sources that at best may be called dubious; the information may be motivated by 
commercial interests, or based on experiences of only a few patients instead of 
high quality clinical research.  This was one of the main focuses of the evidence 
based medicine movement from 1991: identifying, critically appraising, and 
summarizing the available evidence.[1] In 1991 Sir Iain Chalmers founded the 
international Cochrane Collaboration with the objective “to give doctors, other 
health professionals and patients the evidence they need to make informed 
decisions about treatments”.[2] Now, Cochrane Reviews are systematic reviews 
of primary research in human health care and health policy, that are 
internationally recognised as the highest standard in evidence-based health 
care.[3] 
Good-quality information is available, especially for those who work at an 
institution that can afford to pay for subscriptions on scientific journals. By 
means of PubMed, Embase, Google Scholar or other search engines, results of 
peer reviewed medical research are accessible. However, the number of 
published trials is continuously increasing - in 2010 there were already 75 
randomized controlled trials published per day and a plateau in growth was not 
yet reached.[4] Usually there are at least a few papers available on the same 
topic, each paper presenting the results of a different clinical study. If the 
results described by the different papers are similar this gives the impression 
that the conclusions in these papers are reliable and can be trusted. However, 
such similarity is often lacking. Results described in various papers may differ 
markedly, even for studies with similar designs and after correction for chance 
variation. This variability in results is called between-study heterogeneity. The 
reason for this heterogeneity is partly the presence of small differences in study 
set-up: setting (country, type of hospital), intervention (e.g. dosing), patient 
selection, timing and type of outcome measurements, etc.  Also the quality of 
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the studies may fluctuate, with some studies meeting much higher quality 
standards than others. As a result, some studies may conclude that an 
intervention is highly effective whereas others may find that it is hardly better 
than, or as good as no intervention. Variation can also be caused by the 
application of different statistical approaches between studies. In practice 
selection and summarization of reliable high quality evidence is not so 
straightforward: the available evidence needs to be selected and summarized in 
a systematic and valid way, in “systematic” reviews. Selection of the evidence 
has resulted in guidelines to improve the completeness and quality of reporting 
by authors of primary studies, due to frustration over incomplete and misleading 
abstracts and study reports.[5]  
Summarization is not only hampered by differences in reporting quality, but also 
by between-study heterogeneity. Heterogeneity can be present even if study 
selection criteria would always be carefully defined and applied. The reasons for 
heterogeneity can be clinical or statistical by nature. Clinical heterogeneity can 
be caused by differences in patient population, assessment times, assessment 
tools, medication regimen, etcetera. Statistical heterogeneity can be caused by 
differences in the statistical approaches of the studies. Some of them may have 
been adjusted for gender whereas others have been adjusted for co-medication 
and others may not have been adjusted at all. Some of them provide sufficient 
information to derive treatment effects and standard errors, whereas others not 
even present the number of patients included in the study. Analyses may be 
more or less advanced. These factors may result in higher levels of heterogeneity 
in the resulting meta-analysis than would be clinically expected.  
Summarization of the evidence is done by means of meta-analysis: the statistical 
combination of the results of two or more primary studies. Traditionally the 
methodology for meta-analysis is based on large sample approximations[6], 
assuming that there are sufficient studies, that these studies are a random 
sample of all possible studies, and that heterogeneity is equal for all studies in 
the meta-analysis. Ideally, results of similar studies are combined to estimate 
the summary effect. However, sample sizes of the studies may differ 
substantially, e.g. because the research question of the meta-analysis was not 
always the primary question that the study aimed to answer. Large studies tend 
to provide more precise results than small studies. Therefore large studies should 
be more important than smaller studies in the meta-analysis, but how much more 
General Introduction 
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important depends on the approach that is chosen for the meta-analysis. Two 
main approaches to meta-analysis are the fixed-effects and the random-effects 
approach. In a fixed-effects model it is assumed that all studies estimate the 
same intervention effect, even though in practice each clinical trial will result in 
a slightly different estimate for the treatment effect, because trials are 
performed with limited sample sizes. In the fixed-effects meta-analysis, the 
precision (inverse variance) of the estimated treatment effect defines the 
importance of the studies in the weighted summary: imprecise studies receive 
low weights and very precise studies receive high weights. Consequently, the 
summary estimate of the treatment is strongly influenced by the precise, large 
studies. In a random-effects approach it is assumed that the studies are not all 
estimating the same intervention effect, but estimate different, yet related 
intervention effects.[7] The efficacy of the intervention may vary, depending on 
differences in study set up. In the random-effects approach larger studies are 
more important than smaller studies, like in the fixed effects analysis, but now 
the weights are based on the inverse of the sum of the study imprecision plus the 
estimated heterogeneity. If the estimated heterogeneity is small, the summary 
effect estimate will be similar to the fixed effect estimate. However, if it is 
large, small studies will be almost as influential on the summary effect as large 
studies. Further, the standard errors of summary effects estimated with  random-
effects analyses tend to be larger than those of fixed-effects analyses.  
The UK Cochrane Editorial Unit kindly provided us with the statistical data of 
systematic reviews of interventions in clinical studies included in the Cochrane 
Database of Systematic Reviews (CDSR) Issues of 2009-2013. We used these data 
to empirically evaluate various aspects of meta-analysis methodology and to 
design realistic simulation studies for more extensive evaluations. Most meta-
analyses in the Cochrane Database of Systematic Reviews (CDSR) Issues 2009-
2013 were based on only a few small studies: of the 3,263 selected meta-
analyses, 1,025 (31%) were based on two studies and 1,226 (38%) on three to five 
studies. Besides most of the studies were small: overall, of the 20,185 primary 
trials 14,985 (74%) were small. And in more than 50% the between-study variation 
was estimated to be larger than zero.[8]
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This thesis aims to give insight into the application of  meta-analysis 
methodology and to reflect on the role of between-study heterogeneity in the 
realistic setting where most meta-analyses are based on just a few studies and 
where some of these studies are small or very small. 
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Outline of the thesis 
Most medical systematic reviews including meta-analyses are dedicated to 
clinical (human) research. Fewer than 250 systematic reviews of preclinical 
animal studies had been published prior to 2010, as opposed to almost 6000 
Cochrane Reviews of clinical studies to date.[9] However, some questions can 
only be answered by means of experimental animal studies. The number of meta-
analyses of animal studies is increasing, but it is still very much lower than the 
number of meta-analyses of clinical studies, even though the statistical 
methodology is rather similar. To explain the methodology and to stimulate 
animal researchers to perform more meta-analyses, we have written an 
introductory tutorial, which is presented in Chapter 2. An interesting aspect of 
pre-clinical meta-analyses is that heterogeneity is often more than a “nuisance” 
parameter. Animal studies are usually designed to explore various treatments, 
dosages, and interventions, and are usually small. As with clinical questions, 
interest may be on the summary estimate of the intervention effect, but another 
important focus may be the reasons why results vary between settings. A large 
advantage of an animal study meta-analysis is that it may prevent the sacrifice of 
new animals if there are already relevant studies available. Another advantage is 
that meta-analyses may have a positive effect on the methodological quality of 
the primary animal studies in the long term, similar to the effect human meta-
analyses had on clinical studies.[5]  
In Chapter 3 we investigate the basic question with regard to two possible 
approaches to find the best evidence on the effect of an intervention: is it 
preferable to conduct one large new trial or it is better to summarize existing 
trial results by means of a meta-analysis. The effects of three complicating 
factors are evaluated. First, the size of the existing trials: if a meta-analysis is 
preferred to a large trial, is this then also the case if only a few small trials are 
available for the meta-analysis? Second, the influence of reporting bias. It is well 
known that the papers that get published are not always representative of all 
studies that have been performed. Studies with positive findings tend to get 
published more often than those with negative findings, which results in an 
overrepresentation of papers with positive results. Clearly, if a meta-analysis is 
based on the available papers reporting bias might influence the conclusions: 
they tend to be too optimistic. The third issue is the between study variation, or 
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heterogeneity. What is the effect of heterogeneity on the result of the study or 
meta-analysis?  
The DerSimonian and Laird (DL) approach[10], which is based on large sample 
assumptions, is widely used for random effects meta-analysis. However, as most 
meta-analyses only contain a few studies, this often results in inappropriate type 
I error rates. The method described by Hartung, Knapp[11-13], and by Sidik and 
Jonkman[14, 15] (HKSJ) is known to perform better when trials of similar size are 
combined. But evidence in realistic situations, where one trial might be much 
larger than the other trials, is lacking. In Chapter 4 we assess the relative 
performance of the DL and HKSJ methods when studies of different sizes are 
combined. Therefore we simulated meta-analyses of 2–20 trials with varying 
sample sizes and between-study heterogeneity, and allowed trials to have various 
sizes, e.g. 25% of the trials being 10-times larger than the smaller trials. We 
compared the number of “positive” (statistically significant at p < 0.05) findings 
empirically using both approaches, using 689 meta-analyses from the Cochrane 
Database of Systematic Reviews (CDSR) Issues 2012. We also show how DL results 
can be converted to HKSJ results by means of a few steps. 
Especially if there are both small and large primary studies in a meta-analysis, 
the size of the estimated heterogeneity is very important for the conclusions 
because of the weighting method in the random-effects approach. Results of 
small studies are often associated with “small study effects”: the phenomenon 
that results of small studies tend to be more positive than those of larger 
studies.[16-18] This can be due to reporting bias but also to quality issues, both 
of which may occur more often in small trials. Possibly also the heterogeneity 
between small studies is different from the heterogeneity between large studies. 
In Chapter 5 we evaluate the role of small studies in meta-analyses by exploring 
3263 meta-analyses from the CDSR Issues 2009-2013. We focus specifically on the 
size of the heterogeneity in relation to trial size.  
Heterogeneity is not only relevant for the weight of the studies in the meta-
analysis: it also contains clinically relevant information. The existence of a 
positive heterogeneity estimate implies that there are differences in the 
intervention effect between the trials. This occurs often: in approximately half 
of the meta-analyses the estimates for the between-study variation are positive. 
It means that the treatment will appear more effective  in some settings than in 
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others, which clearly is clinically relevant. However, most reviewers and readers 
are uncertain with respect to the clinical interpretation of the heterogeneity 
estimates. In Chapter 6 we argue that the prediction interval is helpful in this 
context, because it shows the range of true treatment effects that is expected in 
future patients. Confidence intervals only estimate the mean treatment effect. 
In case of heterogeneity, prediction intervals will show a wider range of 
expected treatment effects than confidence intervals, and thus may lead to 
different conclusions. We investigated how often this occurred, and how often 
the conclusion was so different that it was indeed clinically relevant, using meta-
analyses of the CDSR Issues 2009-2013. 
Findings of these research questions, and perspectives for future research on 
meta-analysis methodology are presented in Chapter 7. 
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Abstract
In research aimed at improving human health care animal studies still play a 
crucial role, despite political and scientific efforts to reduce preclinical 
experimentation in laboratory animals. In animal studies, the results and their 
interpretation are not always straightforward, as no single study is executed 
perfectly in all steps. There are several possible sources of bias, and many 
animal studies are replicates of studies conducted previously. Use of meta-
analysis to combine the results of studies may lead to more reliable conclusions 
and a reduction of unnecessary duplication of animal studies. In addition, due to 
the more explorative nature of animal studies as compared to clinical trials, 
meta-analyses of animal studies have greater potential in exploring possible 
sources of heterogeneity. 
 
There is an abundance of literature on how to perform meta-analyses on clinical 
data. Animal studies, however, differ from clinical studies in some aspects, such 
as the diversity of animal species studied, experimental design, and study 
characteristics. In this paper we will discuss the main principles and practices for 
meta-analyses of experimental animal studies.  
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Introduction
 Animal experimentation plays a vital role in research aimed at improving human 
health and health care. For example, in 2012 more than four million animal 
studies took place in Great Britain in a research context [1], and in a small 
country as the Netherlands almost 600,000 animal experiments were conducted 
[2]. Many of the animal studies are replicates of studies conducted previously. 
This is not a surprise as replication of study results is one of the main principles 
of science. However, how do we decide when we have enough (reliable) 
information about a specific topic for decision making? Meta-analysis of animal 
studies might be of use herein. 
 
In general, meta-analysis is a tool to evaluate the efficacy of an intervention, 
using all available information. In addition, meta-analysis, especially cumulative 
meta-analysis, can help to visualize unnecessary duplication of animal studies [3, 
4]. A cumulative meta-analysis is a series of meta-analyses in which each meta-
analysis incorporates one additional study. When the meta-analyses are sorted 
chronologically, the display shows how the evidence accumulated, and how the 
conclusions have shifted over a period of time [5]. For example, a cumulative 
meta-analysis conducted by Sena et al. in 2010 on tissue plasminogen activator 
(rtPA) in stroke showed that the estimate of efficacy was already stable in 2001, 
after data from some 1500 animals had been reported. However, this meta-
analysis was only conducted in 2010, and after 2001 another 1888 animals were 
used, which was not necessary to establish the effect of tPA for stroke [4]. Note 
that a  number of these studies were not performed to establish the efficacy of 
rtPA but used rtPA as a positive control or as comparator for novel interventions. 
Nevertheless, meta-analyses of animal experiments are an important tool in 
reducing the amount of unnecessary animal studies. 
 
There is an abundance of literature on how to perform meta-analyses on clinical 
data. Animal studies, however, differ from clinical studies in some aspects, for 
example, animal studies are much more diverse in their populations (e.g. 
species), design and study characteristics. In this paper we will discuss the main 
principles and practices for meta-analyses of experimental animal studies. 
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1. Phrase the research question.
Note: Often consists of four components; 
*population/species/strain; *intervention/ exposure;  
*disease of interest/ health problem; *outcome measures of 
interest. 
2. Define the study in- and exclusion criteria
3. Search for all original papers and abstracts 
Note: Use of the step by step guide (ref) en search filters 
(ref) for animal studies are recommended
4. Select all relevant abstracts and papers 
5. Assess the  study quality and validity of the included 
studies. 
Note: The extent to which a SR can draw reliable conclusions 
depends on the validity 
of the data and the results of the included studies. 
6. Extract the relevant data from all 
included papers
7. Analyse and compare the results of all individual studies, 
and when possible 
conduct a meta-analysis.
8. Present and interpret the data
Note: Often, a table with the characteristics 
of the individual studies, a risk of bias table, 
a forest plot possibly showing the results of the meta-
analysis, and a funnel plot indicating the presence of 
possible publication bias are presented.
a. Check for homogeneity of the included studies 
Note: When the focus of the MA is the relation 
between characteristics of the studies and the outcome instead of the 
summary effect across a series of studies, a wider diversity between 
studies is appropriate.
b. Assemble relevant study data
c. Choose an effect size measure
d. Calculate the effect size for each study 
e. Choose a random-effects or fixed-effects model
Note: A random-effects model allows that the underlying treatment 
effect differs between studies. 
A fixed-effects model assumes that all observed variation between the 
studies is because of chance, 
and that there exists only one true underlying effect. 
f. Specify subgroups (if applicable)
Note: Subgroup analyses play a very important role 
in meta-analyses of animal studies. Mainly because 
meta-analyses of animal studies are especially conducted to investigate 
which factors influence 
the effect of an intervention
g. Calculate the summary effect (per subgroup and overall) 
h. Conduct a sensitivity analysis
Note: Assess the robustness of the findings from the meta-analysis.
i. Check for the presence of publication bias
Note: The reliability of results can also be diminished by unpublished 
studies or unpublished parts of studies. 
j. Interpret the results
Note: Use in the interpretation at least the effect size, confidence 
interval, extent of heterogeneity.
Steps of a systematic review Steps of a meta-analysis
Figure 1.   Steps to be taken in a systematic review (SR) and meta-analysis (MS) of 
animal studies. Figure 1 is party based on the general methods for Cochrane reviews [17].

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Meta-analysis in the context of systematic reviews
When a scientist has an important research question to answer, there are often a 
variety of scientific approaches possible. One option is to design a new animal 
study. Another somewhat less common option is to conduct a systematic review 
of all animal studies. In a systematic review all research evidence relevant to a 
specific question is identified, appraised and synthesized in order to draw 
evidence based conclusions. In general, a systematic review results in a 
transparent overview of the available information, for example  about the safety 
and efficacy of a treatment, and offers new information that was not available 
by analyzing each study individually. So, a systematic review might result in a 
better answer to the research question than a new animal experiment. 
 
Systematic reviews are almost standard practice in clinical studies, but are not 
yet widely conducted in the field of laboratory animal science. Fewer than 250 
systematic reviews of preclinical animal studies had been published prior to 
2010, as opposed to almost 6000 Cochrane Reviews of clinical studies to date [6]. 
Given that many studies using laboratory animals aim at improving human health 
(and health care), it seems reasonable that research using animals be reviewed 
in a similar way and adhere to similarly high-quality standards. Some scientists 
even suggested that a more rigorous assessment of the results of animal studies 
in the form of a systematic review should be a prerequisite before starting 
studies in patients [7]. 
 
Eight different steps need to be taken when a systematic review is conducted 
(Figure 1). In one of these steps (step 7) the results of all individual studies are 
reported and compared, and when possible combined by means of a meta-
analysis. This results in a quantitative summary of the knowledge that is 
available. However, a meta-analysis may also aim to assess the dispersion 
between the individual study effects. Although many systematic reviews contain 
meta-analyses, systematic reviews are also frequently published without a meta-
analysis, especially when the included studies are too heterogeneous or seem to 
be seriously biased. 
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Study or Subgroup
1.1.1 Cortex
Australian 2003
Canadian 2008
Chinese 2011
German 2004
Subtotal (95% CI)
Heterogeneity: Tau² = 0.38; Chi² = 6.50, df = 3 (P = 0.09); I² = 54%
Test for overall effect: Z = 1.74 (P = 0.08)
1.1.2 Hippocampus
American 2011
Dutch 2006
French 2010
Zambian 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.56; Chi² = 4.97, df = 3 (P = 0.17); I² = 40%
Test for overall effect: Z = 5.04 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 1.27; Chi² = 25.93, df = 7 (P = 0.0005); I² = 73%
Test for overall effect: Z = 3.55 (P = 0.0004)
Test for subgroup differences: Chi² = 9.57, df = 1 (P = 0.002), I² = 89.6%
Mean
112
923
620
2.6
2.29
0.95
212
0.63
SD
52
166
41
0.39
1.27
0.29
72
0.17
Total
13
4
8
6
31
6
6
7
6
25
56
Mean
183
718
650
3.91
5
2.11
490
1.83
SD
63
237
36
1.1
1.7
0.29
85
0.33
Total
15
4
8
6
33
6
6
8
7
27
60
Weight
16.1%
12.4%
15.0%
13.3%
56.9%
13.1%
9.5%
11.4%
9.2%
43.1%
100.0%
IV, Random, 95% CI
-1.18 [-2.00, -0.37]
0.87 [-0.64, 2.38]
-0.74 [-1.76, 0.29]
-1.47 [-2.80, -0.13]
-0.74 [-1.57, 0.09]
-1.67 [-3.06, -0.27]
-3.69 [-5.82, -1.56]
-3.30 [-5.01, -1.59]
-4.14 [-6.34, -1.95]
-3.00 [-4.17, -1.84]
-1.71 [-2.66, -0.77]
Omega-3 Control Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours Omega-3 Favours control
A
B
C
1 5 62 3 4 9 1087
D
Figure 2.   Forest plot, summarizing fictive results of eight individual studies, 
comparing the effects of omega-3 fatty acid supplementation vs. control treatment.  
Abbreviations:  SD: Standard deviation; Std. Mean Difference: standardized mean 
difference; IV, Random: a random-effects meta-analysis is applied, with weights based on 
inverse variances; 95% CI: 95% confidence interval; df: degrees of freedom; Tau2, I2: 
heterogeneity statistics; Chi2: the chi-squared test value; Z: Z-value for test of the overall 
effect; P: p value. 
 
The results of a meta-analysis are displayed in a forest plot, see for example 
Figure 2. This plot allows readers to visualize and interpret the results of a meta-
analysis. Figure 2 represents a forest plot summarizing fictive results of eight 
individual studies on the effects of omega-3 fatty acid supplementation on 
neuronal cell death in experimental Alzheimer’s Disease (AD). Four studies 
assessed the amount of neuronal cell death in the cortex, the other four studies 
in the hippocampus. These are presented separately, as subgroups. 
 
The first column shows the references of the included studies. Columns 2 through 
7 show the raw data (mean, standard deviation (SD), and sample size (total)) of 
both the experimental omega-3 group and the control group concerning the 
amount of neuronal cell death due to omega-3 fatty acid supplementation in 
experimental AD. Neuronal death is measured using different scales, therefore 
the means of the various studies vary considerably (0.63 to 923). In this case 
some studies present cell death per inch2 and others per mm2. 
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Based on the raw data an effect estimate for each study can be calculated. In 
column 9, the study effects are represented as standardized mean differences 
(mean difference/ SDpooled), so that the differences are expressed on a uniform 
scale; the fact that the scales of measurement varied across studies is no longer 
a problem. On the right, these differences, with their 95% confidence intervals 
(CIs), are presented with a central square and a horizontal line in the forest plot. 
The size of the central square is roughly equal to the size of the study, or more 
exactly, to the weight (column 8) that the study contributes to the combined 
effect [8]. The weight of a study varies with the statistical model used to pool 
the results (either fixed- or random-effects model). The vertical line represents 
the line of no effect. 
 
In this example it was decided to combine the results of the individual studies. 
The resulting summary effects are depicted as black diamonds, per subgroup 
(arrows A and B) and for all studies combined (C). The location of the diamonds 
represent the point estimates (direction and size) of the treatment effect, and 
the width of the diamonds represent the 95% CI. In this fictive example, the 
diamond corresponding to the total effect (C) is located completely left of the 
vertical no-effect line.  Therefore, we can conclude that there is a statistically 
significant reduction in the amount of neuronal cell death due to omega-3 fatty 
acid supplementation in experimental animal models for AD. 
 
Last but not least, in this forest plot also the amount of heterogeneity is shown, 
expressed as Tau2 (ů2), together with a chi-squared test result (D). The ů2 is an 
estimate of the between-study variation. The corresponding chi-squared test 
assesses whether the ů2  is larger than zero, but is of limited importance as it is 
not very powerful when the number of studies is small and it gives no information 
on the extent of heterogeneity [9]. The I2 (also at D) is a measure of 
inconsistency between the study results and quantifies the proportion of 
observed dispersion that is real, i.e. due to between-study differences and not 
due to random error [10]. It reflects the extent of overlap of the CIs of the study-
effects. If I2 is low (<25%), almost all observed variance is probably spurious. If 
the heterogeneity is large (e.g.  I2 >50%), we should speculate about reasons for 
the large “real” variance [9]. Animal studies are often quite exploratory and 
heterogeneous with respect to species, design, intervention protocols etc, 
compared to clinical trials. Exploring this heterogeneity is one of the added 
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values of meta-analyses of animal studies and might help to inform the design of 
a clinical trial. 
Reasons to conduct a meta-analysis of animal studies 
Although meta-analyses of animal studies are not yet routine in laboratory animal 
experimentation there are many advantages for doing so. 
 
Results from a systematic review that includes a meta-analysis of animal studies 
may be more robust than results from single animal studies, if the meta-analysis 
is based on multiple high quality studies. Therefore the knowledge about the 
efficacy or side effects of a treatment or intervention may be more 
comprehensive. No single research endeavor is perfect, and experts are prone to 
bias. Combining studies that meet specific predefined criteria regarding content 
and quality may result in more reliable conclusions [11].  
 
In many situations human evidence is lacking, for example in toxicity studies 
[12]. A critical evaluation of animal experiments, leading to information about 
the efficacy and possible side effects, can therefore inform clinical trial design 
and improve patient safety. For example, single animal studies are often too 
small to show whether or not a side effect is relevant or to present the full 
spectrum of side effects. When multiple small animal studies are combined, this 
will increase the power of the analysis and give more insight in the significance 
of a side effect.  A meta-analysis about the effects of nimodipine (a calcium 
channel blocker) for acute stroke showed that there was no convincing evidence 
from the animal studies to substantiate the decision to start trials with 
nimodipine in large numbers of patients. However, at the time of the meta-
analysis of the animal experiments, 29 clinical trials with circa 7500 patients 
were already conducted [13].  
 
As mentioned above, the  added value of meta-analyses of animal studies is the 
new knowledge that can be obtained by the evaluation of the heterogeneity 
between the studies. For example, a meta-analysis can make the impact of 
methodological quality on the effect size transparent. Bebarta et al. showed in 
2003 that animal studies that do not utilize randomization or blinding are more 
likely to report a difference between study groups than studies that employ 
Meta-analyses of animal studies 
 
 
21
these methods [14]. Part of the heterogeneity between animal studies can also 
be caused by differences of biological study characteristics (such as species, sex, 
age, dose, intervention schedule etc) on the main effect.  The impact of such 
characteristics can be investigated by subgroup analyses or meta-regression 
(meta-analytical techniques to assess the relationship between study level 
covariates and effect size).  A recent review about the effects of ischemic 
preconditioning (IPC) on ischemic reperfusion injury (IRI) in the animal kidney 
showed, for example, that the timing of the ischemic preconditioning greatly 
influenced the efficacy. The late window of protection (IPC more than 24h prior 
to IRI) appeared to be much more effective than the early window of protection. 
In addition, it was demonstrated that the IPC was more effective in rats than in  
mice [15]. These results obtained from the subgroup analyses resulted in the 
design of a new clinical trial focusing on the late window of protection instead of 
the early window which was used so far. This shows how meta-analyses may 
affect the design of future animal or clinical experiments.  
 
So far, many papers and guidelines have been published regarding meta-analyses 
for clinical data [16-18]. Guidance has been published also for animal data, 
albeit not to the same extent [19]. Animal studies differ from clinical studies in 
some aspects, which has to be taken into account when performing a meta-
analysis. 
Differences between meta-analyses of animal and human studies 
In human research the goal of a meta-analysis of clinical trials is generally to 
estimate the overall effect size of an intervention in order to aid decision making 
in clinical practice. In contrast, meta-analyses of animal studies are more 
exploratory and their results can be used to generate new hypotheses and guide 
the design of clinical trials. The purpose might be to summarize the effect of an 
intervention, to establish the relation between two variables, to summarize a 
parameter in a single group, or to evaluate heterogeneity between studies. The 
size of an effect, for example of an intervention effect in an animal model, is in 
itself not particularly useful information. This is partly because animal studies 
are so diverse in their populations (e.g. species), design and study 
characteristics; a pooled effect size is less meaningful compared to clinical trials. 
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However, as the studies in a meta-analysis are addressing a similar question, the 
direction of the effects is meaningful. 
 
In addition, because animal studies offer a wider range of possibilities to 
examine toxicity of interventions or study pathology and mechanisms of disease 
than provided by clinical trials, meta-analyses of animal studies have a greater 
potential in exploring possible sources of heterogeneity compared to meta-
analyses of clinical studies [19, 20]. We believe that one of the major added 
values of meta-analyses of animal studies is the insight that can be obtained by 
the evaluation of the heterogeneity between the studies. 
 
The methods used for meta-analysis of animal studies are largely similar to 
clinical meta-analyses but in some aspects they are somewhat different [19]. For 
example, an animal study may contain both a placebo group and sham groups. In 
addition, animal studies are in general much smaller and more heterogeneous 
than clinical trials.  Furthermore, the methodological quality of the included 
animal studies is often poor, which increases the risk of bias [21].  
Meta-analysis of animal studies step by step 
As mentioned before, a meta-analysis is often part of a systematic review. Once 
the review is started, i.e. once the scientific research question has been 
formulated, the objectives, study selection criteria, outcomes of interest and 
methodological approach should be described prospectively in a meta-analysis 
protocol. A protocol format for systematic reviews of animal intervention studies 
is submitted by de Vries et al.   We recommend that authors register and/or 
publish the protocol, thereby allowing for feedback on the proposed methodology 
and insight in changes during the review process. When the studies have been 
selected and the relevant study results gathered, the statistical synthesis of the 
results  – the meta-analysis – can be performed. This can be done for each 
outcome of interest, thus a systematic review can contain several meta-analyses 
per research question, for example, a meta-analysis for the outcome measure 
mortality, and one for the number of animals with weight increase. Each meta-
analysis summarizes with statistical methods the results of those studies that 
reported on that outcome. A meta-analysis requires that at least two but 
preferably more studies are available.  
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We suggest the following key-elements and steps, amongst others inspired by the 
Cochrane Handbook [17], which all will be taken in a reproducible sequence 
when performing a meta-analysis of animal studies:  
  
A. Check whether or not the included studies are homogenous enough to 
conduct a meta-analysis  
An important feature of a systematic review – and thus also of the meta-
analyses in the review – is that the systematic review often addresses a 
broader research question than was addressed by the primary studies. 
Consequently, the selected studies may show diversity in animal species, 
types of outcomes, measurement times etcetera. However, in order to be 
able to provide a meaningful answer to a research question like “what is the 
effect of this intervention on weight increase”, a group of studies must be 
sufficiently homogeneous in terms of animals, interventions, designs and 
outcomes. Heterogeneity can be diminished by prospectively defining strict 
in- and exclusion criteria and making only sensible comparisons. It is 
therefore important to conduct a meta-analysis always in collaboration with 
an expert from the field. 
 
On the other hand, if the aim of the meta-analysis was to determine factors 
(study characteristics) which influence the overall effect, especially the 
variation in the effect size is of interest and much more diverse studies may 
be included. In this case, where the focus of the MA is the relation between 
characteristics of the studies and the outcome, a wider diversity between 
studies is appropriate than when the focus is mainly on the summary effect 
across a series of studies. 
 
B. Assemble the relevant study data  
For each outcome of interest, for example weight change, data must be 
gathered for each study and treatment group, like columns 2-7 in the forest 
plot (Figure 2). Most of these can be extracted from the original publications. 
If data were presented only in graphs, they can be measured with digital 
ruler software. When the required data are missing the authors of the study 
should be contacted, which can take some time.  
 
Study results may be expressed on different scales of measurement: counts 
(e.g., number of animals deceased), and mean values with standard 
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deviations (e.g., for weight increase) are most common. Preferably, data per 
group (counts or means and SDs and the total number of animals) are 
gathered for each study. If only medians and ranges or interquartile ranges 
are provided, these must be collected.  If only summary effects are provided, 
e.g. in the form of Odds Ratios with a standard error or CI, these must be 
used. If no more detailed information is available, even only p-values and 
numbers of animals per group, or the direction of the effect size (positive or 
negative) can be useful [16] . 
 
Also, the study design is important. It must be recorded what type of animals 
were used, timing of the measurements, details on the intervention, and 
other study characteristics that may be useful for the interpretation of the 
result. For example, if there are two control groups, including a sham group, 
or if control groups are shared by several experiments, this must be 
recorded. Animals receiving the same intervention are often group housed, 
altering the experimental unit into cage instead of individual animal. 
Furthermore, the animal experiments included in a meta-analysis are often 
not independent: control groups may be shared by two or more experimental 
studies. 
 
C. Choose an effect size measure 
Once the relevant study results are gathered, they may be used in the meta-
analysis. If count data were gathered, you can choose whether you want to 
present the result of the meta-analysis in odds ratios, risk ratios or risk 
differences.  
 
When the study results are continuous, like weight change, the choice is 
between ‘normal’ differences of the group means, standardized mean 
differences, and normalized mean differences. For example, when weight 
changes are measured in different species, the interpretation of an 
intervention effect of 6 g in a study with mice is completely different from 
the same effect in a study with beagles. In such situations standardized 
differences are a useful effect size measure, because they express the 
difference between the groups relative to the standard deviation. For 
instance,  the weight changes of the mice might vary between -5 g and +12 
g, and the SD is 4 g. An increase of 6 g corresponds thus to an increase of 1.5 
SD. However, beagles weight on average 10 to 11 kg, and the individual 
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changes in weights will be much larger than for mice. If the SD of the weight 
changes of beagles is 500 g, the increase of 6 g corresponds to a minor 
change of  0.012 SD. The relevance of the effect is thus much better 
reflected by standardized differences than by the original differences. An 
additional advantage is that the scale in the forest plot automatically 
indicates the relevance of the summary result. This is also clearly shown in 
the forest plot (Figure 2). A normalized mean difference can be used when 
the score of a normal, untreated, unlesioned sham animal is known or can be 
inferred. One of the advantages of this method is that the absolute 
difference in means can be expressed as a proportion of the mean in the 
control group, which might be more easy to interpret [19]. For mean 
differences, standardized and normalized differences the same data must be 
extracted from each study: mean values, SDs and total number of animals 
per group. 
 
When time to a certain event (e.g. death) is the topic of interest, survival 
data must be provided. See Vesterinen et al. [19] for details. 
 
D. Calculate the effect size for each study / study subgroup 
Once all the relevant data are collected and an effect size is chosen, study 
results must be prepared so that they can be used in the meta-analysis. In 
the most simple situation, each study provided separate data for both 
treatment groups; these data can be directly used to calculate effect sizes 
per study. However, from time to time data must be pre-processed, for 
example when median values and ranges or interquartile ranges are reported 
instead of means and SDs. If the data seem sufficiently normally distributed, 
medians and ranges can be used to construct means and SDs [22].  
 
If results of some of the selected studies are not presented per group but 
combined as effect sizes, they can also be used in the meta-analysis. Take 
for example a set of five studies; three studies show weight increase data per 
group (mean, SD and total number of animals), and two studies only present 
the mean difference between the groups with a 95% CI. In this case, the 
result of each study must be transformed into a mean difference with 
corresponding standard error before it can be used in the meta-analysis.  
 
In animal studies often the same control group is used for multiple 
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experimental groups. Sharing a control group makes the comparisons of the 
experimental groups dependent of each other. When such comparisons are 
presented as independent comparisons in a meta-analysis the animals in the 
control group will be counted twice and the comparisons will receive too 
much weight in the estimation of the summary effect. Therefore some 
adjustment must take place. A simple option is to diminish the number of 
animals in the shared control group by splitting the ‘shared’ group into two 
or more groups with smaller sample size [23]. For example, a study with two 
experimental groups sharing a control group with 12 animals results in two 
comparisons, each with six animals in the control group. For advice on other 
complicated situations, see the guidance of Vesterinen et al. [19].
E. Choose a random-effects or fixed-effects meta-analysis model  
Random-effects and fixed-effects models are two statistical approaches 
which are used to combine the study results. They are based on different 
assumptions.  
 
A fixed-effects model assumes that all observed variation between the 
studies is because of chance [24] , and that there exists only one true 
underlying effect. In other words: the variation between the study results is 
only because of variation in sample sizes. This assumption is reflected in the 
calculations of the study weights. Larger studies receive more weight.  
 
A random-effects model allows that the underlying effect size differs 
between studies, thus an effect size can truly be larger or smaller, depending 
on the study characteristics. This heterogeneity is reflected by I2 and was 
discussed above. The assumption that effect sizes truly differ is in general 
not implausible, because studies may have used different doses, routes of 
administration, animals or procedures, or there may be other, unknown 
differences. The random-effects model results in an “average” effect 
estimate, whereas the fixed-effects model results in an estimate of the one, 
true, underling effect [24, 25]. The confidence interval of a random-effects  
estimate will reflect that there is some possible variation in the true study 
effects besides chance alone, and therefore may be wider than that of a 
fixed-effects estimate. The two sources of variance are also taken into 
account in the assigned study weights. 
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F. Whether a fixed-effects or a random-effects model will be used must be 
decided before the meta-analysis is performed, and although one may be 
tempted to look at the level of I2, the decision must be a priori [10] and 
based on substantive arguments, independent of the level or significance of 
I2 [24]. Due to the nature of and diversity in animal studies, random-effects 
models may better reflect reality.  
 
Once the meta-analysis is done, the interpretation of the results should be 
consistent with the model that was chosen. Take for example a fixed-effects 
meta-analysis comparing treatments A and B, that results in a mean 
difference of 1.75 and a 95% CI from 1.5 to 2. Here, 1.75 is the best estimate 
of the common treatment effect, and the CI reflects the uncertainty around 
this estimate. As zero is not in the CI, we can be quite sure that treatment A 
is superior to B. However, if the same numbers are the result of a random-
effects meta-analysis, the interpretation is different. Now, we can be rather 
sure that on average treatment A is superior to B, but the true treatment 
effect may differ between settings. See [24, 25] for more information.
G. Specify subgroups, if applicable 
Sometimes it is expected that the effect size varies across subsets of studies, 
for instance if there are variations between species or between dosages or 
administration routes of an intervention. In other cases we may observe 
heterogeneity in the results of the meta-analysis and want to find an 
explanation. In both situations subgroup analysis or meta-regression may give 
insight in the relation between study characteristics and the effect size. For 
example, our forest plot shows separate subgroups for studies which assessed 
the amount of neuronal cell death in the cortex and in the hippocampus. This 
stratified meta-analysis partitions the heterogeneity and shows that the 
estimated between-study variation is smaller in the subgroups: ů2 in the 
subgroups is 0.38 and 0.56, whereas ů2 in the pooled analysis is larger than 
the sum: 1.27. This suggests that there may be subgroup differences, which 
is confirmed by the test for subgroup differences.  
 
Subgroup analyses play a very important role in meta-analyses of animal 
studies. This is to some extent due to the explorative character of animal 
studies, but also related to the aims of meta-analyses of animal studies. 
Many meta-analyses are especially conducted to investigate which factors 
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influence the effect size. If subgroups significantly differ in the effects, this 
may be an indication not to pool the overall results. It is however important 
to realize that the results of subgroup analyses can be misleading, especially 
if subgroups are not pre-specified. When subgroup analyses are not pre-
specified, the risk on false positive findings, i.e. non-existing relations 
between effect size and study characteristics, increases. Further, subgroup 
analyses are often observational and not based on randomized comparisons 
[26]. In addition, subgroup analyses are often conducted on small numbers of 
studies which impairs the power of the analyses. Therefore, the results 
should be interpreted with caution [27]. Results of subgroups are hypothesis 
generating. 
H. Calculate the summary effect, per subgroup and overall  
In general, the summary effect size is based on the effect sizes and the 
weights of the individual studies. It can be calculated by hand, but there are 
also packages that will perform the calculations and provide forest plots, for 
example RevMan (www.ims.cochrane.org/revman/download), which is free 
software developed by the Cochrane Collaboration. CMA (Comprehensive 
meta-analysis (www.meta-analysis.com)) is not free, but offers simpler data 
entry and more options than RevMan. Stata (StataCorp, College Station, 
Texas) and R (http://www.R-project.org/) also provide meta-analysis 
packages. In case of more complicated designs, like multiple treatment 
groups sharing one control group, or studies with two control groups instead 
of one, it is advisable to consult a statistician. 
 
I. The way the weights of the individual studies are calculated for the overall 
analyses, is dependent of the model (fixed-effects or random-effects) that 
was chosen (step E). In random-effects models, small studies get larger 
weights and are thus relatively more important than in fixed-effects models. 
 
If heterogeneity is the main topic of interest, differences between subgroups 
are of special importance. Subgroup analyses or meta-regression of the 
outcome in relation to study characteristics (e.g. species) can give more 
insight in possible causes of heterogeneity, but should be conducted with 
caution, see point F. 
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If the results of the selected studies are considered too heterogeneous for 
pooling, a comparison between the number of studies with findings in one 
direction, and those with findings in the other direction (irrespective of 
whether or not the findings were significant) can be done with a sign test 
[16]. If pooling of the studies is considered completely inappropriate, no 
combined estimate can be provided.  
 
J. Conduct a sensitivity analysis 
A sensitivity analysis is conducted to assess the robustness of the findings 
from the meta- analysis. Assumptions underlying the initial meta-analysis can 
be challenged by performing another meta-analysis with different 
assumptions. If the results of both meta-analyses are similar, then they seem 
robust. For example, a scientist decided that the duration of an intervention 
might affect the results. Initially, a short intervention was defined as 
between zero and 45 minutes; in the sensitivity analyses the threshold was 
set at 30 minutes. What happens to the results if the threshold is changed? 
When the conclusions of a meta-analysis significantly change, this should be 
discussed.  
 
Also the quality of the primary studies is crucial for the reliability of the 
meta-analysis results and can be assessed with a variety of tools [28, 29]. If 
some of the studies are suspected to present biased results, the meta-
analysis can be performed once without those studies in order to investigate 
the robustness of the combined result.  
 
K. Minimize publication bias 
Reliability of results can also be diminished by unpublished studies or 
unpublished parts of studies. The risk of publication bias can be estimated by 
means of funnel plots [27]. Funnel plots are also provided by standard 
software for meta-analysis. 
 
At the start of the systematic review, a serious attempt to gather all relevant 
study results must be made, in order to minimize possible reporting bias. 
Reporting bias, or publication bias, is the consequence of not all relevant 
data being available. In general, the decision to publish study results may 
depend on the direction of the study results, and negative studies, that are 
often relatively small in sample size are sometimes not published. In case of 
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publication bias, meta-analyses may overestimate the true effect size [30]. 
Publication bias is no less of an issue for animal studies than for human 
studies [31]. 
 
L. Interpretation of results 
A meta-analysis will result in a summary or overall effect with a 95% CI and a 
p-value.  In our forest plot the overall effect was an SMD of -1.71, with a 95% 
CI ranging from -2.66 to -0.77 (arrow C). The pooled estimate -1.71 is an 
average effect, and effects of the original studies will be spread out around 
this average effect. The summary effect of a meta-analysis is expressed as a 
number, for example an OR of 0.6, but in animal studies it is often wiser to 
focus on the direction of the effect than on the size itself. This is in large 
parts due to the unavoidable heterogeneity between animal studies (large 
variation in species, intervention protocols etc) and the explorative nature of 
animal studies compared to clinical research. 
 
The confidence interval contains all likely effect sizes. If a 95% CI for an OR 
ranges from 0.4 to 0.9 this means that the true effect is most likely an OR 
between 0.4 and 0.9. If the 95% CI of an OR contains the value 1 or the 95% 
CI of mean difference contains the value 0, this means that the treatment 
groups are not statistically significantly different at a significance level of 
5%. This is also reflected in a p-value above 0.05. If groups are not 
statistically significantly different, this does not necessarily mean that the 
treatment groups are similar; the only conclusion that can be drawn from the 
meta-analysis is that there is insufficient evidence to prove that the groups 
are different. Note that in general in case of multiple testing the significance 
level should decrease. 
 
Interpretation of the results of subgroup analyses (steps F and G) is even 
more challenging. Subgroups in meta-analyses of animal studies are often 
very small and remain quite heterogeneous as multiple characteristics in 
animal studies vary. Results of subgroup analyses should therefore be used 
to generate rather than test hypotheses. 
 
The forest plot resulted in a p-value of 0.0004 for the overall intervention 
effect. In general, a p-value below 0.05 means that the treatment groups 
are statistically significantly different. However, this does not necessarily 
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mean that the groups are different in a relevant way. It may be that the 
meta-analysis was based on many studies and thus had high power, whereas 
the effect size was only minor. In such a situation the meta-analysis will 
result in a p-value below 0.05, but the difference between the interventions 
may be irrelevant. Therefore not only the p-value but especially knowledge 
on the direction and size of the effect including the 95% CI are essential for 
the interpretation.  
 
Another result of the meta-analysis is the extent of heterogeneity, 
presented with ů2 and  I2, and tested with a chi-squared test. In this paper 
we focus on I2, a reflection of the inconsistency between the effects 
estimated by the individual studies in a meta-analysis. It describes the 
percentage of total variation across studies that is due to heterogeneity 
rather than chance, and lies between 0% and 100%. A value of 0% indicates 
no observed heterogeneity, larger values show increasing heterogeneity 
[10]. When I2 is 40%, for example, this means that 40% of the observed 
variation of the study effects is due to heterogeneity (ů2) and 60% due to 
chance. An I2 value near 100% means that the observed variation of the 
study effects is almost completely due to heterogeneity. The Cochrane 
handbook [26] states that an I2 between 50- 90% might be interpreted as 
substantial heterogeneity. In this case it may be useful to evaluate whether 
some study characteristics may be the reason of this high heterogeneity, in 
order to prevent this in future animal studies.  Note however that when a 
subgroup is found that seems to be the cause of the variation between the 
study results, this should be interpreted with caution.  
 
Finally the strength of the conclusions from the meta-analysis also depends 
on the findings of the sensitivity analysis (H) and the evaluation of possible 
publication bias (I).  
 

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Conclusion 
In this paper we address why meta-analyses of animal studies are a valuable 
addition for science aimed at improving health and healthcare. By conducting a 
meta-analysis of animal experiments, often new and very valuable information 
can be obtained from the already published animal experiments.  In other words, 
the decision not to conduct a  meta-analysis of animal studies may result in a 
waste of information, animals and financial resources.  
 
The steps of a meta-analysis of animal studies are in general comparable to the 
steps taken in a clinical meta analysis, and software designed for clinical meta-
analyses can be used for most of these steps. It is important that only sensible 
comparisons are made in order to reduce the risk on false positive findings and 
diminish heterogeneity. It is therefore important to conduct meta-analysis always 
in collaboration with an expert from the field.  
 
Furthermore, it is very important that each scientist conducting a meta-analysis 
of animal studies realizes that the quality of a meta-analysis is also dependent of 
the quality of the primary studies. Especially if the purpose of the meta-analysis 
is to inform healthcare policy or practice the original research needs to be both 
applicable and of sufficient quality. On the other hand, if the primary studies 
appear to be biased, meta-analyses may provide the empirical evidence for the 
impact of the bias. This might stimulate the use of adequate experimental design 
in future animal studies. As we learned from systematic reviews in the clinical 
field [32], it is to be expected that the methodological quality of animal studies 
will increase as a consequence of conducting systematic reviews. 
 
Briefly summarizing; meta-analyses of animal studies expand the knowledge 
resulting from animal experiments. 
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Abstract 
There is debate whether clinical trials with suboptimal power are justified and 
whether results from large studies are more reliable than the (combined) results 
of smaller trials. We quantified the error rates for evaluations based on single 
conventionally powered trials (80% or 90% power) versus evaluations based on the 
random-effects meta-analysis of series of smaller trials. 
 
When a treatment was assumed to have no effect  but heterogeneity was 
present, the error rates for a single trial were increased more than tenfold above 
the nominal rate, even for low heterogeneity. Conversely, for meta-analyses on 
series of trials, the error rates were correct. 
 
When selective publication was present, the error rates were always increased, 
but they still tended to be lower for series of trials than for single trials. 
 
We conclude that evidence of efficacy based on a series of (smaller) trials, may 
lower the error rates compared with using a single well-powered trial. Only when 
both heterogeneity and selective publication can be excluded, a single trial is 
able to provide conclusive evidence. 

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1. Introduction 
There are conflicting opinions about whether clinical trials that are not 
sufficiently powered (i.e. with power below 80%) are justified. Some authors 
argue that the opportunity to perform such trials makes it easier to initiate and 
complete studies, while subsequent meta-analyses provide information similar to 
that from one large, well-powered study [1, 2]. Other authors object to this 
approach and stipulate that trials should have at least 80% or even 90% power for 
the outcome of interest [3, 4]. They argue that small studies make meta-analyses 
unreliable, mainly because of selective publication [5, 6]. In addition, if there is 
heterogeneity between the trials, meta-analysis is sometimes even avoided, 
leaving uncertainty about the interpretation of the results [7]. However, 
heterogeneity is also mentioned as one of the arguments to conduct several trials 
rather than a single large one, as the series of relatively smaller trials offer the 
opportunity to estimate the level of heterogeneity, which provides an indication 
of the generalizability of the results [8]. When heterogeneity is present, the 
effectiveness of a treatment will vary more than would be suggested by a single 
trial, so it may be premature or even erroneous to draw conclusions based on a 
single trial [4, 8, 9, 10, 11]. 
 
Although those issues have been discussed repeatedly, this has mainly been from 
a conceptual perspective. Here we try to provide more comprehensive evidence 
through a series of simulations. We aim to quantify the pros and cons of different 
approaches for the evaluation of treatments, such as an evaluation based on one 
single conventionally powered trial (80% or 90% power) versus an evaluation 
based on two trials, or on a series of smaller trials, each of which has modest 
power when seen in isolation (30% or 50% power). In particular, we evaluate the 
impact of heterogeneity and selective publication on the error rates and bias in 
the estimated effect sizes. 
 
In sections 2 and 3 we present the extent of heterogeneity and selective 
publication that has been reported during the evaluation of treatments with a 
dichotomous health outcome. These estimates are used in our simulations.  In 
sections 4 to 8 we evaluate the error rates and biases that may result when 
treatments are evaluated through single trials or through a series of trials. 
Finally, section 9 is devoted to the discussion and the conclusions. 
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2. Heterogeneity 
The classical random effects model for a risk ratio meta-analysis assumes that 
trial results follow a distribution with: 
 
      E(Di) = E(log(RRi)) = ši,  ši ~ Normal(š, ů2)     (1) 
  
and  
 
      var(Di | ši ) = Ţi2 and var(ši) = ů2       (2) 
 
where Di = log(RRi) is the observed log-transformed risk ratio in trial i, and š is 
the underlying overall mean of the log-transformed RR.  
 
Usually the treatment effects of studies in a systematic review may differ. But if 
the study effects are more different from each other than one would expect due 
to random error (chance) alone, this additional between-trial variance is called 
heterogeneity. In order to use realistic values in our simulations for the 
heterogeneity  we randomly selected 202 meta-analysis reports that compared 
two treatments by means of a dichotomous outcome variable from reviews of the 
Cochrane data base (25 August 2010). Our findings were similar to earlier 
reports: approximately  half (51%) of the  selected reviews had a point estimate 
for the between trial variance ů2  equal to 0, in a similar range as previously 
reported percentages of 49% [12] and 37% [13].  
 
In our selected reviews, 26% had an estimated ů2  between 0 and 0.05, whereas 
11% of the series had an estimated ů2  between 0.05 and 0.15. The remaining 12% 
had heterogeneity up to 0.88. Based on these figures, we choose heterogeneity 
levels of 0, 0.05 and 0.15 for our simulations. As an illustration of a worst case 
scenario we also included heterogeneity of 0.8.  
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3.  Selective Publication 
Ross et al. investigated the publication rates for a cross section of trials that had 
been registered at ClinicalTrials.gov after December 31, 1999 [14]. They found 
that by June 2007, 61% of trials with a reported end date before 2004 had been 
published. For trials with an end date in 2004 or in 2005, 52% and 42% had been 
reported, respectively. The authors found no major difference between small 
studies with less than 160 participants and larger studies (43% and 46%, 
respectively). However, it is possible that non-registered trials may be more 
likely to remain unpublished and smaller trials may be less likely to be registered 
than large trials. Based on a review of trials supporting new drugs approved by 
the FDA, Lee et al. did report a relation between publication rates and sample 
sizes above 135 participants [15]. Nevertheless, a relationship between trial size 
and publication rates was not found in three other empirical studies summarized 
in a review by Hopewell et al. [16]. 
 
Trials with negative or null findings are clearly less likely to be published than 
trials with positive findings. Dwan et al. have reviewed a series of articles that 
have assessed publication rates of randomised controlled trials [17]. The 
percentages of published trials that the articles reported varied between 21% and 
93%, with a median of 49%. The differences in publication rates between trials 
with and without a statistically significant outcome varied between 10% and 39%, 
with median 26%. Although some articles in the review were more recent than 
others, no strong trend was found. Recent articles that were not included in the 
review reported similar findings [15, 16, 18, 19]. 
 
4.  Analysis method 
We evaluated the error rates and bias that resulted from analyses of single trials 
and analyses of series of trials. We used the risk ratio (RR) as the metric of 
choice. When two or more studies were available for analysis, a random effects 
meta-analysis was carried out. 
 
The commonly used method for random effects meta-analysis is the approach 
according to DerSimonian and Laird [20]. However, we used the method 
described by Sidik and Jonkman [21]. It is a simple approach that is similar to the 
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DerSimonian and Laird method, but it better preserves the error rates when the 
number of studies is small [21, 22, 23]. 
5. The error rates and bias of a series of trials: methods 
Presence of between-trial variance and selective publication can lead to inflated 
error rates and bias in the results of the statistical analysis. In order to 
investigate its magnitude we simulated series of trials with a RR outcome under 
different degrees of heterogeneity and selective publication. The results of the 
subsequent analyses were used to evaluate the false positive error rates and the 
estimation bias. 
 
False positive error rates and estimation bias 
Selective publication ‘favours’ positive results, so it increases the false positive 
(FP) error rates. In addition, false positive error rates may often be more 
relevant than false negative rates (e.g. the consequences of adopting a non-
effective treatment may be grave in terms of cost, potential toxicity, etc; while 
non-adopting a potentially effective treatment may not be as detrimental, 
especially when other effective treatments are also available) . Therefore, we 
focus on changes in the one-sided FP rates, calculated conditionally on H0, i.e. 
the underlying average RR being 1: 
      	 ൌ ୒୭୭୤ୱୣ୰୧ୣୱ୵୧୲୦୮୭ୱ୧୲୧୴ୣୟ୬ୟ୪୷ୱ୧ୱ୭୤୮୳ୠ୪୧ୱ୦ୣୢ୲୰୧ୟ୪ୱȁୖୖୀଵ୒୭୭୤ୱ୧୫୳୪ୟ୲ୣୢୱୣ୰୧ୣୱ    (3) 
 
Here, a positive analysis is defined as an analysis with a one-sided statistically 
significant result (P<0.025) in favour of the treatment under investigation (and 
for single trials also a more stringent criterion: P<0.0005). FP rates reflect the 
percentage of inefficacious treatments that result in a positive analysis.  
 
In order to evaluate the bias, i.e. the effect of heterogeneity and selective 
publication on the final treatment estimate, we present the (geometric) mean of 
the estimated RR (MERR): 
 
      MERR  = exp(mean of log risk ratios of all analyses of published trials).   (4) 
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In absence of bias, the MERR should be equal to the RR used to generate the 
simulation data. The bias is the difference between the MERR and the RR used to 
generate the simulation data (RRtrue).
 
Trial and series characteristics 
We simulated series of trials with an RR outcome under different degrees of 
heterogeneity and selective publication. Also the power, the risk in the control 
group and the number of trials in the series were varied. For each scenario, i.e. 
combination of these parameters we simulated 30,000 series of trials with RRtrue 
=1 for the evaluation of the error rates, and 10,000 series with RRtrue=0.5 and 
RRtrue =0.8, corresponding to a large and modest treatment effect, respectively, 
for the evaluation of the estimation bias. Based on predefined publication rates, 
the simulation algorithm randomly selected which trials in a series were 
'published', i.e. available for analysis, and which were not. On the available trials 
an analysis was performed. 
 
A series of trials consisted of 1, 2, 3, 5, 10 or 20 trials. Between the series, the 
risk in the control group p0 was varied from 0.1 to 0.9, in steps of 0.2. The 
control risks varied between the trials in a series, but remained within a range of 
± p0/2 around the series risk p0 (or around 1-p0 when p0 was larger than 0.5); for 
example, with a series risk of 0.3, the trial control risk varied between 0.15 and 
0.45, with 0.7, the trial control risk varied between 0.55 and 0.85. Trial sizes 
were based on 30%, 50%, 80%, or 90% power, the series control risk p0 and an 
assumed risk ratio RRpower of either 0.5 or 0.8, respectively. The two-sided 
significance level used was 0.05. In the main simulations, each series consisted of 
trials with equal power.  
 
Heterogeneity 
For each combination of power, number of trials in the series, series risk p0 and 
RRpower we generated a series of trials with a risk ratio RRtrue equal to RRpower, i.e. 
0.5 or 0.8 (alternative hypotheses) or RRtrue  equal  to 1 (null hypothesis). 
Heterogeneity was superimposed as described in equation (1): the log-
transformed risk ratios of each trial were normally distributed around š, i.e. 
log(RRtrue), with ů2  equal to 0, 0.05, 0.15 or 0.8.   
 
  
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Selective publication 
The publication rates of trials with a positive statistically significant result (PRS) 
were set at 50%, 70%, 90%, or 100%.  In a series, the publication rate of non-
significant results (PRNS) was set to be 0% (no selective publication), 10%, 20%, 
or 30% smaller than the PRS for that series. 
 
Series of trials with mixed power and power-related selective publication 
Although there was no definitive published evidence for a relationship between 
trial size and selective publication (see section 3), there may be a relationship 
between the power of a trial and its probability of publication. Therefore, we 
executed a limited number of simulations for series with trials of mixed power 
where the publication rates were lower for the modestly powered trials. We 
simulated series of 5, 10 and 20 trials, and assumed that 80% of these trials were 
modestly powered (power 30%) and 20% conventionally powered (power 80%). 
The difference between publication rates for significant and non-significant 
findings šPR was set as follows: for trials with 30% power we assumed publication 
rates of 60% and 30%, and for trials with 80% power we assumed 90% and 80% 
publication rates for significant and non-significant results, respectively.  
 
6. Error rates and bias of single trials when there is no 
selective publication 
Table 1 and 2 show the FP rates for single trials when there is no selective 
publication. For each combination of between-trial variability ů2 and power Table 
1 presents the minimum and maximum error rate over all simulated control risks 
p0 for a two-sided significance level Ş=0.05 (P<0.025). Table 2 shows in a similar 
way the FP rates for a more stringent criterion: Ş=0.001. Note that we evaluate 
the FP rates corresponding to the null hypothesis that the average treatment 
effect š is 0 (corresponding to RR=1, equation (1)). However, in case of 
treatment heterogeneity, an average treatment effect of zero (š=0) allows that 
some of the trials have a truly non-null treatment effect. Trial i may have been 
conducted in a population or under conditions that led to a true effect ši. The 
standard analysis of trial i tests the within-trial null hypothesis ši=0 based on the 
within trial variance ei
2. But, in order to test a nonzero average effect for 
š=E(ši), not only the within trial variance ei2 but also the between-trial variance 
ů2  should be taken into consideration. 
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Table 1 FP rates and RR estimates of single trials when there was no selective 
publication. 
       ů2 Power (%) FP rates (%) RR estimates 
  RRpower=0.5 RRpower=0.8 RRpower=0.5 RRpower=0.8 
   RRtrue =1 RRtrue =1 RRtrue=0.5 RRtrue =0.8 
 0.00 30 2.7-3.2 2.6-2.7 0.49-0.50 0.80-0.80 
  50 2.6-2.9 2.6-2.7 0.49-0.50 0.80-0.80 
  80 2.6-2.7 2.6-2.7 0.50-0.50 0.80-0.80 
  90 2.6-2.7 2.6-2.7 0.50-0.50 0.80-0.80 
       
 0.05 30 4.7-15.1 14.1-22.9 0.49-0.50 0.80-0.81 
  50 6.3-18.3 19.7-27.2 0.50-0.51 0.80-0.81 
  80 9.6-22.9 26.1-33.0 0.50-0.51 0.80-0.81 
  90 11.6-24.5 28.7-35.1 0.50-0.50 0.80-0.81 
       
 0.15 30 8.6-24.8 23.9-32.3 0.50-0.51 0.81-0.81 
  50 12.3-28.3 29.6-35.9 0.50-0.51 0.80-0.81 
  80 18.3-32.3 35.0-39.9 0.50-0.51 0.80-0.81 
  90 21.0-33.7 37.0-41.3 0.50-0.51 0.80-0.81 
       
 0.80 30 21.9-37.8 37.3-41.8 0.51-0.52 0.82-0.83 
  50 27.0-39.9 40.6-43.9 0.51-0.52 0.81-0.83 
  80 33.1-41.8 43.3-45.7 0.51-0.52 0.81-0.83 
  90 35.0-42.6 44.3-46.4 0.51-0.51 0.81-0.82 
FP: False-positive; RR: risk ratio. 
FP rates: Minimum and maximum FP rates over all control risks p0; RRpower: the risk ratio 
used for the power calculation; RRtrue: the risk ratio used in the simulations. 
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Table 2 FP rates (%) of single trials when there was no selective publication and a 
stringent significance level (Ş =0.001, power based on Ş = 0.05 and 0.001). 
ů2 Power RRpower = 0.5 RRpower = 0.8 
 (%) Powered on  
Ş=0.05 
Powered on 
Ş=0.001 
Powered on  
Ş=0.05 
Powered on  
Ş=0.001 
0.00 30 0.1-0.3 0.1-0.1 0.1-0.1 0.1-0.1 
 50 0.1-0.2 0.1-0.1 0.1-0.1 0.1-0.1 
 80 0.1-0.1 0.1-0.1 0.1-0.1 0.1-0.1 
 90 0.1-0.1 0.1-0.1 0.1-0.1 0.1-0.1 
      
0.05 30 0.3-4.6 1.6-11.1 3.7-11.1 14.5-23.1 
 50 0.6-6.8 2.5-14.5 7.9-15.8 18.0-26.1 
 80 1.6-11.1 4.6-18.2 14.7-23.1 22.6-30.3 
 90 2.4-12.8 5.8-20.2 17.7-26.1 24.7-31.9 
      
0.15 30 1.2-13.3 6.6-22.3 12.1-22.3 25.7-33.2 
 50 2.7-17.2 9.4-25.8 18.7-27.2 29.0-35.4 
 80 6.7-22.3 13.9-29.2 25.9-33.2 32.8-38.2 
 90 9.1-24.1 15.9-30.8 28.7-35.4 34.4-39.2 
      
0.80 30 9.9-30.0 22.9-36.6 29.2-36.6 38.8-42.7 
 50 15.8-33.3 26.4-38.7 34.4-39.6 40.5-43.8 
 80 23.1-36.6 30.6-40.7 39.0-42.7 42.3-44.8 
 90 26.0-37.7 32.4-41.4 40.4-43.8 43.1-45.1 
FP: False-positive; RR: risk ratio. 
FP rates: Minimum and maximum FP rates over all control risks p0; RRpower: the risk ratio 
used for the power calculation, with RRtrue (the risk ratio used in the simulations) equal 
to 1. 
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As an illustration, the solid curve in Figure 1 shows the probability density 
function for trial result Di under H0: ši =0, transformed into a standard normal 
density function by division through the root of the within-trial variance, 
neglecting the heterogeneity. The dotted line shows a similar curve, but based 
on the total variance, including heterogeneity. It is clear that the part of the 
latter curve that exceeds 1.96 is much larger than 2.5%. When the analysis of a 
single trial is based on a within trial test ši=0, it is straightforward to show that 
the FP rate of the overall test š= 0 is: 
     -1 2 2 2i iFP rate=1-ĭ ( ĭ (1-Į/2) İ (Ĳ +İ ) )      (6) 
where Ş is the two-sided significance level and Ŕ is the standard normal 
cumulative distribution function [10, 11]. Results from this formula and the 
simulations for the risk ratio presented in Table 1 and 2 are approximately 
similar. Higher powered studies produce lower values for Ţi2  and therefore, in 
combination with heterogeneity, lead to higher FP rates. As shown in Table 2, 
the FP rates when a study is powered for Ş =0.001 instead of 0.05 are even 
higher, especially when power is high. In general the FP rates powered for Ş 
=0.001 and a power of 50% are in the same range as FP rates powered for Ş =0.05 
and a power of 90%. The high error rates illustrate that when heterogeneity is 
present, the result of a single trial is not suitable to draw conclusions on the 
overall mean treatment difference š. As expected, Table 1 also shows there was 
no bias in the RR estimates, since no selective publication was present.  
 
Figure 1. Probability density functions. Solid line based on trial-based (Ţi2) 
variance, dotted line based on real (Ţi2+ů2) variance needed to test the average 
treatment effect.
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7. Error rates and bias  
In current practice, the evaluation of a treatment can be based on a series of 
trials but also on one single study. This single study may be the only one that was 
conducted, but it might also be the only one out of a series of studies that was 
published. Take for example 100 series of two studies. With a publication rate of 
80%, only 64 out of the 100 analyses will be based on both studies. In 32 cases, 
only one study will be available.  
 
When there is no selective publication, the FP rates of series of trials were 
approximately 2.5% and there was no bias (results not shown).  
 
FP rates and bias resulting from a setting with selective publication are 
presented in Table 3 and 4. When there was no heterogeneity, the RR estimates 
were biased, but FP rates were approximately 2.5% (Table 3). Table 4 shows FP 
rates and bias when there was heterogeneity. From some series, as a result of 
the selective publication, only one study was available for analysis and since the 
error rates of single studies are high (previous section), this resulted in markedly 
inflated error rates. Series of two trials, having a higher risk to result in only one 
available study than larger series, produced the highest error rates. When the 
number of trials in the series increased, the error rates decreased. The 
estimation bias was influenced by the selective publication and by the degree of 
heterogeneity. 
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Table 3  FP rates and RR estimates when there was selective publication but  
no heterogeneity. 
Selective publication N  FP rates (%) RR estimates 
šPR PRS PRNS  RRpower=0.5 RRpower=0.8 RRpower=0.5 RRpower=0.8 
(%) (%) (%)  RRtrue =1 RRtrue =1 RRtrue=0.5 RRtrue =0.8 
10 90 80   2 2.5-2.8 2.4-2.8 0.49-0.50 0.79-0.80 
   10 2.5-3.1 2.5-2.8 0.49-0.50 0.79-0.80 
 50 40   2 1.9-2.4 1.9-2.1 0.47-0.49 0.78-0.80 
   10 2.4-2.9 2.4-2.7 0.48-0.49 0.79-0.80 
20 90 70   2 2.5-3.0 2.4-2.9 0.48-0.50 0.79-0.80 
   10 2.5-3.1 2.5-2.8 0.48-0.50 0.79-0.80 
 50 30   2 2.0-2.6 2.0-2.2 0.44-0.49 0.77-0.79 
   10 2.5-3.1 2.5-2.8 0.45-0.49 0.77-0.80 
30 90 60   2 2.6-3.3 2.5-3.0 0.47-0.49 0.78-0.80 
   10 2.5-3.1 2.5-2.8 0.47-0.49 0.78-0.80 
 50 20   2 2.2-2.7 2.2-2.3 0.41-0.49 0.75-0.79 
   10 3.2-3.9 3.2-3.5 0.42-0.49 0.75-0.79 
FP: False-positive; RR: risk ratio; PRS: publication rate for significant results; PRNS: 
publication rate for not-significant results; N: number of conducted trials in each series. 
FP rates: Minimum and maximum FP rates over all control risks p0; RR estimates: mean 
estimated risk ratio; RRpower: the risk ratio used for the power calculation; RRtrue: the risk 
ratio used in the simulations; šPR=PRS-PRNS. 
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8.  The error rates and bias when an ‘at least two trials’ 
approach is used  
In the previous section we saw that false-positive error rates can be considerable 
when any statistically significant evidence (based on single studies or on series of 
more trials) is accepted as evidence of efficacy. Another policy would be to 
accept evidence of efficacy only if it is based on at least two available trials: an 
‘at least two trials’ approach [24, 25]. If the literature search that precedes the 
planned meta-analysis would result in identifying only one trial, this policy leads 
to the conclusion that no sufficient evidence for efficacy is available, whatever 
the outcome of that trial, and one wants to wait for at least two trials to become 
available. To investigate the FP rates and bias from this ‘at least two trials’ 
policy, we simulated the situation that only analyses on at least two published 
studies could provide conclusive evidence of efficacy. In the absence of selective 
publication, the FP rates were approximately 2.5% and there was no bias (results 
not shown). 
 
When selective publication was present, the error rates were increased and 
treatment effects were overestimated (too low estimates of the risk ratios), see 
Table 5. The impact of the selective publication mainly depended on the 
heterogeneity and the absolute difference šPR between the publication rates for 
significant and not-significant studies. Therefore, we used these to summarize 
the results. Each row in Table 5 corresponds to a certain degree of selective 
publication and heterogeneity, and shows the ranges of the error rates and the 
bias, taken over all values of p0 and series of 2, 3, 5, 10 or 20 trials, each with 
30%, 50%, 80% and 90% power.  
 
The error rates and bias increased when ů2 or šPR increased. Yet, when both the 
publication rates for significant and non-significant studies were high, the 
increase in error rates and bias was less extreme than when those rates were 
low.  
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When selective publication is present, FP rates will inevitably be inflated and 
treatment estimates will be biased. However, when šPR was 10% or less, the FP 
rates remained below 5% and the bias remained below 15% (Table 5). When the 
difference between PRS and PRNS increased beyond 10%, the error rates more 
than quadrupled, up to a maximum of approximately 16%. Nevertheless, even 
when šPR for the series was 60% (data not shown), they were below the error 
rates for single trials without selective publication (Tables 1 and 2). In the 
scenarios with high heterogeneity (ů2 of 0.8) and selective publication 
(publication rates of 50% and 20% for the statistically significant and non-
significant trials, respectively), the estimation bias increased up to 33%. Overall, 
a two-trial policy notably reduced the FP rates, whereas the estimation biases 
remained similar (Tables 3 -5). 
   
For series that consisted of a mix of modestly powered (30% to 50%) and 
conventionally powered (80% or 90%) trials, the FP rates were in between those 
of series of trials with only modestly and only conventionally powered studies 
(results not shown). 
 
Finally, yet another approach would be to have an ‘at least three trials’ 
criterion, i.e. to require that evidence of efficacy should be based on at least 
three published studies. We also investigated the consequences of this policy and 
found results that were largely similar to the ‘at least two trials’ policy. 
 
  
Chapter 3 
 
 
54 
Table 5 FP rates and RR estimates of a two-trial policy, when there was  
publication bias. 
ů2 Selective publication FP rates (%) RR estimates 
 šPR PRS PRNS RRpower=0.5 RRpower=0.8 RRpower=0.5 RRpower=0.8 
 (%) (%) (%) RRtrue =1 RRtrue =1 RRtrue=0.5 RRtrue =0.8 
        
0.00 10 90 80 1.6-3.3 1.5-2.8 0.49-0.50 0.79-0.80 
  70 60 0.8-3.2 0.8-2.8 0.48-0.50 0.79-0.80 
  50 40 0.4-3.2 0.4-2.8 0.46-0.50 0.78-0.80 
 20 90 70 1.2-3.4 1.1-2.9 0.48-0.50 0.79-0.80 
  70 50 0.6-3.5 0.5-3.1 0.47-0.50 0.78-0.80 
  50 30 0.2-3.3 0.2-2.8 0.43-0.49 0.76-0.80 
 30 90 60 0.9-3.6 0.8-3.0 0.46-0.49 0.78-0.80 
  70 40 0.4-3.7 0.4-3.1 0.44-0.49 0.77-0.80 
  50 20 0.1-3.2 0.1-2.8 0.41-0.49 0.75-0.79 
        
0.05 10 90 80 1.7-3.5 1.7-3.7 0.49-0.50 0.79-0.79 
  70 60 1.0-3.7 1.0-3.9 0.48-0.50 0.79-0.79 
  50 40 0.4-4.0 0.4-4.5 0.46-0.49 0.77-0.78 
 20 90 70 1.4-5.0 1.4-5.7 0.47-0.49 0.78-0.79 
  70 50 0.6-5.5 0.8-6.4 0.46-0.49 0.76-0.78 
  50 30 0.2-6.3 0.3-8.0 0.42-0.48 0.74-0.77 
 30 90 60 1.1-7.0 1.3-8.4 0.46-0.49 0.76-0.78 
  70 40 0.4-8.3 0.6-10.2 0.44-0.48 0.75-0.77 
  50 20 0.1-10.8 0.3-14.8 0.40-0.47 0.71-0.75 
        
0.15 10 90 80 1.7-3.8 1.8-3.9 0.48-0.49 0.78-0.79 
  70 60 1.0-4.0 1.0-4.1 0.48-0.49 0.78-0.79 
  50 40 0.4-4.3 0.5-4.6 0.46-0.48 0.76-0.77 
 20 90 70 1.4-5.6 1.6-5.9 0.47-0.48 0.76-0.77 
  70 50 0.8-6.4 0.9-6.8 0.46-0.48 0.74-0.76 
  50 30 0.3-7.7 0.5-8.5 0.41-0.47 0.72-0.74 
 30 90 60 1.1-8.3 1.5-8.8 0.45-0.48 0.74-0.76 
  70 40 0.5-10.1 0.8-11.1 0.43-0.47 0.71-0.74 
  50 20 0.2-14.0 0.4-16.0 0.38-0.45 0.67-0.71 
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Table 5 (cont.) FP rates and RR estimates of a two-trial policy, when there was 
publication bias. 
ů2 Selective publication FP rates (%) RR estimates 
 šPR PRS PRNS RRpower=0.5 RRpower=0.8 RRpower=0.5 RRpower=0.8 
 (%) (%) (%) RRtrue =1 RRtrue =1 RRtrue=0.5 RRtrue =0.8 
        
0.80 10 90 80 1.9-3.9 1.9-3.9 0.47-0.48 0.75-0.77 
  70 60 1.1-4.2 1.1-4.3 0.46-0.48 0.75-0.77 
  50 40 0.5-4.6 0.6-4.8 0.44-0.47 0.72-0.74 
 20 90 70 1.6-6.0 1.9-6.1 0.45-0.46 0.72-0.74 
  70 50 1.0-6.8 1.1-7.0 0.43-0.45 0.68-0.72 
  50 30 0.5-8.6 0.5-8.8 0.39-0.42 0.64-0.67 
 30 90 60 1.5-9.1 1.9-9.3 0.42-0.44 0.68-0.70 
  70 40 0.8-11.0 1.1-11.5 0.39-0.42 0.63-0.66 
  50 20 0.4-15.9 0.5-16.4 0.33-0.38 0.56-0.60 
FP: False-positive; RR: risk ratio. 
FP rates: Minimum and maximum FP rates over all control risks p0; RR estimates: mean 
estimated risk ratio; RRpower: the risk ratio used for the power calculation; RRtrue: the risk 
ratio used in the simulations; PRS: publication rate for significant results; PRNS: publication 
rate for not-significant results; šPR=PRS-PRNS. 

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9. Discussion and conclusion 
Robustness of the results of a single trial 
In general, proof of efficacy of a treatment can be based on the results of a 
single study, or on a series of studies. As we discussed before, proof based on a 
single study is often considered preferable over evidence from a series of trials. 
However, when heterogeneity is present and only one trial has been carried out, 
the FP rates may be very high, even if no selective publication is present, and 
even if the heterogeneity ů2 is only 0.05 (Tables 1 and 2).  
It has been suggested that a single well-planned large trial is the best way to 
evaluate the efficacy of a treatment [26-28]. Such a trial should have a detailed 
protocol and be executed according to the highest standards. Besides having 
sufficient power, the inclusion criteria, treatments and endpoints of the trial 
should also reflect clinical practice [29, 30]. From our findings, we conclude 
differently; in general, a single large trial may not be a suitable way to evaluate 
a treatment. This is in accordance with authors who showed that in some cases 
the results of large trials have been challenged and refuted over the course of 
time [2, 8, 31]. Our conclusion supports the FDA and EMA guidance that in 
therapeutic areas which are known for their variation in study results or in which 
seemingly convincing results could not be confirmed by subsequent studies, it 
would be better not to draw conclusions from a single study, even if it is large 
[24, 25]. A single trial, even if it is very significant, may only be sufficient when 
the results of previous trials in a specific therapeutic area were fairly robust and 
when variations in the treatment effects and patient populations were of minor 
importance [29, 30, 32]. However, even in this situation a single trial may have 
its drawbacks, because the trial may be biased by the way it is actually 
conducted or reported [6, 17, 33]. The latter may not be clear from the 
publication and may go unnoticed in one trial. In a series of studies, it is less 
likely that all studies will suffer from the same type of bias; consequently their 
composite picture may be more informative than the result of a single large trial. 
 
Robustness of the results of systematic reviews 
In the absence of selective publication the FP rates of systematic reviews are 
much lower than those of single trials. However, Table 3 shows that the error 
rates of systematic reviews may be very high when there is selective publication. 
Even if the difference between the PRS and the PRNS is only 10%, the FP rate 
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may exceed 10%. Clearly, the error rates may be considerable when single 
studies as well as series of trials are accepted as evidence of efficacy. 
 
Robustness of systematic reviews with an ‘at least two trials’ policy  
Another policy would be to accept evidence of efficacy only if it is based on at 
least two trials. If the literature search that precedes the planned meta-analysis 
or review, results in only one trial, this policy leads to the conclusion that no 
sufficient evidence for efficacy is available, whatever the outcome of that trial.  
When selective publication can be excluded, our results suggest that this 
approach leads to correct error rates and no bias. But even when selective 
publication was strong, the error rates of series of at least two published trials 
were lower than those of single trials without selective publication (Tables 5, 1 
and 2, respectively). However, even for a series of at least two available trials, a 
difference of more than 10% between the publication rates for significant and 
not-significant trials resulted in a substantial increase in FP rates and bias. 
 
Robustness of an ‘at least three trials’ policy 
The robustness of the evidence provided by at least three published trials was 
similar (results not shown). However, adoption of a higher number of trials policy 
may still be preferable, because the trials are more likely to reflect local 
variability, and the effects of potential biases in any of the trials may be diluted, 
unless the biases are pervasive and affect many (or, even worst, all) trials. For 
example, this situation may apply when the entire clinical research agenda is 
designed by the same team or investigator and all trials are almost perfect 
replicas of each other. 
 
Robustness of the evidence provided by a heterogeneity-sensitive-trial 
An alternative approach may be to conduct a heterogeneity-sensitive-trial [8] i.e. 
a trial that produces realistic results that reflect variations in clinical practice. 
The trial procedures have to be sufficiently loose and the protocol must grant 
great freedom to the investigators [2, 30, 32]. In addition, the heterogeneity 
between the centres should be taken into account in the analysis; therefore the 
trial should be analyzed using a random treatment effects approach, as if it were 
a meta-analysis of a series of smaller trials, one in each centre.  
Still, the heterogeneity in such a heterogeneity-sensitive trial may be limited, 
since all centres use the same protocol, follow the same procedures, share the 
same steering committee, etc. The effect of variations in clinical practice may 
Chapter 3 
 
 
58 
therefore be underestimated. Shrier provides an extensive discussion of the 
advantages and disadvantages of a heterogeneity-sensitive trial versus multiple 
smaller trials [8]. 
 
Prospectively defined trial series and meta-analysis 
An approach similar to the heterogeneity-sensitive trial is to organize a series of 
individual trials with a pre-specified prospective meta-analysis [5], possibly 
under supervision of a Research Network. Examples can be found in the pre-
planned meta-analyses by the FICSIT group [34] and the Carotid Stenting Trialists' 
Collaboration [35]. Prospectively planned trials series may be easier to organize 
and may even reflect variations in clinical practice more accurately than 
heterogeneity-sensitive trials [36]. For most new interventions, especially drug 
treatments, it is very common to have a large agenda of multiple trials being 
conducted anyhow [37]. Meta-analyses on the resulting data should preferably be 
planned a priori [37]. 
 
Poor and modestly powered trials  
Here we have explored modestly powered trials (those with power of 30% to 
50%).  Modestly powered trials have the advantage that they are relatively small 
and therefore easier to organise. However, selective publication may be an issue. 
Some recent publications do not reveal a relationship between size and selective 
publication [14, 19], however, others do [15]. It may be prudent to refrain from 
conducting trials with minimal power. When a trial has at least 30% power, as in 
this paper, its size will be approximately a quarter of the size of a trial with 80% 
power. When the power is 50%, its size is half the size of a trial with 80% power. 
When the differences between trial sizes are of this magnitude, the magnitude of 
the selective publication may not be relevantly different. 
 
Another issue that may play a role is the quality of the studies. Studies with low 
power are relatively smaller and the observation that smaller trials are 
sometimes of poorer quality is another potential reason to discourage them [1]. 
However, as the size of trials with 30% or 50% is not dramatically less than the 
size of trials with 80% power, the quality of the former should not necessarily be 
lower than that of trials with 80% power. In addition, the problem of low quality 
trials may become less serious in the future due to increasing regulations and 
codes for proper procedures and trial conduct (GCP, CONSORT [38], trial 
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registration). We agree with Schulz et al. that measures to improve quality are 
more worthwhile than putting emphasis on high power [1]. 
 
Limitations 
Our study has some limitations. First of all, we restricted ourselves to the risk 
ratio metric. Although this limits the scope of our findings, the findings are 
relevant because systematic reviews with risk ratio as primary outcome are very 
common in phase III, when conclusive evidence is sought. Borm et al. provided 
results for a continuous outcome [10, 11]. Furthermore, our simulations are a 
simplification of the real situation. For example, we have not taken into 
consideration the effect of updating meta-analyses on the error rates and bias 
[39]. Neither have we considered ‘opportunistic’ strategies, for example when it 
is decided to change strategy and to do an unplanned second large trial, when 
the first one was not wholly decisive. In addition, we used a standard random 
effects model, assuming equal heterogeneity for small and large trials. However, 
heterogeneity might  different between large and small trials, possibly due to the 
involvement of a higher number of study centres, better design or more rigid 
quality requirements of the larger trials. In that case, a standard random effects 
model might be too simple. Moreover, we focused on power and FP rates, but in 
some circumstances it is possible false-negatives may also be important to 
consider, e.g. if there is no other treatment available about a medical condition 
and thus falsely dismissing an effective treatment would be an unfortunate 
choice. Finally, we focused on a scenario where a trial is judged on a single 
efficacy outcome assessment, but sometimes many efficacy and harm outcomes 
may be important to consider as well. 
 
Conclusions 
When evidence of efficacy is based on at least two published trials, the error 
rates are substantially lower than for evidence based on a single large trial, even 
when selective publication is substantial. Therefore, the evaluation of a 
treatment should preferably be through a series of trials. For these trials, 30% 
power may be sufficient. Only when both heterogeneity and selective publication 
can be safely excluded, a single trial is able to provide conclusive evidence of 
efficacy of a treatment. 
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Abstract
Background 
The DerSimonian and Laird approach (DL) is widely used for random effects 
meta-analysis, but this often results in inappropriate type I error rates. The 
method described by Hartung, Knapp, Sidik and Jonkman (HKSJ) is known to 
perform better when trials of similar size are combined. However evidence in 
realistic situations, where one trial might be much larger than the other trials, is 
lacking. We aimed to evaluate the relative performance of the DL and HKSJ 
methods when studies of different sizes are combined and to develop a simple 
method to convert DL results to HKSJ results. 
Methods 
We evaluated the performance of the HKSJ versus DL approach in simulated 
meta-analyses of 2–20 trials with varying sample sizes and between-study 
heterogeneity, and allowing trials to have various sizes, e.g. 25% of the trials 
being 10-times larger than the smaller trials. We also compared the number of 
“positive” (statistically significant at p < 0.05) findings using empirical data of 
recent meta-analyses with  3 studies of interventions from the Cochrane 
Database of Systematic Reviews. 
Results 
The simulations showed that the HKSJ method consistently resulted in more 
adequate error rates than the DL method. When the significance level was 5%, 
the HKSJ error rates at most doubled, whereas for DL they could be over 30%. DL, 
and, far less so, HKSJ had more inflated error rates when the combined studies 
had unequal sizes and between-study heterogeneity. The empirical data from 689 
meta-analyses showed that 25.1% of the significant findings for the DL method 
were non-significant with the HKSJ method. DL results can be easily converted 
into HKSJ results. 
Conclusions
Our simulations showed that the HKSJ method consistently results in more 
adequate error rates than the DL method, especially when the number of studies 
is small, and can easily be applied routinely in meta-analyses. Even with the 
HKSJ method, extra caution is needed when there are  5 studies of very unequal 
sizes.  
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Background
The commonly used method for a random effects meta-analysis is the 
DerSimonian and Laird approach (DL method) [1]. It is used by popular statistical 
programs for meta-analysis, such as Review Manager (RevMan [2]) and 
Comprehensive Meta-analysis [3]. However, it is well known that the method is 
suboptimal and may lead to too many statistically significant results when the 
number of studies is small and there is moderate or substantial heterogeneity [4-
10]. If a treatment is inefficacious and testing is done at a significance level of 
0.05, the error rate should be 5%, i.e. only one in 20 tests should result in a 
statistically significant result. For the DL method, the error rate can be 
substantially higher, unless the number of studies is large (ب 20) and there is no 
or only minimal heterogeneity [4-10]. 
 
Given this deficiency, alternative methods for random effects meta-analysis have 
been proposed. In particular, the method described by Hartung and Knapp [4-6] 
and by Sidik and Jonkman [11,12] (HKSJ method) is claimed to be simple and 
robust [13]. Simulations have shown that the HKSJ method performs better than 
DL, especially when there is heterogeneity and the number of studies in the 
meta-analysis is small [4-14]. This means that for most meta-analyses the HKSJ 
method might be more appropriate than the conventional DL method. In a 
sample of 22453 meta-analyses, Davey et al. show that the number of studies in 
a meta-analysis is often relatively small, with a median of 3 studies (Q1-Q3: 2–6), 
and only 1% of meta-analyses containing 28 studies or more [15]. Some 
detectable heterogeneity is present in about half of meta-analyses of clinical 
studies [15-18]. 
 
Based on earlier results that showed that the results of a single large trial were 
unreliable [19], we hypothesized that the meta-analyses methods, including 
HKSJ, would perform less adequately when the meta-analysis is carried out on a 
mixture of very unequal-sized studies, e.g. one large and several small trials. 
Such a situation is not uncommon. In a random sample of 186 systematic reviews 
of the Cochrane Database [18] the ratio between large and small trial sizes 
ranged between 1 and 1650, with a median of 5 and an interquartile range from 
3 to 10. Sixty per cent of the reviews contained no large trials, but 40% had one 
trial that was at least twice as large as the median trial size, 25% had one trial 
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that was at least five times larger, and 10% had one trial that was even 10 times 
larger. 
 
Although several simulations have shown that the HKSJ method performs better 
than the DL method, the focus in these studies was not on a systematic 
evaluation of the effects of specific trial size mixtures in combination with low 
trial numbers. They either only reported the overall results of various mixtures 
combined or they studied only a limited number of combinations. In order to 
investigate the impact of unequal study sizes, we used simulations, mimicking 
such realistic conditions rather than situations where trials have implausibly 
similar sample sizes. We focused on meta-analyses with small numbers of studies 
(up to 20) with a dichotomous outcome (odds ratio, relative risk) or a continuous 
outcome. To mimic the variation in trial sizes, we explicitly varied the sample 
sizes of the trials within the simulated meta-analyses, varying from scenarios 
where all trials in a meta-analysis were of equal size, to scenarios with only one 
large trial, 10 times as large as the other trials, or one small trial, 10 times 
smaller than the other trials. 
 
In order to complement the simulations, empirical data, based on recent meta-
analyses - added or updated in 2012 - from the Cochrane Database of Systematic 
Reviews (CDSR) of interventions were used to assess the number of nominally 
statistically significant findings (with p < 0.05) of both methods in practice. This 
allows to examine whether inferences would be very different based on these 
two models. 
 
Currently not all standard software packages like Review Manager provide an 
option to perform an HKSJ analysis, although the HKSJ method is computationally 
not complicated and the importance of suitable methods for meta-analyses with 
small numbers of trials is apparent. Version 3.0 of Comprehensive Meta-analysis 
[3] will contain the HKSJ method (personal communication by Julio Sánchez-
Meca, September 2013). Also the R package metafor [20] and the metareg 
command in Stata [21] include the HKSJ method. However, not everybody will be 
acquainted with the use of R or Stata. Moreover, use of these packages is not 
straightforward when a post-hoc conversion is desired, i.e. when the results of a 
DL random effects analysis must be converted to the HKSJ approach. In order to 
fill this gap, we show step by step how the HKSJ analysis can be performed 
without the use of these packages, when the results of a common random effects 
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(DL) meta-analysis are available, e.g. from a systematic review. This conversion 
is applicable for continuous outcomes and for outcomes where metrics are log-
transformed, like the risk ratio (RR), odds ratio (OR), hazard ratio (HR) or Poisson 
rate. This simple modification of the common random effects analysis will 
improve the summary results, and it can be done through some basic calculations 
or a few statements in Excel. An Excel file is available as Supplemental file 
(Figure S.3 in Appendix 4) and on the web. R code for the metafor package is 
provided in Appendix 3. 
 
The simulations, the selection of empirical data and the statistical analysis are 
described in the Methods section. In the Results section the error rates for the DL 
and HKSJ methods for several realistic simulated scenarios are provided. For the 
Cochrane meta-analyses, we present the number of nominally statistically 
significant findings with the DL and HKSJ methods. The conversion of DL results 
into HKSJ results is illustrated, including examples from systematic reviews as 
presented in the Cochrane Library. 
 
Methods
We used simulated data as well as empirical data of the Cochrane 2012 Issues to 
evaluate the DL and HKSJ approaches. The pooled effect estimate is equal for 
both approaches, but the methods differ with respect to the calculation of the 
confidence interval and the statistical test. For DL, these are based on the 
normal distribution, whereas for the HKSJ method, they are based on the t-
distribution with the degrees of freedom equal to the number of trials minus one, 
and a weighted version of the DL standard error. Detailed statistical methods are 
presented in Appendix 1. 
 
Methods – simulations 
Our first aim was to investigate the error rates of the HKSJ meta-analysis method 
in comparison to the common (DL) method for various realistic scenarios, i.e. 
combinations of study sizes, study size mixtures and heterogeneity in series of 
just a few trials. Therefore we simulated series of trials with two up to 20 
studies, where each series provided the data for one meta-analysis. First, we 
considered series that consisted of equally sized trials, each with two groups of 
25, 50, 100, 250, 500 or 1000 subjects. Second, we looked into series of trials 
with different trial sizes, i.e. the percentage of large trials was 25%, 50% or 75%, 
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e.g. a series of one large trial and three small trials. Average group sizes were 
100, 250, 500 or 1000 subjects, and the large trials had 10 times more subjects 
than the small trials. For example, a series of six small (normal) and two large 
trials, with an average group size of 100, has group sizes of 31 and 308 in the 
small and large trials, respectively. Third, we simulated extreme scenarios, in 
which a series had only small trials, except for one large one, or only large trials, 
except for one small one. Both continuous and dichotomous outcomes were 
evaluated. For continuous outcomes, a normally distributed overall mean 
difference between the group means was simulated. In the trials with a 
dichotomous outcome, the event rates in the groups varied between scenarios 
and ranged from 0.1 to 0.9, in steps of 0.2. The heterogeneity was superimposed 
and set at I2 = 0, 0.25, 0.50, 0.75 and 0.9. I2 represents the heterogeneity, i.e. 
the degree of inconsistency in the studies’ results, in comparison to the total 
amount of variation [16,22]. The levels correspond to no, low, moderate, high 
and very high heterogeneity, respectively [16]. 
 
Our aim was to evaluate the error rate, i.e. the percentage of statistically 
significant meta-analyses when the overall mean treatment difference was zero. 
Hence we simulated series with an overall treatment difference equal to zero 
and performed on each series a DL [1] and an HKSJ [11] random effects meta-
analysis. The two-sided significance level was 0.05. For each scenario, we 
simulated 10,000 series of trials. In the ideal situation, 5% of the 10,000 meta-
analyses should have a statistically significant result when the significance level 
is 0.05. For the scenarios with the dichotomous outcome we determined the 
error rate when the OR was evaluated (logistic model) and when the RR was 
estimated. In these cases, meta-analysis was done on the logarithmic scale, and 
the error rates were determined for OR = 1 or RR = 1. More details can be found 
in Appendices 1 and 2. 
 
Methods - empirical data from the 2012 Cochrane Database of Systematic 
Reviews 
Cochrane Reviews are systematic reviews of primary research in human health 
care and health policy, and are internationally recognised as the highest standard 
in evidence-based health care [23]. The aim of the Cochrane collaboration is to 
provide accessible and credible evidence to guide decision making in medicine 
and public health. We were very fortunate that the UK Cochrane Editorial Unit 
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provided us with the statistical data added to the CDSR in 2012, which allowed us 
to assess the number of statistically significant results in real data. 
Many Cochrane reviews include multiple meta-analyses. Many of those overlap or 
are based on correlated data. Usually, the first analysis is the primary analysis. 
Hence, we decided to use per review only the first meta-analysis that was based 
on at least three studies. In order to maximize the number of meta-analyses, we 
used both the first continuous and the first binary outcome meta-analysis, 
whenever possible. Thus some systematic reviews provided none, and some 
provided one or two meta-analyses for our research. We always performed a 
random effects meta-analysis, even when the authors originally performed a 
fixed-effects analysis. Details can be found in Appendix 1. 
 
It is impossible to determine which of the Cochrane reviews compared 
treatments that truly had equal efficacy. It is thus unknown which of the 
statistically significant results were in fact false positive findings, so we could 
not determine the false positive error rate. Hence we decided to present the 
total number of significant findings of the DL and HKSJ methods instead of the 
error rates. This provides an indication of the impact a change from DL to HKSJ 
would have in practice. 
 
Results 
Error rates for continuous outcomes 
The left side of Figure 1 shows the error rates for the DL method for the 
simulated mixtures of trial sizes. In general with unequal-sized trials, the type I 
error of DL was substantially inflated even with minimal heterogeneity, while 
with equal-sized trials minimal or modest heterogeneity did not inflate the type I 
error substantially. Figure 1A shows the error rates for a setting with studies of 
equal size, Figure 1B for one small trial, 1C for equal numbers of large and small 
trials, and Figure 1D for a setting with one large trial, 10 times as large as the 
other trials. The heterogeneity levels are I2 = 0, 0.25, 0.5, 0.75 and 0.9, and the 
average study group sizes range between 25 and 1000. Vertical bars refer to the 
minimum and maximum error rates over the group sizes. The lines connect the 
means of these error rates. The error rates should all have been 5% (0.05), but 
for I2  0.25, DL error rates were too large, even for series of 20 trials. For 
example, DL error rates for meta-analyses of five studies ranged between 5.7% 
for equally sized trials and 14.7% for mixtures of trial sizes (Table 1). In contrast, 
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the error rates were too low (about 3-4%) when the I2 was 0. DL results for other, 
less extreme, mixtures of trial sizes were in between the results shown. 
In Figure 1 on the right side results for the HKSJ approach are presented. For 
equal trial sizes, the error rates of the HKSJ method were very appropriate. 
When the series contained only one small trial, the HKSJ error rates were 
approximately correct if the series consisted of more than five studies (Figure 
1B). For series containing fewer trials, the error rates were higher, but not as 
high as the respective DL values. They were also too high when the percentage of 
small trials increased (Figure 1C). When there was only one large trial, the HKSJ 
error rates sometimes almost doubled (Figure 1D). When there was no 
heterogeneity, HKSJ error rates were roughly 5%. As expected, the group sizes 
had no impact on the error rates. 
Figure 1 shows that the HKSJ method always outperformed the common random 
effects DL method. The HKSJ error rate was usually roughly 5%. However, some 
mixtures of sizes, especially when there is only one large trial, lead to a doubling 
of the error rate to 10%. This occurred especially when heterogeneity was only 
moderate.
Error rates for risk ratio outcomes 
The results of the simulations for studies with a risk ratio outcome were quite 
similar to the error rates for the continuous outcomes, but there was more 
variation in the error rates: they depended on the group sizes and the risks (from 
0.1 to 0.9). For low heterogeneity (I2 = 0.25), the DL error rates ranged from 
2.2% to 15.5%, whereas the HKSJ rates were slightly better: 2.8–10.6%. However 
for I2 =0.9 the DL rates ranged from 6.4% to 33.7%, compared to HKSJ rates of 
2.7% to 10.2%. When there was no heterogeneity (I2 = 0), the DL error rates 
ranged between 0.9% and 4.3%, and the HKSJ rates between 2.1% and 6.9%. For 
odds ratios, the results were again quite similar. See Table 1 for a selection of 
results, and the Additional file 2: Figure S1 and Additional file 3: Figure S2. 
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Figure 1 (A and B).  DerSimonian-Laird and Hartung-Knapp-Sidik-Jonkman error rates 
for continuous outcomes, for various I2 and mixtures of trial sizes. A: Equally sized 
trials; B: One small trial, 1/10th of other trials. Vertical bars refer to the minimum and 
maximum error rates over the group sizes.  The lines connect the means of these error 
rates. DL: DerSimonian & Laird meta-analysis method. HKSJ: Hartung-Knapp-Sidik-Jonk-
man meta-analysis method.
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Figure 1 (C and D).   DerSimonian-Laird and Hartung-Knapp-Sidik-Jonkman error rates 
for continuous outcomes, for various I2 and mixtures of trial sizes. C: 50–50 small and 
large trials (ratio 1:10), D: One large trial (10 times larger than other trials). Vertical 
bars refer to the minimum and maximum error rates over the group sizes.  The lines con-
nect the means of these error rates. DL: DerSimonian & Laird meta-analysis method. HKSJ: 
Hartung-Knapp-Sidik-Jonkman meta-analysis method.
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Table 1  Minimum and maximum error rates of DerSimonian-Laird and Hartung-
Knapp-Sidik-Jonkman methods for mixtures of trial sizes 
Outcome  No of Equally sized One small trial 
 I2 trials DL HKSJ DL HKSJ 
Continuous 0 2-20 3.4–4.6 4.5–6 3.4–4.5 4.7–5.4 
0.25–0.9 2 6–25 4.7–5.4 13.8–30.9 6.5–9.2 
3 5.9–17.5 4.7–5.6 10.8–21.7 6–8 
4 5.6–14.2 4.5–5.5 9–16.8 5.6–7 
5 5.7–12.7 4.7–5.5 8.2–13.6 5.5–6.7 
10 5.6–8.8 4.8–5.6 6.4–8.8 5–5.6 
20 5.6–6.6 4.6–5.3 5.8–7.1 4.8–5.5 
Risk ratio 0 2-20 0.9–4.2 2.1–6.9 2.8–4.1 2.7–6.5 
0.25–0.9 2 2.5–26.3 2.8–6.7 14.3–33.7 6–10.2 
5 2.5–12.9 3.9–5.7 7.9–15 5.5–7.2 
10 2.6–8.9 2.7–5.4 6–9.7 3.8–5.7 
Odds ratio 0 2-20 1.3–4.3 2.7–6.1 3–4 3–6.7 
0.25–0.9 2 2.9–25.3 3.2–5.9 13.7–33.5 6.1–9.6 
5 3–12.7 3.9–5.3 7.9–14.4 5.4–6.9 
10 2.9–8.8 3.2–5.3 5.7–9.6 3.9–5.7 
   50–50% One large trial 
Continuous 0 2-20 3.3–4.1 4.6–5.4 3.2–4.4 4.5–5.7 
0.25–0.9 2 13.8–30.9 6.5–9.2 13.8–30.9 6.5–9.2 
3 10.2–20.8 5.9–7.7 13.7–22.1 7.1–10.7 
4 11.9–18.4 6.6–9.6 12.6–17.3 5.9–10.5 
5 9.9–14.7 5.6–7.9 11.6–14.5 5.3–9.9 
10 9–10.3 5.4–7.2 8.5–10 5.3–8.8 
20 7.1–7.8 5–6.4 6.9–7.8 4.9–7.2 
Risk ratio 0 2-20 3.0–4.1 2.7–6.8 2.7–4.3 2.7–5.5 
0.25–0.9 2 14.3–33.7 6–10.2 14.3–33.7 6–10.2 
5 9.8–15.7 5.2–7.9 11.4–14.2 5.2–10.6 
10 8.6–11 4.8–9.1 7.3–10.1 3.6–8.7 
Odds ratio 0 2-20 3–4 3–6.7 2.9–4.1 3–5.4 
0.25–0.9 2 13.7–33.5 6.1–9.6 13.7–33.5 6.1–9.6 
5 9.9–15.8 5.3–8.1 11.6–14.2 5.2–10.5 
10 8.4–11.7 4.8–9.3 7.4–10.1 3.8–8.8 
Error rates for the following scenarios: equally sized trials; one small trial, 1/10th of other 
trials; 50–50% small and large trials (ratio 1:10); one large trial (10 times larger than other 
trials). No of trials: number of trials. DL: DerSimonian & Laird meta-analysis method. 
HKSJ: Hartung-Knapp-Sidik-Jonkman meta-analysis method. 
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Empirical results for CDSR 2012 
Selection of the first meta-analyses in the systematic reviews added in 2012 to 
the CDSR and based on at least three studies resulted in 689 meta-analyses (255 
meta-analyses with a continuous outcome and 434 meta-analyses with a 
dichotomous outcome). 
 
The continuous outcome meta-analyses were based on a median of five trials 
(Q1-Q3: 3–9) with a median ratio between the largest and the smallest trial of 5 
(Q1-Q3: 3–10). Using the DL method, 130 (51.0%) of the 255 meta-analyses were 
nominally statistically significant compared to 102 (40.0%) when the HKSJ 
method was used (Table 2). Of the 130 meta-analyses that were significant with 
the DL method, 31 (23.8%) were not significant with the HKSJ method, while 
three meta-analyses were significant with the HKSJ method but not with the DL 
method. In the selection of meta-analyses based on at most five studies and with 
large ratios between the study sizes (ratio > 5) 13 (59.1%) of the 22 meta-
analyses significant with the DL method were not significant with the HKSJ 
method and none of the meta-analyses was only significant with the HKSJ 
method. 
 
The 434 dichotomous meta-analyses were based on a median of six trials (Q1-Q3: 
4–10) with a median ratio between the largest and the smallest trial of 6 (Q1-Q3: 
3–16). Of the 434 meta-analyses, 185 (42.6%) were nominally statistically 
significant with DL and 147 (33.9%) with HKSJ (Table 2). Of the 185 meta-
analyses that were significant with the DL method, 48 (25.9%) were not 
significant with the HKSJ method, while the opposite scenario was seen in 10 
cases. In the selection of small meta-analyses with large ratios between the 
study sizes 14 (50.0%) of the 28 meta-analyses significant with the DL method 
were not significant with the HKSJ method, while the opposite scenario occurred 
once. 
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Table 2  Number (%) of statistically significant Cochrane meta-analyses according to 
the DerSimonian-Laird and Hartung-Knapp-Sidik-Jonkman methods 
Outcome Selected 
meta-analyses 
N DL test
significant 
HKSJ test
significant 
HKSJ test not
significant,
positive DL test 
Continuous All 255 130 (51.0) 102 (40.0) 31/130 (23.8) 
 Ratio > 5,  
      5 studies 
46 22 (47.8) 13 (28.3) 13/22 (59.1) 
Dichotomous All 434 185 (42.6) 147 (33.9) 48/185 (25.9) 
 Ratio > 5,  
       5 studies 
 76 28 (36.8) 15 (19.7) 14/28 (50.0) 
All: all meta-analyses with a continuous or dichotomous outcome that fulfilled the 
following criteria: the first meta-analysis in a review in the Cochrane Database for 
Systematic Reviews Issues of 2012, based on at least three studies. Ratio >5,  5 studies: a 
selection of these meta-analyses based on at most five studies, where the ratio of the 
largest vs. the smallest trial size was > 5. DL: DerSimonian & Laird meta-analysis method. 
HKSJ: Hartung-Knapp-Sidik-Jonkman meta-analysis method. DL test significant: DL p-value 
<0.05; HKSJ test significant: HKSJ p-value < 0.05. Note that in a few cases the HKSJ test 
was significant when the DL test was not. 
 
Summarizing, the DL method resulted in statistically significant results in 
315/689 (45.7%) of the meta-analyses; 79 of these 315 “positive” DL results 
(25.1%) were not significant with the HKSJ method, while the opposite scenario 
(significant only by HKSJ) was rarely seen (14 meta-analyses). In the selection of 
small meta-analyses ( 5 studies) with large ratios between the study sizes (ratio 
> 5), the difference between the DL and HKSJ results was even larger. 
 

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Easy method for the conversion of DL into HKSJ results 
We present two examples to illustrate how DL results can be used to carry out an 
HKSJ analysis, resulting in HKSJ-confidence intervals and p-values. An Excel file 
is available as Supplemental Figure S.3 in Appendix 4 and as web material. The 
results can also be created with R, Appendix 3. 
 
Example1:conversiontoHKSJforacontinuousoutcome
The first three columns of Table 3 show the results of a meta-analysis on the 
effect of zinc for the treatment of a common cold, published in a Cochrane 
review [24].The outcome was severity of cold symptoms scoring, and was based 
on a total of 513 participants. The first column shows the identifiers of the 
studies, the second column the results yi of the individual studies and the third 
column contains the weights wi from the DL analysis, copied from the review. 
Only these three columns are needed for the post-hoc calculations. 
 
The following steps carry out an HKSJ analysis: 
 
1. Determination of the standard error: 
a. Based on the overall summary difference y = î0.39, calculate the HKSJ 
factors 
wi×(yi-y)2 for each of the studies (see the fifth column for the results). 
b. Add the HKSJ factors and divide them by the sum of the weights. This 
results in 20.31/100 = 0.2031. 
c. Divide by k-1, whereby k is the number of studies. In this situation k = 5 and 
0.2031/4 = 0.0508. This is the weighted variance of the pooled treatment 
effect according to the HKSJ approach. 
d. Taking the square root leads to the standard error: SE = ¥0.0508 = 0.225. 
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Table 3  Conversion of DerSimonian-Laird results into Hartung-Knapp-Sidik-Jonkman 
results for a continuous outcome: severity of cold symptoms 
DerSimonian and Laird results Calculations for Hartung-Knapp- Sidik-Jonkman 
Study Study results SMD Weights   
yi wi (yi–y)2 wi ×(yi–y)2 
Kurugol 2006a î0.04 24.0 0.1225 2.94 
Kurugol 2007 î0.07 22.2 0.1024 2.27 
Petrus 1998 î0.31 21.3 0.0064 0.14 
Prasad 2000 î1.36 15.5 0.9409 14.58 
Prasad 2008 î0.54 17.0 0.0225 0.38 
y = î0.39 Sum: 100.0  Sum: 20.31 
 
5 studies, I2 = 75.0%, ů2 = 0.13 
DL pooled result [95% CI]: SMD = î0.39 [î0.77, –0.02]; z = 2.05; P–value = 0.04 
HKSJ pooled result [95% CI]: SMD = î0.39 [î1.02, 0.24]; t = 1.73; P–value =0.16 (df = 4) 
SMD: Standardized mean difference. DL: DerSimonian & Laird meta-analysis method. 
HKSJ: Hartung-Knapp-Sidik-Jonkman meta-analysis method. CI: Confidence Interval, df: 
degrees of freedom, ×: multiplication sign. The pooled effect y and the weights wi 
originate from the DL random-effects analysis. 
 
2. Determination of the 95% confidence interval (CI): 
a. To determine the half-width of the 95% CI, the SE must be multiplied with 
the 97.5%-quantile of the t-distribution with k - 1 degrees of freedom. Its 
value can be obtained through Excel: TINV(0.05, k-1), where k is the 
number of studies. This results in 2.78, so the half-width of the 95% CI is 
2.78*0.225 = 0.63. The t-value can also be found on the internet, for 
example at http://www.danielsoper.com/statcalc3/calc.aspx?id=10. 
The quantiles of the t-distribution can be found through statistical packages 
as well. In SPSS: select ‘compute variable’, function group ‘Inverse DF’, 
function IDF.T(.975,k-1), or in SAS: tinv(.975,k-1). 
b. The HKSJ 95% CI then is y ± half-width of the CI, i.e. -0.39 ± 0.63 or [-1.02; 
0.24]. 
 
 
  
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3. Determination of the p-value: 
a. Calculate the t-statistic: t = y/SE = î0.39/0.225 = î1.73. If the result is 
negative, as in this situation, simply change the sign, so t = 1.73. 
b. Determine the corresponding two-sided p-value with Excel: TDIST(1.73,4,2), 
or with the internet site 
http://www.danielsoper.com/statcalc3/calc.aspx?id=8. The two-sided  
P-value according to the HKSJ method then is 0.16. 
This p-value can also be obtained through SPSS: ‘compute variable’, 
function group ‘CDF & noncentral CDF’, function ‘CDF.T’. This yields 
CDF.T(1.73, 4), similar to SAS, cdf(‘T’, 1.73, 4) = 0.92066. The two-sided 
HKSJ p-value then is 2×(1–0.92066) ~ 0.16. 
 
 
In this example on the efficacy of zinc, based on only five trials and high 
heterogeneity (I2 = 75%), the results of the DL and HKSJ analyses differ 
substantially. 
 
 
Example 2: conversion to HKSJ for outcomes that require a log 
transformation
 
When the outcome of the meta-analysis is a risk ratio (RR), odds ratio (OR), 
hazard ratio (HR) or Poisson rate, the analysis has to be conducted on the natural 
logarithm (ln) of the treatment effect. In all other aspects the procedure is 
exactly the same as for a continuous outcome. As an example we show the 
overall survival for post-remission therapy for adult acute lymphoblastic 
leukemia, comparing patients with and without a donor, as presented in a 
Cochrane Review [25]. The first three columns of Table 4 show the results of a 
meta-analysis with the HR as outcome. 
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Table 4  Conversion of DerSimonian-Laird results into Hartung-Knapp-Sidik-Jonkman 
results for a logarithm based outcome: Hazard Ratios 
DerSimonian and Laird results Calculations for Hartung-Knapp-Sidik Jonkman 
Study Study results HR Weights ln(yi) (ln(yi)–ln(y))2 wi×(ln(yi)–ln(y))2 
yi wi 
Cornelissen 2009 0.81 5.0 î0.21 0.00 0.02 
De Witte 1994 0.67 2.1 î0.40 0.06 0.13 
Fielding 2009 0.80 11.5 î0.22 0.01 0.06 
Goldstone 2008 0.91 46.7 î0.09 0.00 0.15 
Hunault 2004 0.56 2.9 î0.58 0.18 0.53 
Labar 2004 0.98 9.3 î0.02 0.02 0.16 
Ribera 2005 1.24 3.9 0.22 0.13 0.52 
Sebban 1994 0.75 12.7 î0.29 0.02 0.24 
Takeuchi 2002 0.95 3.9 î0.05 0.01 0.04 
Ueda 1998 0.66 2.0 î0.42 0.07 0.14 
 y = 0.86 Sum: 100.0   Sum: 1.99 
10 studies, I2 = 0.0, ů2 = 0.0. 
DL pooled result [95% CI]: HR = 0.86 [0.77, 0.97]; z = î2.48; P–value = 0.013. 
HKSJ pooled result [95% CI]: HR = 0.86 [0.77, 0.96]; t = î3.19; P–value =0.011 (df = 9). 
HR: Hazard Ratio for donor versus no-donor; ln: natural logarithm; DL: DerSimonian & 
Laird meta-analysis method. HKSJ: Hartung-Knapp-Sidik-Jonkman meta-analysis method. 
CI: Confidence Interval, df: degrees of freedom, ×: multiplication sign. The pooled effect 
y and the weights wi originate from the DL random-effects analysis on log scale. 
 
1. Determination of the standard error: 
a. Calculate the natural logarithm of the pooled estimate: ln(y) = ln(0.86) = 
î0.15. Calculate the natural logarithms of the study outcomes (column 4) 
and use these to calculate the HKSJ factors wi×(ln(yi)-ln(y))2 for each of the 
studies (column 6). 
b. Add the HKSJ factors and divide them by the sum of the weights. This leads 
to 1.99/100 = 0.0199. 
c. As there are 10 studies, divide by k-1 = 9: 0.0199/9 = 0.0022. 
d. Taking the square root leads to the standard error: SE = ¥0.0022 = 0.047. 
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2. Determination of the 95% CI: 
a. On the ln scale, the half-width of the 95% CI is TINV(0.05, 9)×0.047 = 
2.26×0.047 = 0.106 (Excel). 
b. The 95% CI for the ln HR is î0.15 ± 0.106, i.e. [î0.26; -0.04]. 
c. The HKSJ 95% CI for the HR is [e-0.26; e-0.04], i.e. [0.77; 0.96]. 
 
 
3. Determination of the p-value: 
a. Calculate the t-statistic: t = ln(y)/SE = î0.15/0.047 = î3.19. Neglecting the 
negative sign, we obtain t = 3.19. 
b. Use Excel, Internet or a statistical package to calculate the two-sided p-
value according to the HKSJ method, see Example 1. Excel: p-value = 
TDIST(3.19,9,2) = 0.011; SPSS: CDF.T(3.19, 9) = 0.995, so that the p-value is 
2×(1–0.995) = 0.011. 
 
 
In this example, results of the DL and HKSJ analyses hardly differ. 
Discussion
The DL approach to random effects meta-analysis is still the standard method, 
almost to the exclusion of all other methods. This might be considered 
remarkable, bearing in mind the high false positive rates of the DL method which 
have been shown repeatedly with simulations [4-14] and also an empirical study 
suggesting that results are sensitive to the choice of random effects analysis 
method [26]. Thorlund et al. did an empirical assessment in 920 Cochrane 
primary outcome meta-analyses of >=3 studies of method-related discrepancies 
[26]. In total, 326 (35.4%) meta-analyses were statistically significant when the 
analysis was based on a t-distribution – as in the HKSJ method – and 414 (45%) 
when it was based on the normal distribution as in the DL method. Our 
evaluation of Cochrane meta-analyses of interventions resulted in a similar 
result: a substantially larger amount of significant findings with the DL method 
than with the HKSJ method. Our simulations suggest that among the DL 
significant findings in the Cochrane reviews there may be a considerable number 
of false positives. 
 
 Hartung-Knapp-Sidik-Jonkman method 
 
 
83
DL results can easily be converted into HKSJ results, which have a much better 
performance. We confirmed this with simulations, for mixtures of trial size 
distributions in settings with up to 20 trials per meta-analysis. When there was 
heterogeneity, the mean error rates of the DL approach were consistently higher 
than those of the HKSJ approach, although also the latter doubled to 10% in 
scenarios with only one large trial. When there was no heterogeneity, the DL 
error rates were lower than 5%, and the HKSJ rates were approximately 5%. 
 
However, there are some limitations with respect to the HKSJ analysis method. 
Although the error rates of the HKSJ method were closer to the 5% level than 
those of the DL method, our simulations showed that in some scenarios the HKSJ 
error rates more or less doubled, although the DL error rates could be more than 
four times too high in these same settings. Hence, the results of the HKSJ 
analysis are also not perfect. Like we hypothesized, the error rates were 
maximal if one of the trials in the meta-analysis was substantially larger than the 
other ones. 
 
Further, when study numbers are small, the distribution of the treatment effects 
is unknown and does not necessarily follow the normal or t-distribution. 
Kontopantelis and Reeves [27] showed that with slight heterogeneity the 
coverage of the HKSJ method was consistently 94% when the true effects were 
not distributed according to the normal or t-distribution, but with larger 
heterogeneity the non-parametric permutation (PE) method of Follmann and 
Proschan [7] performed better than the HKSJ method. However, the PE method 
can only be performed when the number of studies is larger than five, whereas 
many meta-analyses are smaller [15]. Several other methods have been 
developed, like the Quantile Approximation (QA) method [28], the Profile 
Likelihood approach [29], natural weighting instead of empirically based 
weighting of studies [30], use of fixed effects estimates with a random effects 
approach to heterogeneity [31] and more recently, higher-order likelihood 
inference methods [32]. However, most of these methods are based on 
asymptotic statistics and they may therefore be less robust in case of a limited 
number of trials, or they remain difficult to use in practice, because no 
statistical packages are available to perform them and it is very difficult to carry 
out the calculations with standard software. Regarding the non-asymptotic, 
computationally straightforward QA method, Sánchez-Meca and Marín-Martínez 
[13] have already shown that it was outperformed by the HKSJ method. It would 
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require a very extensive evaluation to investigate the performance of all of these 
methods. We restricted ourselves to the HKSJ method, because of its 
computational simplicity and we show that HKSJ results can easily be derived 
from DL results. 
 
As far as we know, we are the first to present systematically the error rates in 
relation to explicit trial size mixtures when the numbers of trials range from 2 to 
20. Follmann and Proschan [7] show that for certain trial size mixtures and low 
numbers of trials the DL error rates can be highly increased, however, they did 
not evaluate the HKSJ method. The results reported by Hartung, Knapp and 
Makambi [4-6,8,9] imply that for meta-analyses of three, six or twelve studies 
the DL error rates for studies with similar sizes were closer to 5% than for studies 
of different sizes, and that the HKSJ method performed much better than DL in 
the latter situation. However they did not report the explicit relationship 
between the trial size mixtures and error rates as we do (Table 1). Sánchez-Meca 
and Marín-Martínez [13] also varied the sample size ratios in their simulations. 
They concluded that the average sample size scarcely affected the performance 
of the different methods, but this was based on the combined results of 5–100 
studies and they presented no results of particular trial size mixtures. 
 
As all studies show that in settings with few studies the HKSJ method always 
resulted in error rates closer to 5% than the DL method, the latter method should 
not be used and the HKSJ method should be the standard approach. To facilitate 
its more widespread application, the conversion of DL results into HKSJ results is 
presented step by step. At the same time, we urge caution when any random 
effects model, including HKSJ, is applied to situations where there are very few 
studies, and even more so when the sample sizes of the combined studies are 
very different. Even the HKSJ confidence intervals may be conservatively narrow 
in these situations and inferences may be spurious, if the confidence intervals 
are taken at face value. 
 

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Conclusions 
Our simulations showed that the HKSJ method for random effects meta-analysis 
consistently results in more adequate error rates than the common DL method, 
especially when the number of studies is small. The HKSJ method can easily be 
applied routinely in meta-analyses. However, even with the HKSJ method, extra 
caution is needed when there are 5 studies of very unequal sizes. 
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Appendices 
Appendix 1: Statistical details 
Random effects meta-analysis model 
For k studies, let the random variable yi be the effect size estimate from the ith 
study. The random effect model can be defined as follows: 
ݕ௜ ൌ ߜ௜ ൅ ݁௜  
for i =1, . . ., k, where Ţi = Ţ + di; ei and di independent, ݁௜̱ܰሺͲǡௗௗ א௜ଶሻ  and di ~ 
N(0, Ű2).א௜ଶ  is the within-study variance, describing the extent of estimation 
error of Ţi, and the parameter Ű2 represents the heterogeneity of the effect size 
between the studies. 
 
For studies with dichotomous outcomes where no events were observed in one or 
both arms, the computation of the random effects model yields a computational 
error. In these cases, before performing any meta-analysis, we added 0.5 to all 
cells of such a study. 
 
Random effects analysis 
Let wi be the fixed effects weights, i.e. the inverse of the within-study variance 
אෝ௜ଶ , and let ݕොி  be the fixed effects estimate of š. 
Let Q be the heterogeneity statistic ܳ ൌ σݓ௜ሺݕ௜ െ ݕොிሻଶ .Then 
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The DerSimonian and Laird method estimates the variance of ݕො௥  by 
1var   ¦DL iwW    
 
and uses the normal distribution to derive P-values and confidence intervals. 
In contrast, the Hartung, Knapp, Sidik and Jonkman method estimates the 
variance of ݕො௥  by 
 
 
 
2
var
ˆ
1
 
¦
¦i i rHKSJ i
w y y
k w
W
W
  
 
 
and uses the t-distribution with k-1 degrees of freedom to derive P-values and 
confidence intervals, with k the number of studies in the meta-analysis. 
 
Heterogeneity estimates 
Although Ƹ߬ ଶ  or Q can be used as measures of the heterogeneity, Higgins and 
Thompson [16] propose 
2 ( 1)  Q kI
Q    
 
I2 is a relative measure. It compares the variation due to heterogeneity (Ű2) to 
the total amount of variation in a ‘typical’ study (Ű2 +א2), where א is the standard 
error of a typical study of the review [33]: 
2
2
2 2   
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Appendix 2: The simulations 
 
The parameters in the scenarios for the simulations 
– the number of trials per series k = 2 – 20; 
– the average group size in a series of trials: 25, 50, 100, 250, 500 or 1000 
subjects per group per trial; 
– the trial size mixtures: we simulated series with 25, 50 or 75% large trials, 
series with exactly one large or one small trial, and series where all trials were 
of equal size; 
– the ratio of the study sizes: for the series with small and large studies, the 
large study was 10 times the size of a small study. 
 
The simulations were programmed in SAS, version 9.2. The scenarios were 
evaluated 10,000 times, for heterogeneity levels I2 = 0, 0.25, 0.5, 0.75, and 0.9, 
and at a nominal significance level Ş = 0.05 (two-sided). 
 
A. The simulation for normally distributed outcomes 
1. For each scenario, and each value of I2, we used eq. (1) to calculate the 
variance ů2. So 
߬ଶ ൌ ߝଶௗ ூమଵିூమ  (2) 
where ɂଶ ൌ ଵ୩ ௗσ
ଶௗ஢మ
୬౟
 , with ni the groupsize of trial i (i = 1…k) and Ů the standard 
deviation of the outcome variable of the trials. As Ů is only a scaling factor and 
the results only depend on the ratio ů/Ů, we have set Ů =1 in the simulations. 
2. For each trial i: 
a. We determined the ‘true’ trial effect size ši, where ši was a random draw 
from the normal distribution with mean 0 and variance ů2. 
b. We generated the trial outcome based on a normal distribution with mean ši 
and variance 2Ů2/ni = 2/ni. 
c. We generated the variance of the trial outcome based on a Ȥ2 distribution 
with 2ni-2 degrees of freedom, divided by ni-1. 
 
 
3. For each series: 
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A DL analysis and an HKSJ analysis were carried out. 
4. For each scenario, I2 and each meta-analysis method, we calculated the error 
rate, i.e. the percentage of series that had a statistically significant (p<0.05) 
outcome. 
 
B. The simulations for the odds ratio 
1. When the outcome was dichotomous, we had to choose an additional 
parameter: the overall event rate p0. We varied the p0 between 0.1 and 0.9 
and for each value we used (2) to calculate ů2, with 
߳ଶ ൌ ଵ௞ ௗσ
ଵ
௡೔ௗ
ௗௗ ቀ ଶ௣బ ൅
ଶ
ଵି௣బቁ   
 
2. For each trial i: 
a. We determined the ‘true’ trial effect size ln(odds ratioi)=ši, where ši was a 
random draw from the normal distribution with mean 0 and variance ů2. 
b. We calculated the event rates pa and pb in the two groups, such that: 
ln(pa /(1- pa)) = ln(p0 /(1- p0)) - ši/2, and ln(pb /(1-pb)) = ln(p0 /(1- p0)) + 
ši/2. 
c. We generated the observed event rates Pa and Pb in each group based on 
Bernouilli distributions with event rates pa and pb, respectively. 
d. Based on Pa and Pb, we calculated the natural log of the odds ratio and its 
variance 
(1/Pa +1/(1- Pa) +1/Pb +1/(1- Pb))/ni. 
 
Steps 3 and 4 were the same as for a continuous outcome. 
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C. The simulations for the risk ratio 
The risk ratio simulation was similar to the odds ratio simulation, but the 
variance was different: 
߳ଶ ൌ ଵ௞෍ భ೙೔ ൬
ʹ
݌଴ െ ʹ൰ 
Furthermore, for each trial: 
a. We determined the ‘true’ trial risk ratio ln(risk ratioi)= ši , where ši was a 
random draw from the normal distribution with mean 0 and variance ů2. 
b. We calculated the event rates pa and pb in the two groups, such that: 
ln(pa) = ln(p0) - ši/2 and ln(pb) = ln(p0) + ši/2. Event rates below 0.01 or above 
0.99 were replaced by 0.01 or 0.99, respectively. 
c. We generated the observed event rates Pa and Pb in each group based on 
Bernouilli distributions with event rates pa and pb, respectively. 
d. This led to the natural log of the risk ratio and its variance  
(1/Pa +1/Pb - 2)/ni. 

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Appendix 3: R code for the conversion of DL to HKSJ results 
The R package metafor [20] can also be used to perform an HKSJ analysis. The 
implementation is based on the meta-regression paper by Knapp and Hartung 
[34]: when no covariates or moderator variables are used, the meta-regression 
reduces to a random effects meta-analysis as proposed by Hartung/Knapp and 
Sidik/Jonkman. 
 
The usual approach to perform an HKSJ analysis with metafor is based on study 
effects combined with fixed effects weights or standard errors. In our examples 
the HKSJ method must be applied on random effects weights instead of fixed 
effects weights. This can be done by choosing a fixed effects analysis 
(method=”FE”) in combination with the HKSJ method. This will result in 
warnings, because in general the HKSJ adjustment is not meant to be used in 
combination with a fixed effects analysis. In this case, the warnings can be 
neglected. The code is kindly provided by G Knapp. 
 

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Code for HKSJ conversion in R: first example 
 
library(metafor) 
 
  y <î c(î0.04, -0.07, -0.31, -1.36, -0.54) 
  w <î c( 24.0, 22.2, 21.3, 15.5, 17.0) 
  rma.uni(y, vi = 1/w, method="FE", knha=TRUE) 
  
 
Output is presented in Table 5. 
 


Table 5  R output for first example (Hartung-Knapp-Sidik-Jonkman method) 
 Estimate SE t-value p-value CI.LB CI.UB 
R output î0.3938 0.2254 î1.7473 0.1555 î1.0195 0.2319 
Relevant part from output from R package metafor. SE: standard error; CI.LB: lower 
bound of 95% confidence interval; CI.UB: upper bound of 95% confidence interval. 

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Code for HKSJ conversion in R: second example (ln HR) 
 
library (metafor) 
  y <î c(0.81, 0.67, 0.80, 0.91, 0.56, 0.98, 1.24, 0.75, 0.95, 0.66) 
  w <î c( 5.0, 2.1, 11.5, 46.7, 2.9, 9.3, 3.9, 12.7, 3.9, 2.0) 
  
# meta-analysis on log scale (ln HR). Note the brackets around the following  
# syntax! 
  (hr <î rma.uni(log(y), vi=1/w, method="FE", knha=TRUE) ) 
  # backtransformation: 
  exp(hr$b) 
  
exp(c(hr$ci.lb, hr$ci.ub)) (Table 6) 
 
Table 6  R output for second example (Hartung-Knapp-Sidik-Jonkman method) 
 Estimate (HR) SE t-value p-value CI.LB CI.UB 
R output î0.1458 0.0470 î3.1031 0.0127 î0.2521 î0.0395 
After back-transformation 0.8643    0.7772 0.9613 
Relevant part from output from R package metafor. HR: hazard ratio; SE: standard error; 
CI.LB: lower bound of 95% confidence interval; CI.UB: upper bound of 95% confidence 
interval. 
 
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Figure S1 (A and B).  DerSimonian-Laird and Hartung-Knapp-Sidik-Jonkman error rates 
for Risk Ratios, for various I2 and mixtures of trial sizes: A: Equally sized trials; B: One 
small trial, 1/10th of other trials. Vertical bars refer to the minimum and maximum error 
rates over the group sizes. The lines connect the means of these error rates. DL: DerSi-
monian & Laird meta-analysis method. HKSJ: Hartung-Knapp-Sidik-Jonkman meta-analysis 
method.
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Figure S1   (C and D). DerSimonian-Laird and Hartung-Knapp-Sidik-Jonkman error rates 
for Risk Ratios, for various I2 and mixtures of trial sizes: C: 50–50 small and large trials 
(ratio 1:10); D: one large trial (10 times larger than other trials). Vertical bars refer to 
the minimum and maximum error rates over the group sizes. The lines connect the means 
of these error rates. DL: DerSimonian & Laird meta-analysis method. HKSJ: Hartung-
Knapp-Sidik-Jonkman meta-analysis method.
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Figure S2 (A and B).  DerSimonian-Laird and Hartung-Knapp-Sidik-Jonkman error rates 
for Odds Ratios, for various I2 and mixtures of trial sizes: A: Equally sized trials; B: One 
small trial, 1/10th of other trials. Vertical bars refer to the minimum and maximum error 
rates over the group sizes. The lines connect the means of these error rates. DL: DerSi-
monian & Laird meta-analysis method. HKSJ: Hartung-Knapp-Sidik-Jonkman meta-analysis 
method.
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Figure S2 (C and D). DerSimonian-Laird and Hartung-Knapp-Sidik-Jonkman error rates 
for Odds Ratios, for various I2 and mixtures of trial sizes: C: 50–50 small and large trials 
(ratio 1:10); D: one large trial (10 times larger than other trials). Vertical bars refer to 
the minimum and maximum error rates over the group sizes. The lines connect the means 
of these error rates. DL: DerSimonian & Laird meta-analysis method. HKSJ: Hartung-
Knapp-Sidik-Jonkman meta-analysis method.
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Conversion of DL to HKSJ for continuous outcomes
Note: Adapt values in the grey cells
Calculation of t-value
Confidence level for 95% conf. interval 95 
 Number of studies 5 
Corresponding t-value 2.77644511 
Reported DL pooled effect -0.39 
Number of decimals required in Confidence Interval 2 
      Reported DL results Calculated HKSJ weights 
study weight study effect (yi - y)2 wi * (yi - y)2
Wi yi
1 24 -0.04 0.1225 2.94 
2 22.2 -0.07 0.1024 2.27328 
3 21.3 -0.31 0.0064 0.13632 
4 15.5 -1.36 0.9409 14.58395 
5 17 -0.54 0.0225 0.3825 
6      0 0 
7      0 0 
8      0 0 
9      0 0 
10      0 0 
11      0 0 
12      0 0 
13      0 0 
14      0 0 
15      0 0 
Sum 100 20.31605 
 
HKSJ Results 
SE HKSJ   0.2253666 
Point estimate -0.39 
CI_lower   -1.02 
CI_upper   0.24 
      
t-value   -1.7305134 
degrees of freedom 4 
p-value   0.1585873 

Figure S3.A   Excel template for the conversion of DL to HKSJ results for continuous 
outcomes, Example 1. SE: Standard error; DL: DerSimonian-Laird result; HKSJ: Hartung-
Knapp-Sidik-Jonkman result; CI: Confidence Interval. Web material available on 
http://www.biomedcentral.com/1471-2288/14/25/additional.  
 Hartung-Knapp-Sidik-Jonkman method 
 
 
99
Conversion of DL to HKSJ for ratio outcomes 
Note: Adapt values in the grey cells
Calculation of t-value
Confidence level  95 
Number of studies 10 
Corresponding t-value 2.262157158 
Reported DL pooled effect 0.86 
Pooled DL effect on ln-scale -0.15082289 
Number of decimals required in Conf.Interval 2 
   Reported DL results Calculated HKSJ weights 
study weight study effect ln(study effect) (ln(yi)–ln(y))
wi*
(ln(yi)–ln(y))2
wi yi ln(yi)
1 5 0.81 -0.210721031 0.00358778 0.017938937 
2 2.1 0.67 -0.400477567 0.06232745 0.130887661 
3 11.5 0.8 -0.223143551 0.00523027 0.060148198 
4 46.7 0.91 -0.094310679 0.00319363 0.149142517 
5 2.9 0.56 -0.579818495 0.18403723 0.533707966 
6 9.3 0.98 -0.020202707 0.01706163 0.158673178 
7 3.9 1.24 0.21511138 0.13390788 0.522240769 
8 12.7 0.75 -0.287682072 0.01873043 0.237876536 
9 3.9 0.95 -0.051293294 0.00990614 0.038633947 
10 2 0.66 -0.415515444 0.07006214 0.140124297 
11     0 0 0 
12     0 0 0 
13     0 0 0 
14     0 0 0 
15     0 0 0 
Sum 100 1.989374005 

HKSJ Results 
SE HKSJ   0.0470151 
Point estimate 0.86 
CI_lower   0.77 
CI_upper   0.96 
      
t-value   -3.20797 
degrees of freedom 9 
p-value   0.0106937 

Figure S3.B    Excel template for the conversion of DL to HKSJ results for ratio 
outcomes, Example 2. SE: Standard error; DL: DerSimonian-Laird result; HKSJ: Hartung-
Knapp-Sidik-Jonkman result; CI: Confidence Interval. Web material available on 
http://www.biomedcentral.com/1471-2288/14/25/additional. 
 
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This excel book contains supplemental information to the following paper: 
The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward 
 and considerably outperforms the standard DerSimonian-Laird method. 
Joanna IntHout, John P.A. Ioannidis, George F. Borm. 
BMC Medical Research Methodology, 2014 
  
  
Contact details 
Joanna IntHout 
Radboud university medical center,  
Biostatics,  
Department for Health Evidence,  
Nijmegen, The Netherlands 
Joanna.IntHout@radboudumc.nl 
  
  
Disclaimer 
This excel book was created with Excel 2007. Please contact the author in case of problems. 
  
Copyright (C) 2013, Joanna IntHout 
  
This program is free software: you can redistribute it and/or modify 
it under the terms of the GNU General Public License as published by 
the Free Software Foundation, either version 3 of the License, or 
any later version. 
  
This program is distributed in the hope that it will be useful, 
but WITHOUT ANY WARRANTY; without even the implied warranty of 
MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE.  See the 
GNU General Public License for more details. 
  
The GNU General Public Licence (GPL) can be found at <http://www.gnu.org/licenses/>. 


Figure S3.C    Information and disclaimer for Excel template for the conversion of DL 
to HKSJ results. Web material available on http://www.biomedcentral.com/1471-
2288/14/25/additional. 

 
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 Chapter 5  
 
 
 
 
 
 
 
 
 
 
Small studies are more 
heterogeneous than large ones:  
a meta-meta-analysis 
 
IntHout J, Ioannidis JP, Borm GF, Goeman JJ. 
Journal of Clinical Epidemiology. 2015;68(8):860-9. 
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Abstract 
Objective   
Between-study heterogeneity plays an important role in random-effects models 
for meta-analysis. Most clinical trials are small, and small trials are often 
associated with larger effect sizes. We empirically evaluated whether there is 
also a relationship between trial size and heterogeneity (ů). 
 
Study Design and Setting   
We selected the first meta-analysis per intervention review of the Cochrane 
Database of Systematic Reviews Issues 2009-2013 with a dichotomous (n=2009) or 
continuous (n=1254) outcome. The association between estimated ů and trial size 
was evaluated across meta-analyses using regression and within meta-analyses 
using a Bayesian approach. Small trials were predefined as those having standard 
errors over 0.2 standardized effects.  
 
Results   
Most meta-analyses were based on few (median 4) trials. Within the same meta-
analysis, the small-study ůS2 was larger than the large-study ůL2 (average ratio 
2.11, 95% Credible Interval (1.05, 3.87) for dichotomous and 3.11 (2.00, 4.78) for 
continuous meta-analyses). The imprecision of ůS was larger than of ůL: median SE 
0.39 vs. 0.20 for dichotomous and 0.22 vs. 0.13 for continuous small-study and 
large-study meta-analyses.  
 
Conclusion   
Heterogeneity between small studies is larger than between larger studies. The 
large imprecision with which ů is estimated in a typical small-studies’ meta-
analysis is another reason for concern and sensitivity analyses are recommended.  
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What is new? 
Key findings 
x In a sample of 2009 meta-analyses with a dichotomous outcome and 1254 
meta-analyses with a continuous outcome of the CDSR Issues 2009-2013, 
the between-study heterogeneity ů was often estimated to be either zero 
or high, and the imprecision of the estimated ů was large, especially for 
meta-analyses based on few and/or small studies.  
x Small studies had higher mean heterogeneity estimates than 
medium/large studies of the same meta-analysis.  
 
What this adds to what was known? 
x Evidence from small studies tends to show not only larger effect sizes but 
also larger and less precise estimates of between-study heterogeneity.    
 
What is the implication and what should change now? 
x In a random-effects meta-analysis the estimated between-study 
heterogeneity directly affects the summary treatment effect and 
prediction interval. It should be realized that the estimated ů is often 
imprecise and on average larger for small studies. Sensitivity analyses to 
check robustness of the pooled effect estimate may be warranted. 
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1. Introduction 
In clinical research many small and possibly underpowered studies are 
conducted. Among interventional trials registered between 2007 and 2010 in 
ClinicalTrials.gov, 62% (17,726/28,458) enrolled at most 100 participants[1]. In 
2008, 70% (10,492/14,886) of the meta-analyses with a binary outcome in the 
Cochrane Database of Systematic Reviews (CDSR), Issue 1, consisted only of 
studies with less than 50% power to detect a 30% relative risk reduction[2].  
 
There is an ongoing debate on the disadvantages of small trials[3]. Small trials 
are associated with larger treatment effect estimates[2, 4, 5], and it is possible 
that between-study heterogeneity also increases when studies are smaller. 
Turner et al[2] observed that removing the underpowered (<50% power) studies 
from 1107 meta-analyses resulted in a median 21% decrease in the estimated ů2. 
Borm et al[6] observed higher heterogeneity between small rheumatoid arthritis 
studies compared to larger studies. Individual study results are influenced by 
many, possibly related aspects, like quality of study, publication bias and study 
size[7-10]. Califf et al[1] observed that small trials contain significant 
heterogeneity in methodological approaches, including reported use of 
randomization, blinding, and data monitoring committees. Button et al[11] 
argued that underpowered studies are prone to several analytical and reporting 
biases. Small studies may be of lower quality in other aspects of their design as 
well. This may affect the between-study heterogeneity. 
 
The current paradigm, in which multiple small studies are conducted and 
subsequently combined in a meta-analysis, is questioned[3, 12]. Especially in 
random-effects models and with substantial heterogeneity, the influence of small 
studies will be major and may affect the reliability of meta-analyses. On the 
other hand, simulations have shown that a meta-analysis containing many, 
possibly small, studies, is better than a single large trial able to estimate the 
treatment effect[6, 13, 14], even when there is some publication bias[15]. Roloff 
et al. [16] showed that in case of cumulative meta-analysis it is more powerful to 
add several small studies than one or a few large studies, because the between-
study heterogeneity can be estimated more precisely when more studies, either 
small or large, are available. However, a questionable assumption underlying 
their calculations is that heterogeneity is similar between small and large 
studies. The same questionable assumption occurs in standard applications of 
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random-effects meta-analysis: one single ů2 is used in the random-effects weights 
for all studies.  
 
If there is heterogeneity, treatment effects in individual studies may deviate 
more from the summary effect than expected by chance. Simulations have shown 
that when there is heterogeneity but no true treatment effect, the frequency of 
false statistically significant findings in single trials increases more than 10-
fold[15]. When small studies have higher than average heterogeneity, the 
increase in error rates for small single trials will be even larger. Also, prediction 
intervals[17] constructed with an average ů will result in too narrow predictions 
for the expected effect for future small trials.  
 
In summary, if there is a difference in heterogeneity between small and large 
trials, this can influence both the reliability of the results of single trials and of 
meta-analyses. Results of the current method for random-effects meta-analysis 
may be overly drawn towards the small-study results, prediction intervals may be 
too narrow, and false-positive findings of single trials may occur more frequently 
than expected.  
 
In this paper we investigate empirically whether the heterogeneity of small and 
large trials is different. We used meta-analyses from 3851 reviews on 
interventions of the 2009-2013 Issues from the Cochrane Database of Systematic 
Reviews (CDSR). First we investigated in a cross-sectional approach the relation 
between study size and heterogeneity across 3263 meta-analyses. As Turner et 
al. [18] showed that the extent of heterogeneity could be related to outcome 
and intervention type, our primary analysis is a paired-data approach, comparing 
the between-study heterogeneity of large trials with the small-study 
heterogeneity of the same meta-analysis.  
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2.  Methods  
2.1  Selected data 
The UK Cochrane Editorial Unit provided us with the statistical data of the 
systematic reviews of interventions, included in the CDSR Issues of 2009-2013. 
We used the mean values and standard deviations per treatment group for meta-
analyses with continuous outcomes, and counts (with/without event) for those 
with dichotomous outcomes. Most Cochrane reviews included multiple meta-
analyses, and meta-analyses from the same review are often correlated. The first 
reported analysis in a review is usually one of the primary analyses. Hence, to 
avoid subjectivity in selecting specific meta-analyses we used only the first 
meta-analysis appearing in the Data and Analyses section that was based on at 
least two studies. In order to maximize the number of meta-analyses for our 
evaluation, we used both the first continuous and the first binary outcome meta-
analysis, if available. A selected meta-analysis could contain sub-analyses. These 
sub-analyses were not always mutually exclusive, e.g. when subgroup analyses 
were done and the same individuals were used in more than one subgroup. If the 
sub-analyses were combined and resulted in a summary effect-size in the original 
review we also combined the subgroups. Otherwise, we selected the subgroup 
analysis based on the largest number of studies. 
 
2.2 Estimation of heterogeneity 
Heterogeneity can be expressed as the between-study variance ů2, with ů in the 
same unit as the meta-analysis outcome, or as a relative measure I2, the relative 
degree of inconsistency across studies [19, 20]. We focused on ů2, because in the 
random-effects analysis[21] and also in the reliability of the results of a single 
trial[13], ů2 plays a direct role as opposed to I2, which - even if ů2 remains the 
same - is expected to increase with increasing sample sizes of the studies:  
E(I2) = ů2/(ů2+Ů2),  where Ů2 is the typical within-study variance[19]. Further, the 
relation between I2 and sample size already has been investigated by others[22, 
23]. We used the empirical Bayes estimator for ů2, equivalent[24] to the 
robust[25] Paule and Mandel[25-27] estimator and more accurate than the widely 
used Method of Moments estimator of DerSimonian and Laird (DL)[21, 28], which 
is based on large sample assumptions[27]. Further, the relative bias is similar for 
small to large heterogeneity, as opposed to the DL and Restricted Maximum 
Likelihood estimators, that underestimate ů2 more as the heterogeneity 
increases, especially for dichotomous outcomes[25, 28]. We estimated ů2 for all 
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meta-analyses, even when the authors originally performed a fixed-effects 
analysis. Regression analyses were done with ů, because ů2 has a very skewed 
distribution. The paired comparisons between heterogeneity in large- and small-
study meta-analyses (section 2.5) were based on Bayesian estimates of ů. 
 
In order to remove unnecessary variation in the outcomes, continuous outcomes 
were analyzed as standardized mean differences (SMDs). Dichotomous outcomes 
were analyzed as log Odds Ratios (ORs), where log represents the natural 
logarithm. If no events were observed in one or both arms, we added 0.5 to all 
cells of such a study before we estimated the heterogeneity. Adding 0.5 will 
slightly move the treatment effect to nil and decrease the between-study 
heterogeneity[29]. As small studies more often have zero events than large 
studies, this is a conservative approach. Effect sizes were tuned, i.e. in order to 
give all meta-analyses a positive summary effect (SMD>0 or OR >1), the 
treatment groups in a meta-analysis were switched if needed. Pooled effect 
sizes, ů2 estimates and its standard errors (SEs) resulted from meta-analyses 
performed with the metafor package version 1.9-2 [30], R software [31] version 
3.0.1. The Bayesian approach was carried out using WinBUGs version 1.4.3[32], 
called from R with the package R2WinBUGS version 2.1-19 [33]. Other statistical 
analyses were performed with SAS/STAT® software version 9.2 for Windows, 
copyright© 2002-2008 by SAS Institute Inc., Cary, NC, USA. 
 
2.3 Definition of trial size 
We categorized trial size based on trial precision (1/SE of the treatment effect). 
For this categorization (only) we converted the precision of the trials with an OR 
outcome into the same order of magnitude as the trials with an SMD by 
multiplying the precision with S/3=1.81[34].  Trials were a priori categorized as 
very small (size<3), small (3size<5), medium sized (5size<7.5) or large 
(size7.5). The cutoff size for separating very small/small trials from 
medium/large trials was set at 5, corresponding to an SE of 0.2 standardized 
effects.    
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2.4 Heterogeneity and trial size - across meta-analyses  
We categorized the (geometric) mean trial size per meta-analysis in the same 
way as the trial size (section 2.3). Grouped by mean trial size, the estimated ů 
was cross-tabulated in three categories (0, 0-0.5, and >0.5), and medians and 
interquartile ranges (25th-75th percentile, i.e. Q1-Q3) of ů were presented for 
those meta-analyses with an estimated ů>0. We explored the relation between ů 
(continuous)  and mean log trial precision (1/SE) with weighted linear regression, 
as the data appeared to be heteroscedastic. We conducted univariable regression 
and multivariable regression adjusted for the log of the number of studies and 
Cochrane group, where Cochrane groups with less than seven observations were 
pooled in an ‘other’ group. Weights were based on the SE2 of ů, where the SE(ů) 
was estimated by taking the squared root of the limits of the 95% confidence 
interval (CI) for ů2, defined as ů2 ± 1.96 SE, and dividing the distance between 
these roots by 3.92. In addition, we explored the association between the 
estimated ů and trial precision per Cochrane group, and also the association with 
other meta-analysis characteristics (geometric mean study N, ratio of 
largest/smallest study, effect size, overall precision, total number of subjects 
and events, and mean event rate), adjusted for the log of the number of studies 
and Cochrane group. 
 
2.5 Heterogeneity and trial size – paired analyses  
An analysis of the association between heterogeneity and trial size across meta-
analyses may be hampered by confounders. For example, the endpoint of the 
analysis may have an impact on both the heterogeneity and the study 
precision[2, 18]. Hence an apparent relationship between heterogeneity and trial 
size may be solely the result of differences in endpoints across meta-analyses. A 
comparison of the heterogeneity of the largest studies versus heterogeneity of 
the smallest studies of the same meta-analysis is less prone to confounding. 
Therefore we also investigated the association between trial size (defined as in 
section 2.3) and heterogeneity within meta-analyses. This has the advantage that 
the results are matched, i.e. controlled for outcome. In the paired analyses small 
studies, categorized as having very low or low size (<5), were compared with 
large studies, i.e. medium or high size (5). In sensitivity analyses we restricted 
the comparison to the very small (<3) versus large trials (7.5). We selected 
meta-analyses that contained at least two trials of each type, i.e. at least two 
smaller and two larger trials and compared the heterogeneity between the larger 
studies with the heterogeneity between the smaller studies. If more studies were 
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available, those were also used in the paired comparison, because heterogeneity 
estimates are more precise when they are based on larger and/or more 
studies[35].  
 
In addition to several other characteristics, we estimated per meta-analysis the 
heterogeneity WS for the selected small studies, and in a similar way WL of the 
selected large studies. Effect sizes were tuned, i.e. in order to give the mean of 
the large-study and small-study meta-analysis a positive summary effect (SMD>0 
or OR >1), the treatment groups were switched if needed. Results were 
summarized with medians and Q1-Q3.  In order to compare WS and WL while 
incorporating the imprecision of the heterogeneity estimates we used a Bayesian 
approach. The ratio between the small-study WS versus the WL of the 
corresponding larger-study meta-analysis was estimated with Markov Chain Monte 
Carlo (MCMC) procedures in WinBUGS, using a bivariate lognormal distribution for 
WS and WL. The information contained in the posterior distributions for the mean 
ratio and the WS and WL was summarized by means and Bayesian (equal-tail) 95% 
credible intervals (CrI), and indicative p-values based on the percentage of times 
that the mean ratio of WS versus WL was 1. For the MCMC procedures we took 
200,000 iterations with 50,000 for burn-in, and thinning 1 per 100. We checked 
that the MCMC procedures had reached convergence by visually inspecting the 
history trace plots, the autocorrelation plots and the cumulative quantile plots 
for irregularities. The WinBUGS syntax of our model is provided in Table S1 in the 
appendix. 
 
3   Results  
3.1  Selected meta-analyses 
In total, 3851 reviews were retrieved from the CDSR Issues of 2009 to 2013 
(Figure 1). Selection of reviews containing a meta-analysis with a dichotomous or 
continuous outcome and based on at least two studies resulted in 2309 reviews: 
2009 contain at least one meta-analysis with a dichotomous outcome and 1254 at 
least one with a continuous outcome that could be used for the across-reviews 
analyses.  
 
Most meta-analyses were based on a few small studies. Of the 3,263 selected 
meta-analyses, 1,025 (31%) were based on two studies, 1,226 (38%) on three to 
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Figure 1.   Flowchart of selection and analysis. CDSR 2009-2013: Issues of the Cochrane 
Database of Systematic Reviews of 2009-2013; SR: systematic review; MA: meta-analysis; 
VS: very small; S: small; M: medium-sized; L: large.
ÀYHVWXGLHVRQVL[WRWHQVWXGLHVDQGRQPRUHWKDQWHQ
VWXGLHV7KHPHGLDQQXPEHURIVWXGLHVSHUPHWDDQDO\VLVZDV44DQG
PRVWRIWKHVWXGLHVZHUHVPDOORYHUDOORIWKHWULDOVZHUH
YHU\VPDOORUVPDOODQGRQO\ZHUHFDWHJRUL]HGDVODUJHU
DVPHGLXPVL]HGDQGDVODUJH0HWDDQDO\VHVZLWKDGLFKRWRPRXVRXW-
FRPHKDGDORZHUDYHUDJHVWXG\SUHFLVLRQ6(WKDQWKRVHZLWKDFRQWLQXRXV
RXWFRPHPHGLDQ44YHUVXV447KHQXPEHURI
very small and small trials was also higher for the meta-analyses with a dichoto-
PRXVRXWFRPHYHUVXVIRUWKRVHZLWKDFRQWLQXRXVRXWFRPH7KHPHGLDQ
HVWLPDWHGůZDV44IRUWKHPHWDDQDO\VHVZLWKDGLFKRWRPRXV
RXWFRPHDQG44IRUWKRVHZLWKDFRQWLQXRXVRXWFRPH0RUH
details of the selected meta-analyses are presented in Table 1. 
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The total number of Cochrane Groups present in our selection is 52. The 
Pregnancy and Childbirth Group provided by far most meta-analyses: 229 (11%) 
with a dichotomous and 135 (11%) with a continuous outcome. An overview of the 
Cochrane Groups including estimated heterogeneity and study precision can be 
found in Table S2 in the appendix. 
 
Table 1  Characteristics of the selected meta-analyses 
Median (Q1-Q3) 
MAs with 
dichotomous  
outcome   
(N=2009) 
MAs with 
continuous  
outcome 
 (N=1254) 
All  
MAs 
 
(N=3263) 
MA Effect size (OR / SMD) 1.64 (1.21–2.61) 0.31 (0.14-0.62) NA 
Precision (1/SE) MA effect size 4.3 (2.4-7.7) 7.0 (3.8-13.0) 5.1 (2.7-9.6) 
Total number of studies 13,116 7,069 20,185 
Total number of small studies a) 10,331 (79%) 4,654 (66%) 14,985 (74%) 
Number of studies per MA 4 (2-7) 3 (2-6) 4 (2-6) 
Number of small studies per MAa) 3 (2-6) 2 (1-4) 3 (2-5) 
Study precision (1/SE)b) per MA  1.5 (1.0-2.3) 4.0 (3.1-5.3) 2.4 (1.3-4.0) 
Study Nb)  per MA 99 (58-202) 67 (41-119) 85 (50-164) 
Ratio of largest/smallest study per 
MA 
4.3 (2.0-11.3) 3.1 (1.7-7.0) 3.7 (1.9-9.3) 
Number of subjects per MA  575 (237-1607) 298 (134-700) 432 (186-1263) 
Number of events per MA 114 (40-343) NA NA 
Mean event rate per MA 0.21 (0.08-0.44) NA NA 
Estimated ů 0 (0-0.41) 0.16 (0-0.46) 0.07 (0-0.43) 
Estimated ů2   0 (0-0.17) 0.03 (0-0.21) 0 (0-0.18) 
I2  (%) 0 (0-43.1) 39.3 (0-77.3) 4.8 (0-58.9) 
Data are summarized with median and interquartile range (Q1-Q3).  
MA: meta-analysis; OR: Odds Ratio; SMD: standardized mean difference; SE: standard 
error; NA: Not Applicable.  
a) Small studies contain the very small studies (size<3) and the small studies (size<5), see 
section 2.3 for the definition of size. b) geometric mean.   
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3.2 Heterogeneity versus study size – across meta-analyses 
In 1559 (48%) of the 3263 selected meta-analyses the estimated heterogeneity 
was zero. This percentage was higher for the meta-analyses with a dichotomous 
than with a continuous outcome: 55% vs. 36%.  
 
Figure 2 shows the estimated ů in relation to the mean study precision. The 
percentages in Table 2 suggest that in small studies the estimated ů is more often 
either equal to zero or larger than 0.5. For larger studies, ů seems more of 
moderate size, i.e. between zero and 0.5. For example, the percentage of 
dichotomous outcome meta-analyses with a moderate ů increased from 13% for 
meta-analyses with on average very small studies to 40% for meta-analyses of 
large studies. A similar increase, from 24% to 59%, is seen for the meta-analyses 
with a continuous outcome. The number of zero and large ů estimates decreased 
correspondingly. This pattern is also observed in the meta-analyses with an 
estimated ů >0. 
 
The estimated ů was negatively associated with the mean study precision 
according to  the univariable regression (Table 2), which suggests that small 
studies on average may have larger between-study heterogeneity. For the meta-
analyses with a dichotomous outcome, the negative association was no longer 
significant after adjustment for log number of trials and Cochrane Group, 
whereas for those with a continuous outcome it was.   
 
Most meta-analysis characteristics were much stronger associated with the 
estimated ů than the study precision. The increase in model R2 due to study 
precision was only 1% and 3% for the meta-analyses with a dichotomous and 
continuous outcome, respectively, compared to a model with only the Cochrane 
Group and log number of studies. Not surprisingly, the precision of the meta-
analysis effect estimate was by far the most associated, with an increase in 
model R2 of 39% and 43%, respectively. The meta-analysis effect size showed the 
second largest increase in R2 (10% and 14%, respectively), see Table S3 in the 
Appendix.  
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Figure 2.   Estimated heterogeneity (ů) versus trial precision across meta-analyses. 
Left: meta-analyses with a dichotomous outcome; right: meta-analyses with a continuous 
outcome. Mean study precision is the geometric mean of the precisions (1/SE) of the 
studies in a meta-analysis. Black dots correspond to meta-analyses with the 25% largest 
weights in the weighted regression, i.e. the 25% ů estimated most precisely.   
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Table 2    Estimated ů in relation to study precision across meta-analyses 
 Mean study size per MA a) 
 Very small Small Medium Large 
MAs with dichotomous outcome (N=2009)     
     
Overall 1108 580 214 107 
Estimated ů (n (%))     
   ů = 0 731 (66) 255 (44)  73 (34) 50 (47) 
   0 < ů 0.5 144 (13) 196 (34) 109 (51) 43 (40) 
   ů > 0.5 233 (21) 129 (22)  32 (15) 14 (13) 
Estimated ů if >0     
   N (MAs with est. ů >0) 377 325 141 57 
   Median ů 0.64 0.43 0.31 0.27 
   Q1-Q3 0.37–1.03 0.29-0.65  0.19-0.46 0.15-0.46 
   P90 1.58 0.96 0.69 0.73 
Linear regressionb)     
   Unadjusted slope -0.041, 95% CI (-0.055, -0.028) p< 0.001 
   Adjusted slope -0.013, 95% CI (-0.028, 0.001) p= 0.078 
MAs with continuous outcome (N=1254)     
     
Overall 282 603 246 123 
Estimated ů (n (%))     
   ů = 0 112 (40) 209 (35)  86 (35) 43 (35) 
   0 < ů 0.5  68 (24) 245 (41) 127 (52) 73 (59) 
   ů > 0.5 102 (36) 149 (25)  33 (13)  7   (6) 
Estimated ů if >0     
   N (MAs with est. ů >0) 170 394 160 80 
   Median ů 0.65 0.38 0.21 0.12 
   Q1-Q3 0.36–1.23 0.23-0.65  0.12-0.41 0.08-0.24 
   P90 1.81 1.01 0.78 0.47 
Linear regressionb)     
   Unadjusted slope -0.096, 95% CI (-0.113, -0.078) p< 0.001 
   Adjusted slope -0.072, 95% CI (-0.091, -0.052) p< 0.001 
MA: meta–analysis; CI: confidence interval; Q1-Q3: 25th and 75th percentile of distribution; 
P90: 90th percentile of distribution.  
a) Based on geometric mean study size per MA (section 2.4). b) Results of weighted linear 
regression with estimated ů as dependent and mean log study precision as independent 
variable, unadjusted, and adjusted for log number of studies and Cochrane group.  
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3.3  Trial size versus heterogeneity – paired analyses 
The 2009 series of trials with a dichotomous outcome resulted in 360 pairs of at 
least two large and two small trials; the 1254 series with a continuous outcome in 
235 pairs. Table 3.A shows the characteristics of the pairs. We found somewhat 
larger effect sizes for the meta-analyses based on small trials than on large 
trials, both for the dichotomous and the continuous outcomes. The imprecision 
(SE) of the ů estimates was higher for the small-study meta-analyses compared 
with the large-study meta-analyses, and much higher for the meta-analyses 
based on very small studies. The number of meta-analyses where ů was estimated 
to be zero was high, especially in the very small/small-study meta-analyses with 
a dichotomous outcome: 53%, compared to 42% for the corresponding pairs of 
medium/large-study meta-analyses, and 30% vs. 29% for the continuous outcome 
meta-analyses. The occurrence of ů>0.5 estimates also differed between the 
(very) small and the medium/large-study meta-analyses: 25% versus 11% for the 
meta-analyses with a dichotomous and 31% versus 9% for those with a continuous 
outcome. Overall, the estimated ůS was larger than ůL, with point estimates of 
0.22 vs. 0.15 and 0.27 vs. 0.15, and estimated mean ratios for W2S /W2L of 2.11 
(95% CrI 1.05–3.87) for the meta-analyses with a dichotomous and 3.11 (95% CrI  
2.00–4.78) for those with a continuous outcome.  
 
We also restricted the comparisons to the more extreme study size differences, 
see Table 3.B. For the meta-analyses with a dichotomous outcome, the 
percentage of ů=0 estimates was 67% for the very small studies versus 41% for the 
large studies, compared to twice 26% for the very small- and large-study meta-
analyses with a continuous outcome. The occurrence of ů>0.5 was 26% versus 6% 
for the very small- and large-study dichotomous and 58% versus 12% for the 
continuous outcome meta-analyses. For the meta-analyses with a continuous 
outcome the mean ratio W2S/W2L was again confidently larger than 1 (7.28, 95% CrI 
2.76–18.03), but for those with a dichotomous outcome the point estimate was 
smaller than 1 and the CrI contained the 1 (0.03, 95% CrI 0.00–2.23). Posterior 
distributions of the mean heterogeneity (WS and WL) are presented in Figure 3. 
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Figure 3.   Posterior distributions of the mean heterogeneity between small (ůS) and 
large (ůL) trials resulting from paired comparisons. Posterior densities are obtained with 
WinBUGS. MAs=meta-analyses. Left column: all possible pairs (very small/small vs. 
medium/large studies). Right column: pairs of very small vs. large studies. 
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Table 3.A Heterogeneity versus trial size – paired comparisons –  
All meta-analyses 
 
 Dichotomous Continuous 
 
Median  
(Q1-Q3) Trial size 
Very Small/ 
Small 
Medium/ 
Large  
Very Small/ 
Small 
Medium/ 
Large 
 
 
N 
 
360 
 
360 
 
235 
 
235 
 
No of studies  6 (3-11) 3 (2-5) 5 (3-9) 3 (2-7)  
Precision (1/SE) a) 1.5 (1.2-
1.8) 
3.9 (3.5-4.7) 3.5 (3.1-3.9) 6.9 (6.0-7.9)  
Study N b)  93 (67-146) 397 (262-734) 52  
(41-66) 
195  
(151-261) 
 
No of subjects   694  
(342-16301) 
1646  
(839-4190) 
284  
(164-518) 
799  
(390-2184) 
 
Effect size c) (OR/SMD) 1.72  
(1.24–2.53) 
1.29  
(1.10–1.71) 
0.40  
(0.20–0.68) 
0.20  
(0.10–0.38) 
 
No of events   125 (62-241) 412 (241-956)    
Mean event rate  0.20  
(0.08-0.42) 
0.29  
(0.13-0.46) 
   
W=0    d) (n (%))  190 (53%) 152 (42%) 71 (30%) 69 (29%)  
W>0.5 d) (n (%)) 90  (25%) 40  (11%) 73 (31%) 20   (9%)  
SE(W) d) 0.39  
(0.31-0.52) 
0.20  
(0.15-0.28) 
0.22  
(0.18-0.35) 
0.13  
(0.09-0.20) 
 
 
Comparison of WS with WL e) 
   
N 360 235  
W  (mean (95% CrI))  0.22  
(0.16,0.28) 
0.15  
(0.12, 0.18) 
0.27  
(0.22, 0.32) 
0.15  
(0.13, 0.17) 
 
      
WS / WL  (mean (95% CrI)) 1.45 (1.02, 1.97), p=0.02 1.76 (1.41, 2.19), p<0.001  
W2S /W2L  (mean (95% CrI)) 2.11 (1.05, 3.87), p=0.02 3.11 (2.00, 4.78), p<0.001  
Data are summarized with median and interquartile range (Q1-Q3), unless otherwise 
mentioned. OR: Odds Ratio; SMD: standardized mean difference; SE: standard error; Q1–
Q3: Interquartile range, with 25th and 75th percentile of distribution; CrI: Credible 
Interval; p: p-values based on CrI, for indicative purposes.   
a) Precision: geometric mean precision (1/SE) of selected large or small studies in the MA. 
b) geometric mean. c) Effect sizes were tuned such that the mean effect size per MA was > 
0 for SMDs and > 1 for ORs.  d) Based on Empirical Bayes estimates for W.  e) Based on 
Markov Chain Monte Carlo estimates.
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Table 3.B Heterogeneity versus trial size – paired comparisons –  
Very small-study versus large-study based meta-analyses 
 
 
 
Dichotomous Continuous 
Median (Q1-Q3) Trial size Very Small Large  Very Small Large  
 
N 
 
111 
 
111 
 
43 
 
43 
No of studies  4 (2-9) 3 (2-5) 3 (2-6) 5 (2-7) 
Precision (1/SE) a) 1 (0.8-1.2) 5.6 (5.0-7.1) 2.5 (2.2-2.6) 9.8 (8.8-10.7) 
Study N b)  79  
(50-146) 
985  
(570-2043) 
28  
(23-33) 
403  
(323-512) 
No of subjects   431  
(216-1233) 
3519  
(1901-8407) 
107  
(59-332) 
1921  
(1294-4007) 
Effect size c) (OR/SMD) 1.98  
(1.39–3.59) 
1.24  
(1.05–1.49) 
0.95  
(0.46–1.43) 
0.31  
(0.13–0.42) 
No of events   42 (24-102) 763 (465-1793)   
Mean event rate  0.11  
(0.04-0.32) 
0.20  
(0.11-0.41) 
  
W=0    d) (n (%))  74 (67%) 45 (41%) 11 (26%) 11 (26%) 
W>0.5 d) (n (%)) 29 (26%) 7 (6%) 25 (58%) 5 (12%) 
SE(W) d) 0.61  
(0.52-0.79) 
0.14  
(0.11-0.20) 
0.46  
(0.30-0.83) 
0.11  
(0.07-0.19) 
 
Comparison of WS with WL e) 
   
N 111 43 
W  (mean (95% CrI))  0.02   
(0, 0.15) 
0.11  
(0.07, 0.15) 
0.50  
(0.31, 0.71) 
0.18  
(0.14, 0.22) 
     
WS / WL  (mean (95% CrI)) 0.17 (0.00, 1.50), p=0.91 2.80 (1.66, 4.25), p<0.001 
W2S /W2L  (mean (95% CrI)) 0.03 (0.00, 2.23), p=0.91 7.82 (2.76, 18.03), p<0.001 
Data are summarized with median and interquartile range (Q1-Q3), unless otherwise 
mentioned. OR: Odds Ratio; SMD: standardized mean difference; SE: standard error; Q1–
Q3: Interquartile range, with 25th and 75th percentile of distribution; CrI: Credible 
Interval; p: p-values based on CrI, for indicative purposes.   
a) Precision: geometric mean precision (1/SE) of selected large or small studies in the MA. 
b) geometric mean. c) Effect sizes were tuned such that the mean effect size per MA was > 
0 for SMDs and > 1 for ORs.  d) Based on Empirical Bayes estimates for W.  e) Based on 
Markov Chain Monte Carlo estimates. 
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4 Discussion  
In a random-effects meta-analysis both the treatment effects of the individual 
studies and the between-study heterogeneity play an important role. Small trials 
are associated with larger effect sizes than large trials. In absence of publication 
bias, sample size in itself does not bias the outcome of a study [36]. However, 
there are several reasons why small trials may also have a different level of 
heterogeneity than larger trials. Only after promising results of the initial, small 
exploratory trials, larger trials tend to be conducted, possibly in different patient 
populations[4, 12, 37]. On the other hand, small trials may suffer from lower 
quality standards and show a diminished effect[38]. These opposite patterns may 
cause increased heterogeneity[20] which can only be studied with empirical 
data.  
 
Using over 3000 first meta-analyses from the CDSR Issues 2009-2013 we have 
investigated whether there is a relationship between study size and 
heterogeneity. Most meta-analyses were based on few (median 4; Q1-Q3: 2-6) 
studies.  On average, the estimated ů weakly decreased when precision was 
larger. In order to minimize effects of outcome and intervention type [18], we 
performed paired analyses, comparing heterogeneity from the smaller with the 
larger studies originating from the same meta-analysis. The findings show that 
the meta-analyses of very small/small studies result in significantly higher mean 
heterogeneity estimates than medium/large studies. Point estimates indicated an 
estimated mean ůS2 that was at least twice as large as ůL2.  
 
In 48% of the meta-analyses the estimated ů was zero, in a similar range as 
previously reported percentages of dichotomous meta-analyses: 49%, based on 
meta-analyses of at least two trials[20] and 37%, based on at least four 
studies[39]. Meta-analyses with low precision for the summary effect, i.e. based 
on few and/or small studies, resulted more frequently in zero or high (>0.5) point 
estimates for ů, and the corresponding imprecision (SE) of the estimated ů was 
large. The high occurrence of zero estimates may be caused by the fact that 
many of the selected meta-analyses were based on a few small studies and that 
sample variances for small studies are large. When studies have equal sample 
variances s2, the ů2 estimator corresponds to the sum of (yi – y)2/(k-1) minus s2 
[21, 25], or zero if the result is negative, where k is the number of studies. 
Consequently, for imprecise studies with large s2 the estimate of ů2 will often be 
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zero, even when the true heterogeneity is substantial. The sample variances of 
the small studies with a dichotomous outcome were larger than those of the 
small studies with a continuous outcome. This may have caused the abundance of 
zero ů estimates in the meta-analyses with a dichotomous outcome. This may 
also be the reason that the estimated mean ratio ů2S/ů2L was below 1 in the 
sensitivity analyses with dichotomous outcomes, whereas the other ratios were 
larger than 1. Also for the primary paired comparisons of the meta-analyses with 
a dichotomous outcome the ratios were lower compared to the ratios of the 
meta-analyses with a continuous outcome. 
 
Our study has some limitations, of which probably the most important is that we 
had to evaluate the relation between ů and study size using the estimates of ů 
instead of the true values. Especially if studies are small, heterogeneity may be 
present but difficult to estimate, which complicated in particular the analyses 
with the dichotomous outcomes. In the current setting of medical interventions, 
most of the estimates were imprecise. This was even more the case in the paired 
analyses, where we have split the original meta-analyses in a large- and a small-
study part. For a stable estimate of I2 approximately 500 events and 15 studies 
are needed[40], and the same may be true for ů. But if we had restricted our 
analyses to meta-analyses with 15 or more studies, the randomness of the sample 
would have become questionable. Performing the paired comparisons decreased 
our sample significantly. Therefore we also evaluated the relation between trial 
precision and heterogeneity across meta-analyses: this gave us the opportunity to 
include all meta-analyses. A second limitation is that the set of interventions for 
which a systematic review is conducted is not random. Some reviews may have 
been conducted for the very reason of conflicting results and between-study 
heterogeneity, while some others may have avoided meta-analyses specifically 
because of high heterogeneity[41]. Further, we used both the first dichotomous 
and the first continuous outcome meta-analysis from a review if available. Our 
conclusions with respect to the heterogeneity in meta-analyses with continuous 
and dichotomous outcomes are thus not independent.  
 
We conclude that the between-study heterogeneity for small studies is larger 
than for large studies, but often the estimate of ů is imprecise and either zero or 
high (>0.5). In future research the behavior of the estimated heterogeneity in the 
context of small studies with a dichotomous outcome should be investigated 
further. When the estimate of ů2 is imprecise, we recommend sensitivity analyses 
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to evaluate the robustness of the estimated combined meta-analysis effect, using 
various ů2 values. Using models that do not assume a common random effects 
distribution across studies ޤe.g. models with different ů2 estimates in the weights 
for small and large studiesޤ  is another possibility, but this would be difficult to 
perform in most meta-analyses, given the limited number of studies. Regardless, 
the results of random-effects meta-analysis need to be interpreted with extra 
caution, especially when small studies are involved. 
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Appendix 
 
Table S1  Winbugs model for paired comparisons 
 
model { 
for (i in 1:MAmax) 
{ 
logtaui[i,1:2]  ~ dmnorm(logtau[], Rtau[,]) 
tauS[i]   <- exp(logtaui[i,1]) 
tauL[i]         <- exp(logtaui[j,2]) 
precS.tau2 [i]  <- pow(tauS[i],-2) 
precL.tau2 [i]  <- pow(tauL[i],-2) 
mui[i, 1:2]  ~ dmnorm(mu[], R[ , ])   
muS[i]  <- mui[i,1] 
muL[i]  <- mui[i,2] 
for(j in offsetS[i]:(offsetS[i+1]-1))        # select studies of small-study MA i 
{ thetaS[j]  ~  dnorm(muS[i], precS.tau2[i]) 
wS[j]       <- 1/varyS[j] 
yS[j]         ~  dnorm(thetaS[j], wS[j])    
} 
for(j in offsetL[i]:(offsetL[i+1]-1))        # select studies of large-study MA i 
{ thetaL[j]  ~  dnorm(muL[i], precL.tau2[i]) 
wL[j]      <- 1/varyL[j] 
yL[j]      ~  dnorm(thetaL[j], wL[j])     
} 
logdelta[i] <- logtaui[i,1]-logtaui[i,2]  } 
# prior distributions 
 logtau[1:2] ~ dmnorm(logtau0[],prec0[,])     
 Rtau[1:2,1:2]  ~  dwish(Omega[,],2)  
 mu[1:2]      ~  dmnorm(mu0[],prec0[,])     
 R[1:2,1:2]       ~  dwish(Omega[,],2)  
  } 
# mu0: vector(0,0);  logtau0: vector (-1,-1) 
# Omega: Identity matrix I 2x2; prec0:  I x 1.0E-6 
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Abstract
Objectives
Evaluating the variation in the strength of the effect across studies is a key 
feature of meta-analyses. This variability is reflected by measures like ů2 or I2 [1, 
2] but their clinical interpretation is not straightforward. A prediction interval is 
less complicated: it presents the expected range of true effects in similar 
studies.[3] Our objective is to recommend the prediction interval as an 
alternative to ů2 or I2.  
 
Design
We show how the prediction interval can help understand the uncertainty about 
whether an intervention works or not. To evaluate the implications of the 
variability in the effect, we selected the first meta-analysis per intervention 
review of the Cochrane Database of Systematic Reviews Issues 2009-2013 with a 
dichotomous (n=2009) or continuous (n=1254) outcome, and compared the values 
in the prediction intervals with clinical thresholds.  
 
Results 
In 72.4% of 479 statistically significant (random effects p<0.05) meta-analyses in 
the Cochrane Database 2009-2013 with positive heterogeneity, the 95% 
prediction interval suggested that the intervention effect could be null or even 
be in the opposite direction. In 20.3% of those meta-analyses, the prediction 
interval showed that the effect could be completely opposite to  the point 
estimate of the meta-analysis. The prediction interval can also be used to 
calculate the probability that a new trial will have a negative effect and to 
improve the calculations of the power of a new trial. 
Conclusions 
The prediction interval reflects the variation in treatment effects over different 
settings, including what effect is to be expected in future patients such as the 
patients that a clinician is interested to treat. Prediction intervals should be 
routinely reported to allow more informative inferences in meta-analyses. 
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Strengths and limitations of this study 
 In many meta-analyses there is variation in the strength of the effect.  
 The prediction interval helps in the clinical interpretation of the 
heterogeneity by estimating what true treatment effects can be 
expected in future settings. 
 In case of heterogeneity, prediction intervals will show a wider range of 
expected treatment effects than confidence intervals, and thus may lead 
to different conclusions. This occurred in over 70% of statistically 
significant meta-analyses with positive heterogeneity of the Cochrane 
Database of Systematic Reviews. Completely opposite effects were not 
excluded in over 20% of those meta-analyses. 
 Prediction intervals should be routinely reported to allow more 
informative inferences in meta-analyses. 
 Limitations of this study are that the calculations and inferences for the 
prediction interval are based on the normality assumption, which may be 
unjustified. Further, the interval will be imprecise if the estimates of the 
summary effect and the ů2 are imprecise, for example if they are based 
on only a few studies. Inferences based on the prediction interval are 
only valid for settings that are similar (exchangeable) to those on which 
the meta-analysis is based.
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Introduction
Interventions may have heterogeneous effects across studies because of 
differences in study populations, interventions, follow-up length, bias, and other 
factors.[4] Nevertheless, the usual reporting of a meta-analysis is focused on the 
summary effect size combined with a confidence interval (CI) and p-value. 
Typically also some measure of the between-study heterogeneity is presented 
such as ů2 or the inconsistency measure I2.[1, 2]  However, neither of these two 
metrics can readily point to the clinical implications of the observed 
heterogeneity. Our objective in the current article is to recommend the 
prediction interval as an alternative to ů2 or I2 because its clinical meaning is 
much more straightforward. The prediction interval presents the heterogeneity 
on the same scale as the original effect size measure, in contrast to ů2 or I2. 
Reporting a prediction interval in addition to the summary estimate and 
confidence interval will illustrate which range of true effects can be expected in 
future settings. We describe its merits and provide an example to show how it 
can be calculated. 
 
Interpretation of heterogeneity 
Between-study variation cannot be neglected. One of the main merits of a meta-
analysis may even be that it reveals the variation of effects in different 
studies.[3] Therefore summarizing the findings of a meta-analysis in a single 
summary value sacrifices potentially informative variation.[5] However, the 
information that can be directly retrieved from ů2 and I2 with respect to the 
variation in the effects is limited. The clinical interpretation of I2 is ambiguous: a 
high I2 does not necessarily imply that the study effects are dispersed over a wide 
range[6] and a low I2 might correspond to high dispersion[7], because I2 depends 
on sample size. With very large (highly precise) studies, even tiny differences in 
effect size may result in a high I2, while with small (imprecise) studies, very 
different treatment effects can yield an I2 of 0. Dispersion in treatment effects is 
better reflected by ů because ů is the standard deviation of the between-study 
effects. One could for example estimate the ratio of the effect size over ů, which 
can convey how many times larger the treatment effect is compared to the 
standard deviation of the effect across studies.[8] But this may still be not very 
intuitive to a clinical reader. Another popular way to express variation in effect 
sizes is the CI, e.g. the 95% CI. The CI in a random effects model contains highly 
probable values for the summary treatment effect. However, it does not convey 
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what range of treatment effects are likely to be seen in other patients, e.g. in 
the next study or in the patients a clinician wants to treat in her clinic.  
 
Prediction intervals 
Not so often reported but much more insightful is the prediction interval.[9] A 
prediction interval always presents the heterogeneity on the same scale as the 
original outcomes, in contrast to W, W2 or I2. A 95% prediction interval estimates 
where the true effects are to be expected for 95% of similar (exchangeable) 
studies that might be conducted in the future.[3] Therefore it is well suited to 
evaluate the variability of the effect of an intervention over different settings. In 
the absence of between-study heterogeneity, the prediction interval coincides 
with the respective CI. However, in case of heterogeneity a prediction interval 
covers a wider range than a CI. Consequently, in case of a statistically significant 
effect (where all values of the 95% CI are on the same side of the null) the 
corresponding 95% prediction interval may indicate that values are possible on 
both sides of the null. This means that there will be settings where conclusions 
based on CIs will not hold. In the same framework, one can also calculate the 
probability that the true effect will be harmful (on the other side of the null) in a 
next study. Table 1 presents an overview of measures of between-study 
heterogeneity. 

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Table 1 Some frequently used measures for heterogeneity
Measure Advantages Disadvantages 
W2   
x W (the square root of W2) is the standard deviation 
of the between-study variation on the scale of 
the original outcome 
x W2 is the direct estimate of the between-study 
variation and therefore useful in calculations, 
e.g. for the prediction interval 
x A direct clinical interpretation based on 
W2  is difficult, especially when W2 belongs 
to outcomes that were analyzed on log-
scale, e.g. odds ratios. 
x When the W2 estimate is based on only a 
few studies it will be imprecise 
I2  
x I2 presents the inconsistency between the study 
results and quantifies the proportion of observed 
dispersion that is real, i.e. due to between-study 
differences and not due to random error (Ref 
Higgins 2003).  
x I2 reflects the extent of overlap of the 
confidence intervals of the study-effects.  
x I2 represents the inconsistency always on a scale 
between 0 and 100, therefore it can be 
compared with suggested limits for low or high 
inconsistency (Cochrane handbook) 
x A direct clinical interpretation of I2 is 
difficult.  
x I2 is also ambiguous because its size 
depends on sample size:  
o with very large studies, even tiny 
between-study differences in effect 
size may result in a high I2 
o with small (imprecise) studies, very 
different treatment effects can yield 
an I2 of 0 
Confidence interval (CI)  
x The CI in a random effects model contains highly 
probable values for the summary (mean) 
treatment effect. 
x The CI gives no information on the range 
of true treatment effects that are likely 
to be seen in other settings, e.g. in the 
next study or in the patients a clinician 
wants to treat in her clinic.  
Prediction interval  
x The prediction interval in a random effects 
model contains highly probable values for the 
true treatment effects in future settings, if those 
settings are similar to the settings in the meta-
analysis. 
x The values in the interval can be compared with 
clinically relevant thresholds to see whether they 
correspond to benefit, null effects or harm. 
x The prediction interval can be used to estimate 
the probability that the treatment in a future 
setting will have a true positive or negative 
effect, and to perform better power calculations 
x Conclusions drawn from the prediction 
interval are based on the assumption 
that W2 and the study effects are 
normally distributed  
x The estimate of the prediction interval 
will be imprecise if the estimates of the 
summary effect and the W2 are imprecise, 
for example if they are based on only a 
few studies and if these studies are small  
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Example: Topical steroids for nasal polyps 
 A 2012 review on the use of topical steroids for treatment of chronic 
rhinosinusitis with nasal polyps, based on seven randomized studies, resulted in a 
larger decrease in overall symptom scores in favor of steroids compared to 
placebo, reflected by a standardized mean difference (SMD) of -0.51, with a 95% 
CI from -0.96 to -0.07 (Figure 1).[10] The I2 was 73.9% (95% CI, 44.2% to 87.8%), 
which can be considered substantial heterogeneity[11], and the estimated ů2 was 
0.148. Notwithstanding these numbers, it is difficult to evaluate what the clinical 
consequences of this heterogeneity may be for future settings. 
 
In order to estimate the prediction interval for the SMD we need the point 
estimate of the SMD, its standard error (SE) and the estimated ů2. As the SE was 
not reported, we derive it from the 95% CI of the SMD (formula 1 appendix), 
which results in an SE of 0.182. We can calculate the standard deviation of the 
prediction interval SDPI as ¥(0.148 + 0.1822) and the lower and upper limit of the 
95% prediction interval as -0.51 r 2.45 × SDPI. The value 2.45 results from the 
t0.05/2,6-distribution. Prediction intervals with a different coverage could be 
calculated by using a different t-value, e.g. t0.20/2,6 for an 80% prediction interval 
(formula 1 appendix). 
 
The resulting prediction interval, ranging from -1.55 to 0.53, can be interpreted 
as the 95% range of true SMDs to be expected in similar studies. We present it in 
Figure 1 as a rectangle below the diamond for the 95% CI.[12] The prediction 
interval contains values below zero, which corresponds to a decrease in symptom 
scores of at best approximately 1.5 SD after steroid use compared to placebo. 
But it also contains values above zero which means that the steroids may exhibit 
no or even a harmful effect (SMD>0) in some settings, with a (95%) worst case 
increase in SMD of 0.53.  Consequently, the effect in a new study may be even 
opposite to the summary point estimate of the meta-analysis, i.e. an increase of 
0.51 instead of a decrease of -0.51 may occur. The estimated probability that the 
true effect of the steroids will be null or higher in a new study is equal to 13.6%, 
based on the t-distribution with 6 degrees of freedom (formula 2 appendix).  
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Figure 1.    Forest plot of the standardized mean difference in symptom scores in nasal 
polyps. Steroids versus placebo, Analysis 1.1 in Cochrane Review CD006549.[10]
Note that our results differ from the original analysis, as we used a random-effects 
analysis with the Hartung-Knapp/Sidik-Jonkman adjustment[13] and the empirical Bayes 
estimator for τ2. 
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Cochrane database 
In order to investigate how often there is a discrepancy in conclusions based on 
prediction intervals and CIs we evaluated this in statistically significant meta-
analyses (p<0.05 by random effects calculations) of the Cochrane Database of 
Systematic Reviews Issues 2009-2013, kindly provided by the UK Cochrane 
Editorial Unit. To avoid subjectivity in the selection we used the first meta-
analysis with a dichotomous or continuous outcome and based on at least two 
studies in the Data and Analyses section. Details can be found in another 
paper.[14] In brief, of a total of 3263 meta-analyses, 920 were statistically 
significant: 479 with an estimated I2>0 and 441 with an estimated I2=0.  
 
Calculations
We used the Hartung-Knapp/Sidik-Jonkman[13] random effects meta-analysis 
approach combined with the empirical Bayes estimator for ů2. We estimated ů2 
for all meta-analyses, even when the authors originally performed a fixed effects 
analysis. Prediction intervals were calculated according to formula 1 (Appendix). 
We categorized the statistically significant meta-analyses with positive 
heterogeneity by number of studies (2-6 studies or >6) and heterogeneity (I2<30%, 
30-60%, or >60%, based on the Cochrane Handbook[11] stating that an I2 between 
30% and 60% corresponds to moderate heterogeneity). For significant meta-
analyses where the heterogeneity estimate was zero, we assessed the impact of 
possibly low but non-zero heterogeneity by assuming an I2 of 20%,  calculating 
prediction intervals using formula 3 (appendix). We used R software[15] version 
3.1.2 and the R packages metafor[16] version 1.9-5 and meta[17] version 4.1-0.  
Results 
Overall, 132 (27.6%) of the 479 statistically significant meta-analyses with an  
I2 > 0 had both the 95% CI and the 95% prediction interval excluding the null 
effect (Table 2). Consequently, almost three-quarter (72.4%) had a prediction 
interval that contained the null effect. This means that it is likely that for these 
comparisons some patient populations might experience null effects or effects in 
the opposite direction, i.e. a treatment might be more harmful than the 
comparator even though the point estimate suggests benefit (or vice versa). Not 
surprisingly, significant meta-analyses with low heterogeneity more often had 
prediction intervals that excluded the null than meta-analyses with high 
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heterogeneity.  The percentage of prediction intervals containing the null effect 
was slightly higher for meta-analyses with a continuous outcome (80.4%) than for 
those with a dichotomous outcome (65.8%),  and for meta-analyses based on 
more than six studies (74.1%) than for those with at most six studies (69.1%).  
(Tables S1.A and S1.B in the Appendix).  
 
Prediction intervals containing the opposite effect 
If the prediction interval just includes the null effect, this may be less worrying 
than when it contains the opposite effect of the pooled summary effect, e.g. if it 
contains an OR of 0.5 when the meta-analysis summary estimate is an OR of 2, or 
if it contains an SMD of -0.7 when the summary estimate was 0.7. Of the 479 
significant meta-analyses with an I2 > 0, 97 (20.3%) had a prediction interval that 
contained the opposite effect. This percentage was higher for the meta-analyses 
with a continuous outcome (65/219, 29.7%) than for those with a dichotomous 
outcome (32/260, 12.3%). It occurred also more frequently in meta-analyses with 
more than 6 primary studies (57/139 and 30/178 for meta-analyses with a 
continuous or dichotomous outcome, respectively) than for those based on at 
most 6 studies (8/80 and 2/82). 
Meta-analyses with estimated I2 = 0 
A substantial part of meta-analyses have an estimated I2 of 0. However, there is 
typically very large uncertainty about the exact amount of heterogeneity and this 
is demonstrated by very large 95% CIs for the values of I2.[18] The same applies 
to ů: an estimate of 0 is often accompanied by large uncertainty. The true I2 and 
ů are unlikely to ever be exactly 0, although low values are possible. To assess 
the impact of possibly low but non-zero heterogeneity  among the 441 Cochrane 
meta-analyses with estimated I2=0 and statistically significant results, we 
imputed an I2=20% (suggestive of low between-study heterogeneity). Under this 
assumption, in 329 (74.6%) of these 441 meta-analyses the 95% prediction 
interval would span both sides of the null (Table 2), similar for meta-analyses 
with a dichotomous (74.7%) or continuous (74.4%) outcome (Tables S1.A in the 
Appendix). This is a sensitivity analysis that is useful to perform to see whether 
the inferences of a meta-analysis that seemingly does not have detectable 
heterogeneity may be influenced by even a small amount of heterogeneity.   
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Table 2  Proportion of statistically significant meta-analyses where both the 95% 
confidence and prediction intervals excluded the null 
 Estimated heterogeneity I2
Statistically significant meta-analyses I2=0a) I2>0  >0ޤ30% 30-60% >60% 
N 441 479  123 150 206 
Both 95% CI and 95% PI excluded null (n (%))  112  
(25.4) 
132 
(27.6) 
  88 
(71.5) 
 39 
(26.0) 
    5 
(2.4) 
CI: confidence interval; PI: prediction interval.  
a) When the estimated heterogeneity I2 was equal to 0, I2=20% was imputed for the calculation of the 
prediction interval. 
Power calculations for a future study 
Meta-analysis results can also be used for power calculations for a new study. 
However, the expected true effect in a new study is not necessarily equal to the 
point estimate of the meta-analysis: it can be any of the values in the prediction 
interval. In case of heterogeneity an apparent power of 80% based on the point 
estimate will be overly optimistic because the power function is asymmetric. If 
the true study effect is larger than the point estimate the real power of the 
study will be higher, up to a maximum of 100%, but if the effect is smaller the 
power may decrease substantially, even to 5% or less in case of a null effect. 
Consequently the expected power of a new study in case of heterogeneity will be 
lower than 80% (formula 4 appendix). For example, if the prediction interval 
shows that 30% of future studies may have a true null or negative effect, the 
power can never be much larger than 70%.  The sample size should be increased 
to compensate for this loss in power, see also Roloff et al.[19]
 

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Conclusions and outlook 
In meta-analyses a CI is inadequate for clinical decision making because it only 
summarizes the average effect for the average study. The prediction interval is 
more informative as it shows the range of possible effects in relation to harm and 
clinical benefit thresholds. While we have focused on the situation where the 
separating threshold is the null, a different threshold may be considered. For 
example, in the prediction interval framework one can calculate the probability 
that an effect is larger than B, where B may be a clinically meaningful effect (if 
the treatment benefit is less than B, then it is felt not to be worth it). A narrow 
prediction interval that lies completely on the beneficial side of a clinically 
relevant threshold increases confidence in an intervention. A broad prediction 
interval may indicate the existence of settings where the treatment has a 
suboptimal and possibly even harmful effect. In more than 70% of statistically 
significant meta-analyses of the Cochrane Database with some estimated or 
assumed between-study heterogeneity the prediction intervals crossed the no-
effect threshold, indicating that there are settings where those treatments will 
have no effect or even an effect in the opposite direction. In 20.3% of those 
meta-analyses the prediction interval even contained the opposite effect of the 
summary estimate, for example an OR of 0.5 when the summary point estimate 
was an OR of 2. This occurred most frequently for meta-analyses with a 
continuous outcome and for meta-analyses based on more than six studies, 
probably because such meta-analyses have more power to detect smaller effects, 
which means that also the opposite effects will be smaller. 
 
Graham en Moran[20]  evaluated prediction intervals in 72 meta-analyses with a 
dichotomous outcome in critical care published between 2002 and 2010. They 
found a higher percentage of significant meta-analyses (50/72, 69.4%), compared 
to 28.5% (572/2009) in our set of meta-analyses with an odds ratio outcome. The 
difference may be caused by publication bias, the higher number of primary 
studies in their sample (medium 9 versus 4 in our set[14]), and by their use of the 
DerSimonian-Laird approach which can result in too many significant findings, 
whereas we used the HKSJ approach.[13] However, results with respect to the 
prediction interval were remarkably similar. In 32 (64.0%) of their 50 significant 
meta-analyses the 95% prediction interval included the null, similar to 65.8% in 
our dataset. Seven (14.0%) of their 50 meta-analyses suggested a high probability 
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of efficacy or harm, similar to 12.3% of our meta-analyses where the prediction 
interval contained the opposite effect, despite the fact that they used a 
different definitions for possible “harm” and that they do not mention whether 
there was positive between-study heterogeneity in their significant meta-
analyses.  
 
It is straightforward to calculate a prediction interval if we can assume that the 
effects are normally distributed and that ů2 is known and stable across studies. 
However, one should realize that the prediction interval is dependent on this 
assumption and on the precisions of the estimated ů2 and study effect, and will 
be imprecise if the number of studies in the meta-analysis is small. If the number 
of studies is large, estimates will be more precise and the normality of the 
distribution of ů2 can be evaluated. A final caveat is that the uncertainty 
conveyed by the prediction interval pertains to the uncertainty about the extent 
to which future studies are similar (exchangeable) to those that have already 
been done, but this applies to all inferences from a meta-analysis. If the future 
studies evaluate patients and settings that are entirely different from what was 
evaluated in past studies, this exchangeability is questionable and uncertainty 
may be even more prominent than what the prediction interval conveys. In 
practical terms, if the patients treated by a physician are considered to be very 
different from the patients seen in all studies that have been done in the past, 
even the prediction interval cannot tell us what we might expect for these 
patients.  
 
Summarizing, the prediction interval reflects the variation in true treatment 
effects over different settings, including what effect is to be expected in future 
patients such as the patients that a clinician is interested to treat. Therefore it 
should be routinely reported in addition to the summary effect and its 
confidence interval, and used as a main tool for interpreting evidence, to enable 
more informed clinical decision making.  
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Appendix 
Formula 1 Prediction interval 
In order to calculate the 95% prediction interval, the summary meta-analysis 
estimate M, the two sided critical t-value t0.05/2, k-1 and the standard deviation for 
the prediction interval SDPI are needed. Here, t is the two-sided critical t-value 
that can be calculated via 
http://www.danielsoper.com/statcalc3/calc.aspx?id=10. Fill in DF=k-1 and 
probability level 0.025, with k the number of studies in the meta-analysis. SDPI is 
the standard deviation of the prediction interval: SDPI  = ¥(ů2+SE2),where ů2 is the 
estimated heterogeneity and SE is the standard error of M[4, 16]. If the SE was 
not reported, it can be approximated by dividing the distance between the limits 
of the 95% CI of the SMD by 3.92. The lower and upper limits of the 95% 
prediction interval are equal to M ± t0.05/2, k-1× SDPI.  Of course it is possible to 
estimate prediction intervals with a different coverage, e.g. an 80% prediction 
interval would be based on t0.20/2,6. 
 
Estimations for ORs, risk ratios and hazard ratios are generally performed on the 
natural logarithm scale. As an example we take the calculation of a 95% 
prediction interval for an OR of 2.28 with a 95% CI from 1.05 to 4.96, ů2= 0.353 
and k=7. The prediction interval will first be estimated on log scale. Note that 
the reported ů2  is in general already the heterogeneity for log OR, not for OR, 
and can thus be used directly in the calculations. The SE of the log OR is 
calculated by dividing the distance between the log of the limits of the 95% CI of 
the OR by 3.92. This results in SE=0.318.  
 
The lower and upper limits of the 95% prediction interval for the log OR are 
log(2.28) r 2.45¥(0.353 + 0.3182). The value 2.45 results from the t0.05/2-
distribution with 6 DF. Finally, we exponentiate the limits to return to the OR 
scale. The resulting prediction interval ranges from 0.44 to 11.86, and can be 
interpreted as the 95% range of true ORs to be expected in similar studies.  
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Formula 2 Probability that effect is larger than threshold  D 
The probability P that the true effect in a new study will be below a threshold D 
(e.g. the null effect) can be calculated with the left-tail cumulative t-
distribution with k-1 degrees of freedom. The probability that the effect is above 
D equals 1 – P. 
 
In our example on nasal polyps the probability that the SMD  0 can be estimated 
as follows:  
1. Start to calculate the probability P that a true SMD  0. This is equivalent to 
the probability that a t-value  T, where T is equal to (D – M)/SDPI, with 
summary treatment effect M= -0.51, SDPI = 0.425 and D=0. This results in T = 
1.207, with 6 degrees of freedom (DF). 
2. The probability P can be calculated online at 
http://www.danielsoper.com/statcalc3/calc.aspx?id=41. Fill in t value = 
1.207 and DF = 6. The one-tailed probability P(t 1.207)= 0.864. 
3. We want the probability that the SMD 0, this is 1 – P= 0.136. 
In the example on the OR (see formula 1), if we are interested in the probability 
of a null or negative effect, we are interested in the probability that a true OR  
1. For ORs, calculations must be based on the ln OR, with M= ln(2.28)=0.824, SDPI 
= 0.674, and DF=6. A true OR  1 corresponds to a true ln OR  0.  
Fill in T = (0-0.824)/0.674 = -1.223 and DF=6. The probability that a true OR  1 
is equal to 0.134.
Formula 3 Prediction interval starting with I2
In order to calculate prediction intervals starting with an assumed I2 value (as 
percentage), we first calculated the corresponding ů2value:  
߬ଶ ൌ ݏଶௗ ܫ
ଶ
ͳͲͲ െ ܫଶ 
 
with s2 the typical study variance, equal to  
σ୵౟ሺ୩ିଵሻ
ሺσ୛౟ሻమିσ௪೔మ
,   
and wi equal to the inverse of the study variance of study i (i=1..k) and k the 
number of studies.[21] Subsequently formula 1 can be applied. 
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Formula 4 Power of a future study 
Usually sample size calculations are performed without consideration of the 
heterogeneity. If we do take into account the heterogeneity, the expected 
power, i.e. the probability that a new study with N patients will have a positive 
result at significance level Ş, given values for the standard error s of the new 
study and õ and ů2 as above, can be approximated with the delta method if ů2 is 
not too large:  
ܧሺ݌݋ݓ݁ݎሻ ൌ ݃ሺߤሻ ൅ ͲǤͷ߬ଶ݃ȬȬሺߤሻ     
where ݃ is the power at the meta-analysis summary estimate õ, and ݃ȬȬሺߤሻis the 
second derivative of ݃ at õ. For ݃ȬȬሺߤሻ we can take the second derivative of the 
normal cumulative distribution function if N is sufficiently large.  
This results in ݃ȬȬሺߤሻ ൌ ௭ഋ௘
షబǤఱ೥ഋమ
௦మξଶగ , with ݖఓ ൌ
ଵǤଽ଺ୱȂ
ୱ Ǥ  
 
If the sample size N of the new study is such that the power for an effect of size 
õ is 80%, the expected power of the study will be smaller than 80%  if ů2 is 
positive, because the corresponding value of zõ is negative. 
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Table S1.A Proportion of statistically significant meta-analyses where both the 
95% confidence and 95% prediction intervals excluded the null 
Separately for dichotomous and continuous outcomes  
 I2=0 I2>0  <30 30-60 >60 
All meta-analyses (N=3263)       
MA stat. significant  (N) 441 479  123 150 206 
Both 95% CI and 95% PI excluded the null a) 
(N (%)) 
112 
(25.4) 
132  
(27.6) 
 88 
(71.5) 
39 
(26.0) 
5  
(2.4) 
      
MAs with dichotomous outcome (N=2009)       
MA stat. significant (N) 312 260  88 96 76 
Both 95% CI and 95% PI excluded the null a)  
(N (%)) 
79 
 (25.3) 
89  
(34.2) 
 61 
(69.3) 
23 
(24.0) 
5  
(6.6) 
      
MAs with continuous outcome (N=1254)       
MA stat. significant  (N) 129 219  35 54 130 
Both 95% CI and 95% PI excluded the null a) 
(N (%)) 
33  
(25.6) 
43  
(19.6) 
 27 
(77.1) 
16 
(29.6) 
0  
(0.0) 
MA: meta-analysis; CI= 95% confidence interval; PI= 95% prediction interval;  
a) When the estimated heterogeneity I2 was equal to 0, I2=20% was imputed for the 
calculation of the prediction interval 
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Table S1.B Proportion of statistically significant meta-analyses where both the 
95% confidence and 95% prediction intervals excluded the null 
Separately for dichotomous and continuous outcomes and 2-6 vs. >6 
studies 
2-6 studies I2=0 <30 30-60 >60 
All meta-analyses      
MA stat. significant  (N) 322 44 59 59 
Both 95% CI and 95% PI excluded the null a) 
(N (%)) 
74 (23.0) 32 (77.7)  17 (18.8) 1 (1.7) 
MAs with dichotomous outcome      
MA stat. significant (N) 210 32 30 20 
Both 95% CI and 95% PI excluded the null a)  
(N (%)) 
50 (23.8) 24 (75.0) 7 (23.3) 1 (5.0) 
MAs with continuous outcome     
MA stat. significant  (N) 112 12 29 39 
Both 95% CI and 95% PI excluded the null a) 
(N (%)) 
24 (21.4) 8 (66.7) 10 (34.5) 0 (0.0) 
>6 studies I2=0 <30 30-60 >60 
All meta-analyses      
MA stat. significant  (N) 119 79 91 147 
Both 95% CI and 95% PI excluded the null a) 
(N (%)) 
38 (31.9) 56 (70.9) 22 (24.2) 4  2.7) 
MAs with dichotomous outcome     
MA stat. significant (N) 102 56 66 56 
Both 95% CI and 95% PI excluded the null a)  
(N (%)) 
29 (28.4) 37 (66.1) 16 (24.2) 4 (7.1) 
MAs with continuous outcome     
MA stat. significant  (N) 17 23 25 91 
Both 95% CI and 95% PI excluded the null a) 
(N (%)) 
9 (52.9) 19 (82.6) 6 (24.0) 0 (0.0) 
MA: meta-analysis; CI= 95% confidence interval; PI= 95% prediction interval;  
a) When the estimated heterogeneity I2 was equal to 0, I2=20% was imputed for the 
calculation of the prediction interval 
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The aim of this thesis was to give more insight into the application of  meta-
analysis methodology and to reflect on the role of between-study heterogeneity 
in the realistic setting where most meta-analyses are based on just a few studies 
and where some of these studies are small or very small.
There is much interest in the application of meta-analysis, as it provides a 
suitable quantitative method to summarize the continuously increasing amount 
of information resulting from more than 75 publications on randomized 
controlled trials per day.[1] Moreover, a meta-analysis can result in a better 
estimate of an effect size than a new large study, particularly if there is 
between-study variation in the results, which is the case in approximately 50% of 
the meta-analyses. Due to this heterogeneity the results of a single trial may be 
overly positive or negative, and one cannot know how far they deviate from the 
average effect without knowing the results of other studies. The simulations 
presented in Chapter 3 show that even if there are only two or three primary 
studies - possibly subject to publication bias - the estimate of the effect size 
provided by the meta-analysis is preferable to the results of a single new trial, 
because the meta-analysis results in lower error rates for false positive findings.  
Estimates of the between-study heterogeneity are imprecise if they are based on 
small numbers of studies. Data retrieved from the Cochrane Database of 
Systematic Reviews Issues 2009-2013 clearly show that many meta-analyses are 
based on only a few (medium 4, interquartile range 2-6) primary studies. The 
imprecision of the estimated heterogeneity is neglected in the commonly used 
DerSimonian and Laird (DL) method for random effects meta-analysis. For meta-
analyses with realistic numbers of primary studies (2-20 studies) we showed that 
a simple variation on the DL method, developed by Hartung and Knapp and also 
by Sidik & Jonkman (HKSJ) results in more adequate false positive error rates 
than the DL method (Chapter 4). Of course there exist other, possibly more 
advanced methods that result in an improvement of error rates compared to DL, 
for example the restricted maximum likelihood method. However, the HKSJ 
method has been shown to perform very well in simulations[2] and is easy to 
apply.
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In Chapter 5 we showed that the estimated heterogeneity between small studies 
was larger than between large studies and its imprecision was also larger. 
Apparently results of small studies are more different from each other than those 
of large studies, even after adjustment for the additional random variation due 
to the smaller sample sizes. The common weighting of studies in the random 
effects approach is based on only one estimate for the heterogeneity, equal for 
small and large studies. Consequently, results of small studies will receive too 
much emphasis in the summary estimate. However, the low number of primary 
studies makes it difficult to provide a single reliable estimate of the between 
study heterogeneity in most meta-analyses; it will be even harder to provide 
study size dependent estimates. Another complicating factor is that studies that 
are selected for a meta-analysis are not a random sample of all possible studies, 
but are conducted in a setting where one study may be a reaction on another 
study. For example, after a small study with promising results a number of larger 
studies may be started. However, if the outcome of a first study was 
disappointing or counterintuitive, only a  small trial may be started or the 
research might be discontinued. A basic assumption of the random effects 
approach is that the primary studies are a random sample of all possible studies, 
and that results may be generalized to similar settings or studies. Clearly further 
research in this area is needed. Henmi et al.[3] advocated the combination of a 
fixed effect estimate with a confidence interval based on a random effects 
model. Although their objective was to make results of meta-analyses less 
sensitive to the effects of publication bias, approaches like this might be a way 
to proceed if small studies seem too influential 
If there is heterogeneity, i.e. when effect sizes differ widely over the studies, 
this variation is clinically relevant and should be clearly visible in the results. For 
example if some results strongly favour the experimental treatment whereas 
others strongly favour the control, this is relevant information for the 
interpretation of the results of the meta-analysis. Usually the extent of 
heterogeneity is reported with an estimate of W2 or I2, in addition to the summary 
estimate of the meta-analysis and its confidence interval. However, we argue 
that this approach is too limited. A prediction interval shows the expected range 
of true effect sizes in future settings, whereas a confidence interval only 
represents the summary effect size  and its imprecision. In Chapter 6 we wrote a 
plea for routinely presenting the prediction interval as a result of meta-analyses, 
in addition to the confidence interval and the summary estimate. More than W2 or 
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I2, the prediction interval can help the reader to understand the uncertainty 
about whether a treatment works or not. In roughly 70% of statistically 
significant (random effects p<0.05) meta-analyses in the CDSR Issues 2009-2013, 
the 95% prediction interval suggested that the intervention effect could even be 
in the opposite direction, and in approximately 20% of these meta-analyses the 
opposite effect was as least as large as the summary estimate of the meta-
analysis  (e.g. the prediction interval contained an OR of 0.5 when the point 
estimate was an OR of 2. Although we were not the first to describe the 
advantages of presenting prediction intervals, it is still far from common practice 
in meta-analyses of interventions, in contrast to prediction regions in meta-
analyses on diagnostic test accuracy. Perhaps this is related to the fact that the 
methodology in diagnostic test accuracy meta-analyses in general is more 
complex and further developed than in the traditional pairwise meta-analyses, as 
the correlation between sensitivity, specificity and prevalence has to be 
incorporated in the statistical models. 
Although meta-analyses on animal studies are far less often performed than 
meta-analyses on clinical studies, the advantages of a meta-analysis on animal 
studies may be even larger. Results of animal studies are more heterogeneous 
than those of human studies, therefore the results of a meta-analysis can be 
more reliable than those of a new trial. Besides less animals need to be 
sacrificed. Further, we hope that as a consequence of the increased emphasis on 
“old” study results, quality of reporting will improve. Therefore we wrote an 
introductory tutorial on meta-analysis methods for animal studies (Chapter 2).
However, animal studies have their complexities, even more than human studies. 
First, they are extremely small compared to most human studies. Their results 
show high heterogeneity: responses of 0% and 100% in the same meta-analysis are 
far from uncommon. Designs may include measurements over time, resulting 
from a few animals that are sacrificed each time period. The same control group 
may be used repeatedly. Moreover there is still ample room for improvement in 
the quality of reporting of the studies. The nature of the tutorial was explicitly 
introductory, aiming at animal scientists who want to learn more about meta-
analyses. There is ample room for a more advanced tutorial focussing on more 
sophisticated statistical analysis methods, as shown by the list of complexities 
specific to animal studies. However, this requires additional methodological 
research. 
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Outlook
In 1959 it was already stated that approaches to meta-analysis were too simple 
and that more advanced methodology should be applied.[4] In 2015 Hoaglin 
repeated this complaint and stated that, despite the extensive literature, most 
of the methodology development had limited relevance to actual practice.[5] As 
reasons he mentioned the use of incorrect (but convenient) assumptions, 
inaccurate approximations, preference for simplicity, unrealistic simulations and 
inertia. However, recently there have been quite a few developments. Up  to a 
few years ago meta-analyses were usually paired comparisons leading to 
summary estimates based on inverse variance approach, with as major discussion 
point whether a random or a fixed effects model was to be used. Nowadays the 
share of network meta-analyses, individual participant meta-analyses and  
diagnostic test accuracy meta-analyses is increasing. Also a more advanced 
method like the multivariate approach is gaining popularity, since Van 
Houwelingen et al. wrote a tutorial in 2002.[6] Multivariate techniques are the 
standard approach already for network and diagnostic meta-analyses. However, 
they can be rather complicated and it will be difficult to turn them into 
automated procedures like Review Manager (RevMan).[7] Another advanced 
method is the Bayesian approach, which explicitly models the imprecision. The 
Bayesian approach also offers opportunities, like a ranking of interventions in a 
network meta-analysis based on the probability that an intervention is the most 
efficacious one, that are difficult to perform with a frequentist analysis. It was 
even suggested to analyse single studies from a Bayesian meta-analysis 
perspective, in order to shrink unrealistically extreme study effect estimates 
towards the prior mean.[8] However, the Bayesian approach is still far from 
mainstream, even though statistical software to implement it is more readily 
available since it has been incorporated in some SAS procedures and R packages. 
Summarizing, the landscape of evidence based medicine is changing, and the 
methodology of meta-analysis is maturing. The evidence base is changing from 
the single study results via paired treatment comparisons based on a group of 
studies, to a set of studies evaluating similar interventions in one large (network) 
meta-analysis. There are many initiatives stimulating the data sharing of 
individual participant data. The availability of individual data will allow a 
consistent approach to the decisions that must be taken during the preparations 
for the analysis and the statistical models. This will enable a more consistent 
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approach to the meta-analysis as well as more thorough insight in the reasons for 
the heterogeneity. Currently, most source data consist of aggregated study data, 
which makes it difficult to deal with heterogeneity. If evident and measurable 
clinical reasons for heterogeneity exist, they should be taken into consideration 
and investigated. It is possible to use meta-regression to adjust for differences  
between studies and to possibly decrease the extent of residual between-study 
heterogeneity. However, especially for variables that summarize individual 
patient characteristics on study level, like mean age, results of a meta-regression 
may be unreliable due to the ecological fallacy[9], that may result in an apparent 
relationship between the moderator variable and the treatment effect that may 
even be opposite to the one that would be found if individual patient data would 
have been used. Another complication is that there will be studies that did not 
report aggregated data for the moderator variable. Up till now, not much 
research has been published on missing data imputation for meta-regression. 
However, at least part of these problems will be solved once individual 
participant data will be available.  
Multivariate methods are available to answer advanced research questions in 
network meta-analysis or individual participant meta-analyses. These methods 
enable also the incorporation of more complex designs of the primary studies, 
e.g. stepped wedge or repeated measures designs. In addition to outcomes based 
on approximations of the normal distribution, also outcomes that have a binomial 
or other distribution can be modelled. Missing data imputation is another 
opportunity for methodological development.  
Recommendations
Heterogeneity, either clinical or statistical, is of direct importance for the size 
and the interpretation of the results of the meta-analysis. First of all, the meta-
analyst should take care that it is not caused by careless study selection. 
Unsuitable studies (for example with a too different target population) should 
not be included in meta-analysis. 
Due to the limited number of primary studies in most meta-analyses, the 
estimate of the heterogeneity may be imprecise. We recommend that the meta-
analysis method should recognize this fact, and not be too reliant on large 
sample approximations where possible. Ideally, the method should be robust, and 
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insensitive to the exact size of the estimated heterogeneity. Sensitivity analyses 
may be performed by using some values from the confidence interval of the W2
estimate. 
Further we recommend that the heterogeneity estimate should be presented 
with prediction intervals on the scale of the clinical outcome, so that results of a 
meta-analysis illustrate which range of true effects can be expected in future 
settings, for example in a hospital. Meta-analysis based on individual participant 
data will greatly increase the possibility to get insight in the reasons for the 
heterogeneity, which is very important for the interpretation of the variation in 
the study results. Whenever possible, the reasons and the remaining unexplained 
heterogeneity should be clearly reported, so that individual doctors may assess 
how large the effect sizes are that they may expect if they apply the 
intervention in their hospital.  
Conclusion 
The underlying rationale for the use of a random-effects approach to meta-
analysis is the acceptance of heterogeneity in effect sizes. Heterogeneity plays 
an important role both in the statistical estimation of the summary effect and 
the clinical interpretation of the results of a meta-analysis. Evaluating the 
variation in the strength of the effect across studies is a key feature of meta-
analyses. 
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Summary  
The theme of the Cochrane Colloquium 2015 is “Filtering the information 
overload for better health decisions”.  Per day more than 75 publications on 
randomized controlled trials are published; a huge amount of information, which 
is even continuously increasing. One of the most important quantitative tools 
which can be used to extract valuable information from this data overload is 
meta-analysis.  
 
Study reproducibility is another issue which is high on the research agenda. Study 
results are difficult to reproduce, even of studies that are published in high-
impact journals. Publication bias and variation due to sample size limitations 
were mentioned as possible reasons. However, another reason may be the 
between-study variation in the results caused by clinical or statistical differences 
between studies.  
 
The main objective of this thesis is to give insight into the application of  meta-
analysis methodology and to reflect on the role of between-study heterogeneity 
in the realistic setting where most meta-analyses are based on just a few studies 
and where some of these studies are small or very small. Default meta-analysis 
methodology is based on large sample approximations, for which a sufficient 
number of studies must be available.  
 
The UK Cochrane Editorial Unit kindly provided us with the statistical data of 
systematic reviews of interventions in clinical studies included in the Cochrane 
Database of Systematic Reviews (CDSR) Issues of 2009-2013. We used these data 
to empirically evaluate various aspects of meta-analysis methodology and to 
design realistic simulation studies for more extensive evaluations. 
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Meta-analyses of animal studies – tutorial 
Most medical meta-analyses are dedicated to clinical (human) research. 
However, some questions can only be answered by means of experimental animal 
studies. The number of meta-analyses of animal studies is increasing, but it is 
still very much lower than the number of meta-analyses of clinical studies, even 
though the statistical methodology is rather similar. The advantages of a meta-
analysis on animal studies may be even larger than for clinical studies. Results of 
animal studies are more heterogeneous than those of human studies, as animal 
studies are often more diverse in their populations (e.g., species), design, and 
other study characteristics. Therefore the pooled results of a meta-analysis can 
be more reliable than those of a new trial. If the meta-analysis provides a 
convincing result, fewer animals need to be sacrificed. Further, the increased 
emphasis on “old” study results will reveal gaps in the reporting of those results. 
We hope that as a consequence reporting quality will improve. To explain the 
methodology and to stimulate animal researchers to perform more meta-
analyses, we have written an introductory tutorial, which is presented in 
Chapter 2. However, animal studies have their complexities, even more than 
human studies: they can be very small, show high between-study heterogeneity 
in effect sizes, use a variety of designs, and the quality of reporting needs 
improvement. There is ample room for a more advanced tutorial focussing on 
more sophisticated statistical analysis methods. However, this requires additional 
methodological research. 
 
Meta-analysis of several modestly powered trials outperformed the evidence 
generated by a single well-powered trial 
In Chapter 3 we investigate a fundamental question with regard to two possible 
approaches to find the best evidence on the effect of an intervention: is it 
preferable to conduct one large new trial or it is better to summarize existing 
trial results by means of a meta-analysis. We also evaluate the effect of three 
complicating factors. First, the number and size of the trials: if a meta-analysis is 
preferred to a large trial, is this then also the case if only a few small trials are 
available for the meta-analysis? Secondly, we investigate the influence of 
reporting bias. Studies with positive findings tend to get published more often 
than those with negative findings, which results in an overrepresentation of 
papers with positive results. The third issue is the between study variation, or 
heterogeneity.  
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Extensive simulations show that a meta-analysis tended to result in a better 
estimate of an effect size than a new large study, particularly if there was 
between-study variation in the treatment effect, which is shown to be the case 
in approximately 50% of the meta-analyses. Due to this heterogeneity the results 
of a single trial may be overly positive or negative, and one cannot know how far 
they deviate from the average effect without knowing the results of other 
studies.  When a treatment was assumed to have no effect but heterogeneity was 
present, the error rates for a single trial were increased more than tenfold above 
the nominal rate, even for low heterogeneity. In contrast, for meta-analyses on 
series of trials the error rates were correct. When selective publication was 
present, the error rates were always increased, but they still tended to be lower 
for series of trials than for single trials. Even if there were only two or three 
primary studies, subject to publication bias and heterogeneity, the meta-analysis 
resulted in lower rates of false positive findings than a single large new trial.  
 
The Hartung-Knapp-Sidik-Jonkman method outperformed the standard 
DerSimonian-Laird method  
In a random effects meta-analysis the size of the estimated heterogeneity 
directly affects the meta-analysis result through the weighting of the primary 
studies. If a meta-analysis is based on only a few studies, the estimate of the 
heterogeneity will be imprecise. Data retrieved from the CDSR Issues 2009-2013 
show that many meta-analyses were based on only a few (medium 4, 
interquartile range 2-6) primary studies. However, the default method for 
random effects meta-analysis is (still) the DerSimonian and Laird (DL) approach, 
even though it is based on large sample approximations and the imprecision of 
the estimated heterogeneity is neglected. The method described by Hartung, 
Knapp(11-13) and by Sidik and Jonkman(14, 15) (HKSJ) is known to perform 
better, but evidence in realistic situations, where one trial might be much larger 
than the other trials, was lacking. In Chapter 4 we assessed the relative 
performance of those methods when studies of different sizes are combined. We 
simulated meta-analyses of 2–20 trials with varying sample sizes and between-
study heterogeneity. Results show that the HKSJ method resulted in lower, more 
adequate false positive error rates than the DL method.  We illustrated this 
empirically by demonstrating that the number of “positive” (statistically 
significant at p < 0.05) findings using the DL approach was much higher than by 
the HKSJ approach, using 689 meta-analyses from the CDSR Issues 2012. Further 
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we showed how DL results can be converted to HKSJ results by means of a few 
steps and provided an Excel sheet for this conversion. 
 
Small studies were more heterogeneous than large ones 
Results of small studies are often associated with “small study effects”: the 
phenomenon that results of small studies tend to be more positive than those of 
larger studies. This can be due to reporting bias but also to quality issues, both of 
which may occur more often in small trials. Whether also the heterogeneity 
between small studies is different from the heterogeneity between large studies, 
was investigated in  Chapter 5.  By exploring 3263 meta-analyses from the CDSR 
Issues 2009-2013 we showed that the estimated heterogeneity between small 
studies was larger than between large studies and its imprecision was also larger. 
Results of small studies are more different from each other than those of large 
studies, even after adjustment for the additional random variation due to the 
smaller sample sizes.  
A plea for routinely presenting prediction intervals in meta-analysis 
Heterogeneity is not only associated to the weights of the studies in the meta-
analysis: it also contains clinically relevant information. The existence of a 
positive heterogeneity estimate implies that there may be differences in the 
intervention effect between the trials. This occurs often: in approximately half 
of the meta-analyses the estimate for the between-study variation is positive. 
This means that the treatment will appear more effective  in some settings than 
in others, which clearly is clinically relevant. However, most reviewers and 
readers are uncertain with respect to the clinical interpretation of the 
heterogeneity estimates. In Chapter 6 we argue that the prediction interval is 
helpful in this context, because it shows the range of true treatment effects that 
is expected in future studies. Confidence intervals only relate to the mean 
treatment effect. In case of heterogeneity, prediction intervals will show a wider 
range of expected treatment effects than confidence intervals, and thus may 
lead to different conclusions. In roughly 70% of the statistically significant 
(random effects p<0.05) meta-analyses in the CDSR Issues 2009-2013, the 95% 
prediction interval suggested that the intervention effect could even be in the 
opposite direction, and in approximately 20% of these meta-analyses the opposite 
effect was as least as large as the summary estimate of the meta-analysis  (e.g. 
the prediction interval contained an OR of 0.5 when the point estimate was an 
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OR of 2). Although we were not the first to describe the advantages of presenting 
prediction intervals, it is still far from common practice in meta-analyses of 
interventions. 
 
Conclusion and discussion 
The landscape of evidence based medicine is changing and the methodology of 
meta-analysis is maturing. This is described in Chapter 7. Meta-analyses are no 
longer restricted to the paired comparison of two interventions: network meta-
analysis enables the comparison of a group of interventions for the same medical 
condition. Further there are many initiatives stimulating the data sharing of 
individual participant data. The availability of these data will allow a consistent 
statistical approach as well as more thorough insight in clinical reasons for the 
heterogeneity. Evaluating the variation in the strength of the effect across 
studies is a key feature of meta-analyses. Acceptance of this variation is crucial 
and fundamental to the use of a random-effects approach. Heterogeneity plays 
an important role, both in the statistical estimation of the summary effect and in 
the clinical interpretation of the results of a meta-analysis. 
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Nederlandse samenvatting 
Het thema van het Cochrane Colloquium 2015 was “Filtering the information 
overload for better health decisions”, wat zoveel betekent als: de overvloed aan 
informatie filteren om betere beslissingen met betrekking tot de gezondheid te 
kunnen nemen.  Per dag verschijnen er meer dan 75 publicaties over 
gerandomiseerde gecontroleerde klinische studies: een (nog immer) groeiende 
berg aan informatie. Een van de belangrijkste manieren om informatie uit deze 
informatieberg te destilleren is meta-analyse.  
 
Reproduceerbaarheid van studieresultaten is een tweede issue dat hoog op de 
wetenschapsagenda staat. Resultaten blijken moeilijk te reproduceren, zelfs als 
het gaat om studies die gepubliceerd werden in tijdschriften met hoge 
impactcijfers. Publicatiebias en beperkte steekproefomvang van studies (met als 
gevolg random variatie) worden vaak als mogelijke oorzaken genoemd. Ook 
klinisch inhoudelijke of statistische verschillen tussen de studies zijn een 
mogelijke oorzaak voor de variatie in de resultaten. Deze variatie in resultaten 
van verschillende studies wordt tussen-studie heterogeniteit genoemd. 
 
De belangrijkste doelstelling van dit proefschrift is inzicht geven in de 
methodologie voor meta-analyse, en dan met name in de rol die heterogeniteit 
tussen de studieresultaten hierin speelt. De standaardmethodologie is gebaseerd 
op benaderingen die valide zijn voor grote steekproeven, dat wil zeggen dat deze 
methodologie ervan uitgaat dat er voldoende studies beschikbaar zijn. In de 
praktijk zijn de meeste meta-analyses echter gebaseerd op slechts een paar 
studies die soms ook nog klein van omvang zijn. 
 
De UK Cochrane Editorial Unit was zo vriendelijk ons de statistische gegevens van 
alle systematische reviews van klinische interventie studies uit de Cochrane 
Database of Systematic Reviews (CDSR) van 2009 tot 2013 ter beschikking te 
stellen. Deze gegevens hebben we gebruikt om verschillende aspecten van de 
meta-analyse methodologie empirisch te evalueren, en om realistische 
simulatiestudies te kunnen uitvoeren om zodoende nog meer inzicht te 
verkrijgen. 
 
Chapter 8 

 
174 
Meta-analyses van dierstudies – handleiding 
De meeste medische meta-analyses zijn gericht op klinisch (humaan) onderzoek. 
Sommige vragen kunnen echter alleen beantwoord worden door experimentele 
dierstudies. Het aantal meta-analyses van dierstudies is groeiende, maar toch 
nog steeds veel lager dan het aantal meta-analyses van klinische studies, ondanks 
het feit dat de statistische methodologie vergelijkbaar is. Wellicht zijn de 
voordelen van een meta-analyse van dierstudies zelfs groter dan die van klinische 
studies. Resultaten van dierstudies zijn meer heterogeen dan die van humane 
studies, omdat dierstudies vaak meer variatie kennen wat betreft de 
onderzoekspopulatie (denk aan diersoorten), studieopzet, en andere 
studiekenmerken. Daarom kan het gecombineerde resultaat van een aantal 
studies (met behulp van meta-analyse) betrouwbaarder zijn dan de resultaten 
van een nieuwe studie. Daarnaast geldt dat als een meta-analyse overtuigende 
resultaten laat zien, er geen nieuwe studie gedaan hoeft te worden, waardoor er 
minder dieren hoeven te sterven. Bovendien maken meta-analyses op basis van 
dierstudies de tekortkomingen in de rapportage van deze studies zichtbaar. 
Daarom hopen we dat ook de rapportagekwaliteit zal toenemen met het aantal 
meta-analyses van dierstudies.  
 
Om de methodologie uit te leggen en om dieronderzoekers te stimuleren meer 
meta-analyses uit te voeren, hebben we een inleidende handleiding geschreven, 
die te vinden is in Hoofdstuk 2.  Dierstudies zijn echter (statistisch gezien) vaak 
complexer dan humane studies: ze  kunnen erg klein zijn, er is veel 
heterogeniteit tussen de studies, ze gebruiken een keur aan verschillende 
soorten studie-opzet en de rapportage laat vaak te wensen over. Er zijn dus 
onderwerpen genoeg voor een uitgebreidere handleiding met meer geavanceerde 
statistische methoden. Maar hiervoor is eerst additioneel methodologisch 
onderzoek nodig.  
 
Het gecombineerde resultaat van een meta-analyse op basis van een paar 
kleine studies is betrouwbaarder dan het resultaat van één grote studie 
In Hoofdstuk 3 vergelijken we twee benaderingen om een behandeling te 
evalueren: het uitvoeren van één nieuwe, grote studie versus het samenvatten 
van de resultaten van een aantal al bestaande studies door middel van een meta-
analyse. We hebben dit geëvalueerd in samenhang met drie complicerende 
factoren. Ten eerste: aantal en omvang van de bestaande studies. Maakt het uit 
Nederlandse samenvatting 


175 
voor het antwoord hoeveel studies er zijn, en hoe groot deze studies zijn? Ten 
tweede hebben we gekeken naar de invloed van publicatiebias: het verschijnsel 
dat studies met positieve resultaten vaker worden gepubliceerd dan studies met 
negatieve resultaten. Gevolg hiervan is dat het aantal beschikbare studies met 
positieve resultaten onevenredig groot is.  De derde factor waar we rekening 
mee hebben gehouden is de mate van heterogeniteit tussen de studies.  
 
Met behulp van uitgebreide simulaties hebben we aangetoond dat een meta-
analyse een betere inschatting van de werkzaamheid van een behandeling gaf 
dan een nieuwe studie, met name als er  sprake was van heterogeniteit tussen de 
studies, hetgeen het geval is in ongeveer 50% van de meta-analyses. Vanwege de 
heterogeniteit kunnen de resultaten van één enkele studie positiever of 
negatiever uitvallen dan gemiddeld het geval zou zijn. Maar als je slechts de 
resultaten van één studie kent, is het moeilijk inschatten hoe ver de gevonden  
resultaten afstaan van het effect dat je zou vinden als je beschikking had over 
voldoende studies. Simulatiestudies met een behandeling die gemiddeld geen 
effect had maar wel heterogeniteit,  resulteerden in veel te hoge percentages 
fout positieve bevindingen, namelijk tot meer dan tien maal verhoogd, ook als de 
heterogeniteit maar laag was. Dit terwijl de foutpercentages correct waren voor 
meta-analyses op basis van twee of meer studies. Als er sprake was van 
publicatiebias waren de foutpercentages van de gecombineerde resultaten ook 
verhoogd, maar minder sterk dan voor de resultaten van één enkele studie. Zelfs 
als er slechts twee of drie studies beschikbaar waren voor de meta-analyse en als 
deze ook nog onderhevig waren aan publicatiebias en heterogeniteit, resulteerde 
de meta-analyse in betere, lagere percentages fout positieve bevindingen dan 
een nieuwe grote studie.  
 
De Hartung-Knapp-Sidik-Jonkman methode werkt beter dan de standaard 
DerSimonian-Laird methode  
In een random-effect meta-analyse beïnvloedt de grootte van de geschatte 
tussen-studie heterogeniteit hoe zwaar de primaire studies meewegen in het 
gecombineerde resultaat van de meta-analyse. De schatting van de 
heterogeniteit heeft dus direct invloed op het eindresultaat. Maar als de meta-
analyse op slechts een paar studies is gebaseerd zal deze schatting niet erg 
nauwkeurig zijn, en dit komt vaak voor. De meta-analyses uit de CDSR 2009-2013 
waren op maar weinig primaire studies gebaseerd: mediaan 4, 
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interkwartielafstand 2-6 studies. Toch is de standaardmethode voor random-
effect meta-analyse nog steeds die van DerSimonian en Laird (DL), zelfs al is 
deze gebaseerd op de aanname dat er voldoende studies beschikbaar zijn, en ook 
al negeert deze methode de onnauwkeurigheid in de schatting van de 
heterogeniteit. Het is bekend dat de methode zoals beschreven door Hartung, 
Knapp en door Sidik en Jonkman (HKSJ) beter werkt,  maar tot nu toe was er 
geen bewijs daarvoor in realistische situaties, waarbij studies sterk van grootte 
kunnen verschillen. In Hoofdstuk 4 hebben we beide methoden vergeleken voor 
situaties waarin studies van verschillende groottes worden gecombineerd. We 
hebben simulaties uitgevoerd van meta-analyses op basis van 2–20 studies van 
verschillende grootte en met verschillende heterogeniteit. De resultaten laten 
zien dat de HKSJ methode resulteerde in lagere, meer adequate percentages 
fout positieve resultaten dan de DL methode.  We hebben ook beide methoden 
toegepast op 689 meta-analyses van de CDSR jaargang 2012: het aantal 
“positieve” bevindingen (statistisch significant  met een p-waarde <0.05) met de 
HKSJ benadering was veel lager dan met de DL benadering. Daarnaast hebben we 
aangetoond hoe DL resultaten omgezet kunnen worden in HKSJ resultaten door 
middel van een paar stappen, of door gebruik te maken van een door ons 
bijgeleverde Excel sheet.  
 
Kleine studies waren meer heterogeen dan grote studies  
Resultaten van kleine studies worden vaak geassocieerd met “kleine-studie-
effecten”: het verschijnsel dat de resultaten van kleine studies vaak wat 
extremer zijn dan die van grotere studies. Dit kan veroorzaakt worden door bias 
in de rapportage, maar ook door kwaliteitsissues, en beide komen vaker voor bij 
kleine studies. In Hoofdstuk 5 hebben we onderzocht of er ook verschil is tussen 
kleine en grote studies in de mate van tussen-studie heterogeniteit. Hiervoor 
hebben we gebruikt gemaakt van 3263 meta-analyses van de CDSR 2009-2013. We 
hebben laten zien dat de schatting van de heterogeniteit tussen kleine studies 
gemiddeld groter was dan voor grote studies. Bovendien was ook de 
onnauwkeurigheid van deze schattingen voor de kleine studies groter. Resultaten 
van kleine studies verschillen meer van elkaar dan die van grote studies, zelfs na 
correctie voor de extra random variatie die veroorzaakt wordt door de kleinere 
steekproeven in de kleine studies.  
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Een pleidooi om predictie-intervallen in meta-analyses altijd te rapporteren 
De mate van heterogeniteit tussen de studies bepaalt niet alleen hoe zwaar 
individuele studies meewegen in de meta-analyse, maar bevat ook klinisch 
relevante informatie. Als er heterogeniteit is (>0) impliceert dit namelijk dat het 
effect van een behandeling verschilt van studie tot studie. Dit komt in ongeveer 
de helft van de meta-analyses voor. Het betekent dat een behandeling in 
sommige situaties effectiever zal zijn dan in andere situaties. Dit is belangrijk 
voor de klinische praktijk, maar de meeste lezers van een publicatie over een 
meta-analyse weten niet goed hoe ze de schatting van de heterogeniteit klinisch 
moeten interpreteren. In Hoofdstuk 6 beargumenteren we dat het rapporteren 
van een predictie-interval hierbij zou kunnen helpen, omdat dit aangeeft welke 
ware effecten er verwacht kunnen worden in een toekomstige studie.  Predictie-
intervallen zijn niet hetzelfde als betrouwbaarheidsintervallen. 
Betrouwbaarheidsintervallen geven aan hoe groot het geschatte gemiddelde 
behandelingseffect is, maar niet hoe groot de variatie hiervan is over de studies. 
Als er heterogeniteit is, zullen predictie-intervallen een breder bereik van 
verwachte effecten laten zien dan betrouwbaarheids-intervallen, en daarom ook 
tot andere conclusies kunnen leiden. In grofweg 70% van de statistisch 
significante (random effect p-waarde<0.05) meta-analyses in de CDSR 2009-2013 
suggereerde het 95% predictie-interval dat het effect van de behandeling in 
sommige situaties nihil of zelfs tegengesteld kon zijn aan het gemiddelde effect, 
en in ongeveer 20% van deze meta-analyses was dit tegengestelde effect 
minstens zo groot als het gemiddelde effect van de meta-analyse (bijvoorbeeld, 
een predictie-interval dat een odds ratio van 0.5 bevat, terwijl de puntschatting 
een odds ratio van 2 betreft).  
 
Weliswaar zijn wij niet de eersten die de voordelen van predictie-intervallen 
beschrijven, maar de praktijk laat zien dat de meeste publicaties van meta-
analyses nog geen predictie-intervallen bevatten.  
 
Conclusie en discussie 
Meer en meer moeten medische behandelingen aantoonbaar effectief zijn 
(Evidence Based Medicine). Meta-analyses zijn daarom steeds relevanter en de 
vragen die ze moeten beantwoorden zijn dan ook complexer dan  vroeger. Dit 
fenomeen wordt beschreven in Hoofdstuk 7. Van oudsher waren meta-analyses 
beperkt tot de vergelijking van twee behandelingen, gebaseerd op de 
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geaggregeerde resultaten van een aantal studies. Netwerk meta-analyse maakt 
het mogelijk om in één keer een vergelijking te maken tussen een groter aantal 
behandelingen voor dezelfde medische indicatie. Daarnaast zijn er steeds meer 
initiatieven die stimuleren dat de (geanonimiseerde) oorspronkelijke gegevens 
van individuele patiënten ook voor anderen dan de aanvankelijke  onderzoekers 
beschikbaar komen. Als gebruik wordt gemaakt van individuele patiëntgegevens 
kan er voor alle studies in de meta-analyse een consistente statistische 
benadering worden toegepast, hetgeen de statistische heterogeniteit vermindert. 
Bovendien geven de individuele gegevens meer inzicht in de klinische oorzaken 
voor heterogeniteit dan de geaggregeerde gegevens.  
 
Meta-analyse maakt het mogelijk om variatie in de sterkte van de werking van 
een behandeling over studies heen te bestuderen. Vaak krijgt deze variatie 
echter niet de aandacht die het verdient. Om een random-effect benadering 
goed te kunnen toepassen is het cruciaal dat deze variatie wordt geaccepteerd 
en bestudeerd. Heterogeniteit speelt een belangrijke rol, zowel bij het 
statistisch proces van het tot stand komen van het gecombineerde effect als in 
de klinische interpretatie van de resultaten van een meta-analyse. 
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